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Abstract 
Chronic fatigue syndrome (CFS) and Overtraining syndrome 
(OTS) are separate, complex conditions which have so many 
similar debilitating effects that it has led some researchers to 
conclude that OTS is a sub-condition of CFS. The purpose of 
this research was to compare the force and damage-recovery 
characteristics of skeletal muscle in CFS patients and control 
normals, after a single damaging bout of eccentric contractions 
in the non-dominant forearm flexors. The subjects (n = 25), a 
convenience sample were assigned to three groups; [1] CFS + 
eccentric damage (n = 8), [2] Control Damage (CD) + eccentric 
damage (n = 10), and [3] Control (ND) + no damage (n = 7). 
The research was carried out over a four week period using the 
following format. CFS & CD groups received eccentrically 
induced muscle damage of the forearm flexors by 35 isokinetic 
eccentric (7 x 5, 2 minutes recovery between sets) contractions 
at 90° sec-I with the forearm returning passively at 15°sec-1. 
Testing was undertaken pre-damage and 1, 2, 4, 6, 8, 12, 16, 20, 
24, & 28 days post-damage, by measurements of voluntary 
maximal concentric isokinetic force at l 50°sec-l, isometric 
maximal voluntary contraction at approximately 90° elbow 
flexion, electrically stimulated 20 : 50Hz isometric force ratio at 
approximately 90° elbow flexion, muscle pain, and blood CK. 
Groups were compared on these variables using Students 
independent t-test and repeated measures two way ANOV A with 
simple contrasts. Alpha was set at 0.05 level. The results of this 
study were significant for the eccentric force produced in the 
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damage bout with the CFS group producing less force after the 
4th set (p < 0.05). Serum CK concentration, which following 
eccentric damage was significantly higher in the CFS group than 
the CD group (Q < 0.01), and the ND group (Q < 0.001). The 
low frequency fatigue (LFF) ratio was significantly lower in the 
CFS group 2, 4, 6 & 8 days post-damage when compared to the 
CD group. Maximal isometric voluntary force and isokinetic 
concentric peak torque (PT) & average peak torque (AT) loss 
was significantly greater in the CFS group compared to the CD 
group (isometric Q < 0.01, PT Q < 0.01; & AT Q < 0.001) and 
ND group (isometric Q < 0.01; PT Q < 0.001; & AT Q < 0.001). 
The intensity of delayed onset muscle soreness (DOMS) was 
significantly less 6 days post-damage in the CFS group, when 
compared to the CD group (Q < 0.05). The combination of an 
increased CK efflux and low frequency fatigue, that is of both 
greater depth and longer lasting, together with greater isometric 
and concentric force losses, indicates that the subjects with CFS 
have a lower threshold for muscular damage, that is more 
profound and slower to recover than in healthy individuals. 
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CHAPTER 1 
INTRODUCTION 
1.1 The Background & Significance of the Study 
Chronic fatigue syndrome (CFS) is a very complex and 
debilitating condition that has been described as having various 
possible aetiologies including psychological (Krupp, Mendelson, 
& Friedman, 1991), viral (Behan & Behan, 1993), combined 
viral and psychological (Byrne, 1991 ), immunological, neuro-
physiological (Parker & Brukner, 1994) and a hypothalamic 
disorder (Lee, 1994 ). Due to its complexity, CFS is generally 
diagnosed by exclusion of psychiatric or possible other 
pathogenesis (Behan & Behan, 1993 ), though recent research 
(McGregor, Bu~ Zerbes, Dunstan, Roberts, & Klineberg, 1994) 
claims to have isolated a urinary biomarker which the 
researchers have titled CFSUMl. 
Overtraining syndrome (OTS), like CFS, is also a clinical 
condition of uncertain aetiology and apparent complexity which 
can result in many symptoms including depression, central 
fatigue, and immunosuppression (Parry-Billings, Matthews, 
Newsholme, Budge~ & Koutedakis, 1993). Diagnosis is 
generally made by "monitoring physiological markers such as 
aerobic capacity, changes in muscle force [in prolonged 
contractions], and by comparing [performance] times" (Sharp & 
Parry-Billings, 1992, p. 34 ), as well as by reduction of the 
performance attainable at the 4 mmol blood lactate concentration 
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(Lehmann, Foster, & Keul, 1993), which indicates a reduced 
anaerobic threshold in the athlete. 
Whilst being acknowledged as separate syndromes both CFS 
and OTS share common symptoms, in particular profound 
fatigue, and myalgia. In fact, so similar are the two diseases that 
many researchers (Eichner, 1991; Fitzgerald, 1991; Fry, Morton, 
& Keast, 1991a, Fry, Morton, & Keast, 1991b; Gross, 1992; 
Keast & Morton, 1992; Lehmann, et al., 1993; Parker, 1990; 
Parker & Brukner, 1994) feel that overtraining syndrome can be 
classified as a sub-condition of CFS. 
Myalgia is often, but not always, associated with muscle damage 
(Byrnes & Clarkson, 1986). Edwards, Newham, & Peters, 
(1991) indicate that the serum biochemistry of the intramuscular 
enzymes creatine kinase (CK), lactate dehydrogenase (LDH), 
and aspartate transaminase (AST), are consistently found to be 
within the normal range (CK: 60-200, AST: 11-35, LDH: 80-
190 UI/L, Nosaka, Clarkson, & Apple, 1992) in persons 
diagnosed with post viral fatigue syndrome (PVFS) a condition 
which has been reclassified as CFS. On the other hand in OTS it 
is sometimes reported that there is elevated CK serum 
concentration (300 ill/L) when compared to the normal 
concentration for a trained athlete (200 UI/L ), which may be due 
more to the effects of acute training overload, than as a symptom 
of OTS (Fry, et al., 1991a). Therefore, it seems that although 
there may be myalgia present in CFS and OTS, generally there is 
no syndrome related muscle damage in either CFS or OTS as in 
many of these cases the plasma CK, AST and LDH 
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concentrations are within the normal range (Edwards, et al., 
1991), (refer to Table 2.3 for normal ranges). 
From a patho-physiological view-point the similarities between 
CFS and OTS pose the questions; To what extent can the 
symptom of myalgia, be reflected in the degree of damage? Does 
CFS (including OTS) affect the normal recovery processes 
occurring during muscle regeneration? 
1.2 Purpose of the Study 
The overall objectives of this research are twofold 1) attempt to 
establish a physiological diagnostic protocol and 2) indicate the 
pathology for CFS (including OTS), based on the damage-
recovery characteristics of skeletal muscle. 
1.3 Hypotheses 
1. After damage, muscle force characteristics of subjects with 
CFS will be different from the Control Damage (CD) group. 
2. After damage, the contractile properties of skeletal muscle 
as determined by the level of low frequency fatigue (LFF), 
will differ in subjects with CFS when compared to the CD 
group 
3. The time course of serum CK efllux, and the serum CK 
concentration in subjects with CFS will be different from the 
CD group. 
4. The time course of delayed onset muscle soreness (DOMS) 
during recovery in subjects with CFS will be different from 
the CD group. 
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5. The degree ofDOMS in subjects with CFS will be different 
from the CD group. 
1.4 Organisation of the Thesis 
An overview and the purpose of the study, outlining the 
hypotheses to be tested is covered in Chapter 1. This is followed 
by the review of the literature with reference to the 
methodological rationale and theoretical framework in Chapter 
2. Methodology of the thesis is covered in Chapter 3. Results 
and :findings of significance of the research are provided in 
Chapter 4 with the discussion of these results in Chapter 5. A 
summary of the study including recommendations for future 
research are included in Chapter 6. 
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CHAPTER2 
REVIEW OF THE LITERATIJRE 
2.1 Introduction 
The task of providing relevant information on CFS, and the 
relationship of OTS to CFS, as well as the physiology of muscle 
damage is a complex one. Therefore, each of these topics will be 
dealt with separately. 
2.2 Chronic Fatigue Syndrome (CFS) 
2.2.1 Overview. 
CFS, which can have a myriad of debilitating conditions (Manu, 
Lane, & Matthews, 1992) has a long recorded history. The main 
features of the illness were first described by Manningham in the 
18th century, and later discussed as a persistent illness following 
infections, by George Beard in 1869 ( cited in Behan & Behan, 
1993 ). Since then it has been known under a number of different 
names such as Post-Viral Fatigue Syndrome, Chronic Epstein-Barr 
Virus, Royal Free Disease, and Myalgic Encephalomyelitis, (Parker 
& Brukner, 1994 ), with a more complete list of names used for 
CFS shown in Table 2.1. More recently in Australia the syndrome 
has been generally referred to as CFS, though it is still commonly 
referred to as Post Viral Fatigue Syndrome (PVFS) in Europe. The 
Prince Henry's Hospital (Sydney, NSW) criteria for the diagnosis 
of CFS are shown in Table 2.2. 
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Table2.r 
Conditions which have been described as chronic fatigue syndrome 
Addington disease 
Akureyi disease 
Allergic fatigue syndrome 
Allergic tension fatigue syndrome 
Anxiety neurosis 
Anxiety reaction 
Autonomic imbalance 
Benign myalgic encephalomyelitis 
Cardiac neurosis 
Chronic Epstein-Barr virus infect. 
Chronic hyperfatiguability synd. 
Chronic mononucleosis 
Chronic mononucleosis-like synd. 
Combat fatigue 
Da Costa syndrome 
Disordered action of the heart 
Effort syndrome 
Epidemic myalgic encephalomyelitis 
Epidemic vegetative neuritis 
Epidemic neuromyasthenia 
Icelandic disease 
Irritable heart 
Lake Tahoe mystery disease 
Myalgic encephalomyelitis 
Nervous exhaustion 
Nervous tachycardia 
Neuritis vegetiva 
(Fry, Morton, & Keast, 1991 c, p. 77) 
Neurasthenia 
Neuromyasthenia 
Neurocirculatory asthenia 
Post viral fatigue syndrome 
Postinfection fatigue synd. 
Post viral exhaustion synd. 
Post viral syndrome 
Psychoneurosis 
Royal Free disease 
Shell shock 
Soldier's heart 
Somatization reaction gen. 
Somatization psychogenic 
asthenic reaction 
Somatization psychogenic 
cardiovascular reaction 
Somatization reaction 
psychogenic cardiovascular 
reaction 
SyndromeX 
Tapanui flu 
Vaso regulatory asthenia 
Vasomotor instability 
Vasomotor neurosis 
Yuppie flu 
20th century disease 
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Table 2.2 
Criteria for diagnosis of CFS 
1. Chronic persisting or relapsing fatigue exacerbated by minor 
exercise, causing significant disruption of usual daily 
activities, present for greater than 6 months 
2. Neuropsychiatric dysfunction, including, impairment of 
concentration and short-term memory and depressed mood. 
3. Exclusion of common medical and psychiatric disorders 
(Prince Henry's Hospital, 1988/93) 
(Parker & Brukner, 1994, p. 15) 
The relationship between CFS and OTS are increasing and OTS is 
viewed as a sub-condition of CFS by some researchers (Fry et al, 
1991b). There are two basic types ofOTS. Firstly, there is Classic, 
sympathetic or Basedowoid OTS, which is relatively rare and tends 
to occur more often in anaerobic type sports. And secondly, 
Modem, parasympathetic or Addisonoid OTS, which is the most 
common form of OTS and occurs mainly in the aerobic type sports 
(Lehmann, et al., 1993 ). The general symptoms for OTS, like CFS 
are varied with elevated pulse rate, painful and heavy muscles, 
gastrointestinal disorders, upper respiratory tract (URT) infections, 
delayed healing from cuts and bruises, as well as central fatigue, 
irritability, depression and sleep disturbances being common 
(Parry-Billings, Budgett, Koutedakis, Blomstrand, Brooks, 
Williams, Calder, Pilling, Baigrie, & Newsholme, 1992). More 
specifically the main symptoms of the sympathetic form of OTS 
including restlessness and excitation in conjunction with 
performance decrements, whereas inhibition and depression in 
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conjunction with performance decrements are indicative of the 
parasympathetic form of OTS (see Table 2.3). 
Table 2.3 
Findings in the "classical" and "modem" forms of overtraining 
syndrome for which conformation is still lacking in part. 
Overtraining Syndrome 
Classic, Sympathetic or 
Rasedowoid Form 
Performance reduction 
Easily fatigued 
Restlessness excitability 
Disturbed sleep 
Loss of weight 
Accelerated resting HR 
Delayed recovery 
(Lehmann, et al., (1993, p. 856) 
Modem, Parasympathetic, 
or Addisonoid Form 
Performance reduction 
Easily fatigued 
Depression, inhibition 
Sleep not disturbed 
Constant weight 
Bradicardic HR 
Good recovery capacity 
Fry, et al., (1991 b, p.48) stated: "Athletes who are exposed to 
excessive training, psychological, environmental, nutritional or 
lifestyle stressors may suffer performance decrements and other 
stress related symptoms reflective of a state described in the 
literature as overtraining". If recognised in the early stages ( up to 2 
weeks) a full recovery from overtraining may be attained after only 
a few days to two weeks rest. On the other hand, if the overtraining 
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persists for longer it may take weeks or even months for recovery, 
and it is this condition that is known as OTS (Lehmann, et al. 
1993), which can be considered as a sub-condition of CFS. 
2.2.2 Serum Biochemistry of CFS. 
From a biochemical viewpoint, Edwards, et al., (1991) indicate that 
cytoplasmic enzymes of skeletal muscle, notably CK, LDH, and 
AST are consistently found to be within the normal range in 
persons diagnosed with PVFS (Table 2.4), so although there may 
be myalgia present in CFS there is no indication of muscle damage. 
On the other hand.there is sometimes a reported elevation in LDH 
or CK serum levels (Table 2.4) in persons with OTS (Fry, et al., 
1991 b ), though this may well be more due to acute overload of 
training than to the effects of OTS (Fry, et al., 1991 a). 
Table 2.4 
Biochemical markers for muscle damage. adults normal range. * 
CK 60 -200 U/L 
LDH 80 - 190 U/L 
AST 13 - 35 U/L 
Myoglobin 6- 85 ng/ml 
* method of assay and test principles are shown in Appendix A. 
(Modified from Nosaka, et al., 1992, p. 184) 
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2.2.3 Physiological Parameters. 
Research by Stokes Cooper & Edwards, ( 1988) found that muscles 
of patients with effort syndromes were no weaker or more fatigable 
than that of healthy controls. Similarly, Lloyd, Hales, & Gandevia, 
( 1988) found normal isometric strength and dynamic force 
capabilities in patients with CFS when compared to healthy 
controls, though with an impaired recovery. Kent-Braun, Sharma, 
Weiner, Massie & Miller ( 1993) whilst generally supporting Lloyd 
et al. (1988), also found that CFS patients showed an inability to 
fully activate muscle during intense sustained exercise, which they 
concluded was due to central fatigue. Later research by Lloyd, 
Gandevia & Hales (1991), concluded that failure of the contractile 
properties of skeletal muscle in patients with CFS was not 
important in the pathogenesis of fatigue in CFS. Patients with CFS 
in the form of PVFS have been found to have a reduced aerobic 
capacity, which in tum pre-disposes these patients toward a 
reduced work capacity (Behan & Behan, 1993; McCluskey, 1993) 
and as such CFS patients have been shown to have a limited 
exercise capacity in graded exercise tests (Buchwald & Komarofl: 
1991 ). Further, research by Arnold and co-workers, ( 1984) cited 
by Behan & Behan ( 1993) suggests an increased level of glycolytic 
metabolism due to an excessive level of acidosis during exercise. 
And finally, whilst other metabolic studies (Byrne & Trounce, 
1987 cited by Buchwald & Komarofl: 1991; Kent-Braun, et al., 
1993) have concluded that adenosine tri-phosphate (ATP) levels 
are not effected in patients with CFS, Wong, Lopaschuk, Zhu, 
Walker, Catellier, Burton, Teo, Collins-Nakai, & Montague, (1992) 
suggest that from their research using 31 P nuclear magnetic 
resonance spectroscopy, there is a oxidative metabolism defect 
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within skeletal muscle in patients with CFS detennined by a 
significantly lower ATP level in skeletal muscle of patients with 
CFS at the point of exhaustion when compared to healthy subjects 
during exercise testing. Though they conclude that the aetiology of 
profound fatigue in CFS is unclear and could be as a result of 
deconditioning, post-viral effect, or due to some other cause . 
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There are numerous physiological symptoms of OTS (for a full 
review refer to Fry, et al., 1991 a, 1991 b ), some of which include: 
a) A reduced 4 mmol blood lactate threshold whereby the lactate 
curve shifts to the left and becomes more vertical (Fry, et al., 
1991 a; Lehmann, et al., 1993; O'Brien, 1993) which results in a 
reduced anaerobic threshold of the athlete. b) An increased heart 
rate for the same workload (McKinnon & Hooper, 1992; O'Brien, 
1993 ). c) A reduced V02max by as much as 5-10°/o (McKinnon & 
Hooper, 1992), with a concurrent increase in ventilation (Fry, et 
al., 1991a). And d) a reduction in the amount of muscular force 
that can be applied in prolonged contractions (Sharp & Parry-
Billings, 1992). 
2.2.4 Electrophysiological Effects. 
Kent-Braun, et al., (1993) indicate that electromyograph (EMG) 
activity is generally normal in patients with CFS, though research 
cited by Behan & Behan, ( 1993 ), found a reduction in the 
recruitment patterns of voluntary motor units as well as abnormal 
single fibre electromyograph (EMG) in patients with PVFS with 
the peripheral component of the motor unit (muscle fibre) as the 
most likely site. This indicates a likely myopathic disease 
involvement affecting contractile tissue in PVFS rather than 
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neurogenic disease affecting the motoneurone (Rothwell, 1994 ). 
Similarly, Newsholme (1990) cited by Fry et al. (1991a) proposes 
that due to reduced glutamine release from skeletal muscle in OTS 
there is a resultant decrease in motor unit recruitment with an 
increased level of fatigued myofibres during rest. Other nervous 
system abnormalities in OTS include: a) an increased difficulty in 
temperature control (Parker, 1990) which may be related to 5-HT 
(serotonin) levels (Behan & Behan, 1993 ); b) sensory nerve 
disturbances including hypaesthesia (numbness) and paraesthesia 
(pins & needles); c) vertigo; and d) palpitations and tachycardia 
(Parker, 1990). 
2.2.5 Pathology of CFS. 
A significant proportion of patients with PVFS, following muscle 
biopsy, show mild to severe atrophy of Type 2 muscle fibres and 
mitochondrial degeneration in oxidative muscle fibres (Behan & 
Behan, 1993). Conversely Edwards, et al., (1991, p. 826) state: 
"Clinical examination of muscle bulk reveals normal findings in 
PVFS patients, particularly in early stages of the disorder." 
Therefore, whether the cause of these aforementioned myopathies 
is due to CFS or due to immobilisation as a result of de-
conditioning is not clear. In OTS, Fry, et al., (1991a, p. 52) 
concludes that. "Most muscle damage [in OTS] reflects acute 
overload and is therefore more likely to be associated with 
overreaching than with advanced overtraining". 
2.2.6 Immunology of CFS. 
The immunology of CFS is varied (Table 2.5) and often shows 
many abnormalities such as increased auto-antibodies, abnormal 
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complement metabolism, and abnormal concentrations in various 
immunoglobulins (Behan & Behan, 1993; Wessely & Thomas, 
1991 ). Other responses include an abnormality in the cell-mediated 
response with either an increase or decrease in absolute numbers of 
T-helper (CD4) or T-suppressor (CD8) cells, an imbalance in CD4 
: CD8 ratio, and a reduced hypersensitivity skin response (Lloyd, et 
al., 1991). These immunological findings suggest that the immune 
system of patients with PVFS is compromised by a persistent viral 
infection (Behan & Behan, 1993). Horrobin (1990) hypothesises 
that levels of Q-3 and Q-6 essential fatty acids (EFA's) found in 
patients with PVFS may be inadequate due to the inability of an 
individual with PVFS to correctly metabolise the Q-3 linoleic acid 
(Figure 2. l) 
Linoleic 
l Viral infections block this step This step defective in atopic eczema 
Gamma-Linolenic 
i 
Dihomogammalinolenic -----.f---...... •- Pro~iaglandins i Interferon activates this step 
Arachidonic ______ __.t..__ __ -;;. Prostaglandins 
Figure 2.1. The interactions between essential fatty acid (EFA) 
metabolism, viral infections, atopic eczema and interferon. 
(Horrobin, 1990, p.214 ). 
It is generally accepted that moderate exercise can enhance the 
immune system, whereas excessive exercise levels as undertaken 
26 
by many elite athletes can damage the immune system (Fitzgerald, 
1991 ). The immunological effects in OTS are markedly similar to 
that of CFS shown in Table 2.5, with significant variations in CD4 
to CD8 ratio common (Fry, et al., 1991a). Any reduction in CD4 or 
CD8 numbers may be linked to a possible decrease in nocturnal 
catecholamine secretion, particularly epinephrine (Lehmann, 
Schnee, Scheu, Stockhausen, & Bachl, 1992) as CD4 and CD8 
lymphocyte proliferation is enhanced by catecholamines (W eicker 
& Werle, 1991). 
Table 2.5 
Immune dysfunction in CFS 
Humoral immune responses; 
1) elevated antibodies to viral proteins, 
2) low antibodies to EBNA or EBMA-1, 
3) partial hypogammaglobulinaemia, 
4) normal immunoglobulin, 
5) elevated circulating immune complexes, and 
6) decreased immunoglobulin release in vitro from mitogen 
stimulated lymphocytes. 
Lymphokine and interleukin responses; 
1) increased leucocyte 2-5-oligoadenylate synthase, 
2) decreased interleukin-2 synthesis in vitro, 
3) decreased immune (gamma) interferon synthesis 
in vitro by mitogen-stimulated lymphocytes, and 
4) normal gamma interferon production. 
Lymphocyte number and function; 
1) increased helper (CD4) to suppressor (CD8) ratio from 
decrease CD8 count, 
2) increased CD8 and decreased CD4, and 
3) normal CD4 to CD8 ratio. 
(Modified from Wessely & Thomas, 1990, p. 109). 
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Research (Parry-Billings, et al., 1993) found significantly lower 
levels of plasma glutamine in conjunction with significantly higher 
levels of glutamate in overtrained athletes when compared to 
healthy controls and they propose that the level of glutamine, 
which is the primary metabolite of the immune system, is reduced 
due to being metabolised as a substrate within the skeletal muscle 
rather than being released from skeletal muscle so as to become 
available for the immune system. 
As a result of the imbalances that occur in the immune system 
overtrained athletes become more susceptible to upper respiratory 
tract infections (URTI), (MacKinnon, 1994) which can be 
illustrated by Figure 2.2, with the cause of the immunological 
imbalance may well be as a result of reduced glutamine levels. 
RiskofURTI 
High 
Athletes 
Avg. 
Low 
Sedentary Moderate Exercise Excessive Exercise 
Figure 2.2. Modified "J-shaped" model of the relationship between 
the amount of exercise and the risk of upper respiratory tract 
infection (MacKinnon, 1994, p. 192) 
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2.2. 7 Neuroendocrine Effects. 
Hans Selye's General Adaptation Syndrome (GAS) whereby the 
neuroendocrine system responds to increased stress levels by 
release of hormones that enable physiological repairs to be carried 
out (Powers & Howley, 1994 ), is of importance to CFS and OTS. 
In that, these hormones, catecholamines, and glucocorticosteroids 
all have a significant role in immunoregulation (Keast & Morton, 
1992), and in a healthy individual react positively. 
However, in CFS or OTS the hormonal balance may be lost Fry, et 
al., (1991a) indicate that hormonal imbalances in OTS sufferers 
may result in various responses including: a) an increase in resting 
levels of catecholamines ( epinephrine and norepinephrine ); b) 
higher concentrations of the neuropeptides ( including endorphins 
and encephalins ); c) increased resting levels of cortisol (Fitzgerald, 
1991); d) increased resting levels of thyroid hormones (Keast & 
Morton, 1992); e) decreased resting testosterone level; f) increased 
insulin resistance, and; f) a decreased glucose tolerance that may 
be related to growth hormone release. ( O'Brien, 1993 ). 
Some interesting research into the role of the neurotransmitter 5-
hydroxytryptamine ( 5-HT or serotonin) which is a derivative of the 
amino acid tryptophan, and its involvement in CFS and OTS has 
been recently carried out (Newsholme, Blomstrand, McAndrew, & 
Parry-Billings, 1992; Parry-Billings, et al., 1992; & Parry-Billings, 
et al., 1993 ). Brain levels of 5-HT are thought to influence sleep 
and tiredness and has been implicated in central fatigue 
(Newsholme, et al., 1992), other functions that may involve 5-HT 
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include memory, appetite, mood, and temperature regulation 
(Behan & Behan, 1993). 
The 5-HT receptors in patients with PVFS have been shown to be 
more active when compared to a healthy control group and a 
control group with primary depression, and as such depression in 
PVFS is likely to be different from primary depression (Behan & 
Behan, 1993). Whereas in OTS researchers (Newsholme, et al., 
1992) propose that 5-HT, which is widely spread in the brain is 
involved in three main physiological functions of; a) wakefulness 
and mood, where it is thought to have a role in disturbing· sleep and 
in central fatigue; b) motor neurone excitability where 5-HT has a 
role in increasing monosynaptic reflexes and decreasing 
polysynaptic reflexes which could be involved in a reduction of 
work capacity; and c) autonomic and endocrine function where it 
has been implicated in the reduction in the release of luteinizing 
hormone (LH) and follicle stimulating hormone (FSH) which are 
used to regulate the levels of testosterone. 
2.2.8 Psychological Aspects of CFS. 
In a review of the pathophysiology of CFS conducted on 32 
research publications, Manu et al., (1992) confirmed the following 
trends found, though the cause-effect relationship is not evident. 
These trends included findings that CFS patients are more likely to 
be: a) middle aged Caucasian females, b) have a major depression 
and lifetime somatization disorder, c) may have a abnormal 
personality trait such as histrionic, schizoid or avoidance 
personalities, and ( d) have the general belief in physical causation 
of chronic fatigue. Parker (1990, p. 580) states. "Like all chronic 
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illnesses, mental ramifications of the illness [CFS] naturally occur 
and add to the debility of the disease. Extreme mood swings, 
depression, anxiety, anger, frustration and consequently low self-
esteem are common secondary aspects faced by CFS sufferers." 
She goes on to conclude that the psychological depression 
associated with CFS is reactive and as such is a symptom and not 
synonymous with CFS (see also Sect. 2.2.7). 
The psychological aspects of OTS are very similar to those of CFS 
or primary depression (Fry, et al., 1991a), with mood swings, 
depression and irritability common (Lehmann, et al., 1993; 
MacKinnon & Hooper, 1992). Moreover, the link between 
psychological stress and the immune system has been well 
documented (Fitzgerald, 1991 ). As with CFS, the cause-effect 
relationship between psychological stress and the symptoms of 
OTS is not clear. However, it is reasonable to assume that elite 
level athletes may feel extreme pressures to perform during 
particular meets. 
2.2.9 Conclusion. 
It is evident from the literature, that the aetiology of CFS (including 
OTS) is probably multi-factorial. Consequently, the psychoneuro-
immunologic (PNI) model (La Perriere, Antoni, Schneiderman & 
Fletcher, 1992) which deals with the interaction between 
psychological factors and the nervous and the immune systems 
(Figure 2.3) is an attractive model to use in the pursuit of 
understanding the dynamics of CFS. The PNI model was suggested 
by La Perriere et al., (1992) for the progression of HIV-1 and later 
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refined to include other chronic diseases (La Perriere, Ironson, 
Antoni, Schneiderman, Klimas, & Fletcher, 1994 ), 
Stressors 
i 
Increased Anxiety and 
Depression 
Acute 
Active Coping Passive Coping 
t t 
SAM activation HP AC Activation } t . 
NE and E Release Neuropeptide and 
~ Corticosteroid Release 
Immune Supp~ 
Decreased Number of Lymphocytes and NK Cells 
Decreased Lymphocyte and NK Function 
! 
Accelerated Disease Progression 
Figure 2.3: A suggested p5ychoneuroimmunologic model for stress-
related immuno-modulator effects (La Perriere, et al., 1994, p. 183. 
La Perri ere, et al., ( 1992, 1994) explain Figure 2 .3 as follows; a) 
Stressors of a physical and/or mental nature can increase anxiety 
and/or depression, and how these stressors are perceived 1s 
dependent on the psychological coping mechanism ( active or 
passive) of the individual. b) An active coping mechanism is 
generally considered adequate and in this instance the 
sympathoadrenomedullary (SAM) system is activated to release the 
catecholamines epinephrine and norepinephrine to meet the 
demands of the stress. c) Should the stressors become too much for 
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the individual by becoming uncontrollable, unrelenting or 
unpredictable, then the individual tends to withdraw and adopt a 
passive coping mechanism. d) This results in activation of the 
hypothalamic-pituitary adreno-cortical system which results in 
increased secretion of corticotropin-releasing hormone (CRH) and 
adrenocorticotropic hormone (ACTH) which in turn result in 
increased cortisol levels, which along with catecholamines is a 
known immunosuppressant. 
2.3 Physiology of Muscle Damage 
2.3.1 Overview. 
It has been suggested that muscle damage and the associated pain, 
occurs as a result of exercise involving high force contractions 
(Friden, Sjostrom, and Ekblom, 1983; Newham, Jones, Tolfree & 
Edwards, 1986; Newham, Mills, Quigley, & Edwards, 1983). This 
is particularly so when the exercise is of a novel nature or it has 
been some time since this particular type of exercise has been 
undertaken by the individual (Newham, et al., 1986). Recent 
research (Lieber & Friden, 1993) has failed to support the high 
force-damage notion, instead they propose that the damage is 
caused by active muscle strain. That is, the magnitude of the strain 
on the muscle during the lengthening process is the determinant of 
damage, not the force. Either way, damage still occurs and is 
evidenced by; a) reduced force production (Ebbling & Clarkson, 
1989; Jones & Round, 1993 ); b) increased serum levels of muscle 
proteins, (Newham, Jones, & Clarkson, 1987); and c) increased 
tenderness of the muscle and possibly central fatigue (Ebbling & 
Clarkson, 1989; Jones & Round, 1993 ). 
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2.3.2 Force Characteristics. 
Immediately following an eccentrically-induced damage bout there 
is a loss of force (isometric and concentric) in the muscle, which 
can return to pre-damage levels from 24 hours to some weeks 
depending on the level of damage (Clarkson, Nosaka, & Braun, 
1992; Ebbling & Clarkson, 1989; Ebbling & Clarkson, 1990; 
Newham, Mills, et al., 1983). This loss of force may be bought 
about due to one or a combination of the following: a) low-
frequency fatigue (LFF); b) possible fatigue, both central & 
peripheral; c) perceived pain; and d) damage within the muscle, 
which may be due to sarcomere "creep" whereby sarcomeres of 
shorter length situated at the end of myofibres, which have greater 
innate strength than longer sarcomeres situated in the middle of the 
myofibre, cause damage to these longer fibres during eccentric 
stretch (Jones & Round, 1993), therefore effectively reducing the 
cross sectional area of muscle and thus the force that can be 
applied. The first two points will be discussed in the next two 
sections dealing with fatigue and contractile properties of the 
muscle. 
2.3.3 Fatigue. 
Both central and peripheral fatigue that anses as a result of 
exercise, reduces the force that can be applied in isometric and 
concentric contractions. Conversely, with peripheral fatigue the 
level of force that can be produced in eccentric contractions may 
increase with fatigue, due to the action of metabolites at the 
crossbridge (Jones & Round, 1993). In the fatigued state peak 
power from concentric contractions decreases and moves to the left 
of the power curve which means the individual can no longer 
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maintain a similar performance level, which is of course the 
rationale behind training. Appell, Soares, & Duarte ( 1992, p. 108) 
state: "A good training status may attenuate the clinical signs of 
fatigue and muscle damage". 
Jones & Round, ( 1993) separate central fatigue into two mam 
areas; a) the sense of effort, and b) Central nervous system (CNS) 
factors. Sense of effort (Figure 4) is an area that is poorly 
understood though there are two main trains of thought. Firstly it is 
thought that a signal that originates in the motor centre, radiates to 
the area responsible for the perception of effort. The other view 
held deals with the notion that sensory receptor afferents in muscle 
provide feedback information in much the same way as 
proprioceptors do (Jones & Round, 1993), which may explain the 
increased electro myograph (EMG) activity following eccentric 
exercise bouts (Ebbling & Clarkson, 1989). Moreover, things such 
as motivation and attitude certainly effect the individual and may 
well have an effect on the individual's sense of effort. 
Motor Centre 
f 0
~f{I 
o ..-,/ I 
Sense of Effort 
a) 
Motor Centre 
0 
0 
Sense of Effort 
b) 
Figure 2.4. Possible origins of the sense of effort. a) sense of effort 
due to a collateral pathway reaching a conscious centre, b) sense o 
effort due to afferent information from the active muscle ( Jones & 
Round, 1993,p. 135) 
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CNS involvement in fatigue can be determined by the use of 
electrical or magnetic stimulation of the cerebral cortex, direct 
electrical stimulation of a peripheral nerve, or stimulation of a 
muscle by percutaneous means. All of these methods provide 
information as to the integrity of the CNS distal from the point of 
stimulation, with the use of superimposed stimulation providing 
data as to the level of central fatigue ( Jones & Round, 1993 ). 
In exercise there is an generally only overall small reduction in the 
level of ATP, therefore it is unlikely that ATP levels have much 
impact on fatigue (Jones & Round, 1993), though this may not be 
the case in CFS whereby recent research (Wong, et al., 1992) using 
31 P NMR revealed significantly lower muscle ATP levels in CFS 
subjects at peak exercise levels when compared to healthy controls. 
On the other hand changes in the pH levels in muscle which can 
reduce from a pH of 7.4 to 6.5 in exhaustive exercise which place 
significant stress on the buffering system, inhibits glycolysis; and 
in combination with increased phosphate (Pi) levels, particularly in 
the monobasic form, results in fatigue (Cady, Jones, Lynn & 
Newham, 1989). Moreover, at lower pH levels (pH 6.5) the 
sensitivity to calcium of troponin reduces. All of these factors are in 
tum associated with a reduction of 10 - 30% in maximal muscular 
force, particularly in type 2 fibres which in tum results in a 
reduction in performance. 
2.3.4 Contractile Properties. 
In · a healthy individual, prolonged repetitive activity such as 
extensive sub-maximal exercise, can result in low-frequency fatigue 
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(LFF or 20 Hz fatigue). LFF is force loss in electrically stimulated 
muscular contractions, which is greater at lower frequencies than 
higher frequencies indicating a reduced force output per action 
potential (Jones & Round, 1993). LFF most probably results from 
damage occurring at the excitation-contraction coupling ( Jones, 
Newham & Torgan, 1989), specifically at the electron dense feet 
(EDF) (Figure 2.5). These are receptors sensitive to T-tubule 
depolarisation which transduces the electrical action potential into 
a release of Ca2+ from the intracellular sarcoplasmic reticulum 
(SR). Damage to the EDF could result in a reduction of Ca2+ 
release for each action potential (Ebbling & Clarkson, 1989; Lee, 
1994 ). Because of this damage, a higher stimulation frequency is 
required to elicit the same intracellular Ca2+ induced force 
response. Thus by comparing the electrically stimulated responses 
at 20 & 50Hz, damage at the EDF can be deduced. LFF is more 
pronounced following eccentric exercise and may take up to 3-4 
days for an individual to fully recover (Jones, et al., 1989). 
Nerve Tes move along membrane of muscle cell 
EDF Sensors detect fr Muscle cell 
impulses and SR stores 
transmit signal Ca2+ 
to SR 
T-tubule 
4 Pump acts to 
, - return Ca2+ 
~ to SR 
ca2+ -+ Muscle filaments 
Nerve impulse triggers 
release of Ca2+ into muscle, 
contraction results 
Figure 2.5: Site of damage in LFF (Adapted from Lee, 1994, p.2) 
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2.3.5 Creatine Kinase Release. 
Creatine Kinase (CK) is an intracellular enzyme that as the name 
suggests is involved in the phosphorylation of adenosine di-
phosphate (ADP) to ATP (Jones & Round, 1993). Edwards, et al., 
( 1991) indicate CK is consistently found to be within the normal 
range in persons diagnosed with PVFS (Table 2.4). On the other 
hand in OTS it is sometimes reported that there is elevated CK 
serum concentration (300 UI/L) when compared to the normal 
concentration for a trained athlete (200 UI/L ), though it is possible 
that this may be due more to the effects of training, than as a 
symptom ofOTS (Fry, et al., 1991a). 
Following muscle damage the muscle cell membrane becomes more 
permeable and it results in CK being released into the interstitium 
and then into the blood via the lymph system. As a further result of 
cell membrane permeability sodium ions accumulate in the 
cytoplasm followed by an increase in cytosolic and mitochondrial 
Ca2+, beginning the process of muscle cell breakdown (Byrd,. 
1992; Knochel, 1993; Soares, Duarte, Carvalho, & Appell, 1993).). 
In severe cases this condition involving increased membrane 
permeability and resultant muscle fibre breakdown is known as 
rhabdomyolysis (Knochel, 1993; Poels & Gabreels, 1993). 
Muscle cell lysis takes place immediately following high force 
eccentric exercise, myofibrillar disn1ption occurs, histologically 
demonstrated by Z-line disruption which is often termed Z-line 
streaming (Armstrong, 1990). Three to six hours post exercise 
there is in increased efflux of intracellular proteins (CK, LDH, AST 
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and myoglobin) into the blood. This efflux generally peaks between 
2 - 5 days but in some instances may not occur until 7 days post 
exercise (Ebbling & Clarkson, 1989). 
Whilst all serum levels of these aforementioned proteins rise, CK 
has the most dramatic increase and can increase x 100 from resting 
(Jones, & Round, 1993), and is thus the most common intracellular 
marker used to confirm that muscle damage has taken place. 
However, care needs to be taken when assessing the amount of 
muscle damage based upon CK results for the following reasons: a) 
Standard spectrophotometry does not differentiate between the CK 
isoenzymes and this can result in significant under or over 
estimation of the serum concentration of CK from skeletal muscle 
( Galasso, Litin, & O'Brien, 1993 ). b) Research (Manfredi, Fielding, 
O'Reilly, Meredith, Lee, & Evans, 1991; Nosaka & Clarkson, 
1992) has shown that the level of serum CK does not correspond 
wholly to the level of skeletal muscle damage. Manfredi, et al., 
( 1991) showed that whilst there was no significant difference 
between the levels of CK attained in two separate groups, based 
upon age (20-30, 59-63 yrs), undergoing exercise-induced damage, 
there was a significant difference in damage based on electron 
(EM) and light microscopy (LM) examination, with the older 
subjects showing damage in > 90°/o of examined fibres compared 
with 5-50o/o of fibres in the younger group showing damage. In 
similar research, Nosaka & Clarkson, (1992) failed to show any 
significant difference in serum CK levels of subjects who 
underwent eccentrically-induced muscle damage in both upper 
limbs when compared to subjects who underwent damage in only 
one upper limb. 
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Figure 2.6. Summary of some mechanisms involved in the response 
of an exercise-induced injury (Almekinders & Almekinders, 1992, 
pl54). 
During the post-damage period, a senes of immunological and 
biochemical processes take place (Figure 2.6) in which muscle 
fibres that have reached a "threshold" value of damage are lysed via 
a raised intracellular Ca2+ signal that activates intracellular 
phospholipase A2 which in tum activates prostaglandins and 
leukotrienes (Almekinders & Almekinders, 1992; Armstrong, 
1990). Damaged muscle fibres are then either repaired or replaced 
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by the activation of satellite cells to provide new myofibres (White 
and Esser, 1989 ). 
2.3.6 Delayed Onset Muscle Soreness (DOMS). 
Pain is a sensation, which occurs as a result of activation of 
nociceptors by chemical (refer to Table 2.6), mechanical or thermal 
stimuli ( Jessell & Kelly, 1991 ). Following activation the threshold 
for a painful response may be lowered and the magnitude of pain 
response to a supra-threshold stimuli may increase. Thus, the 
sensation of pain following damage may be increased by these two 
avenues and this phenomenon is called hyperalgesia. Equally the 
sensation of pain may be modulated through methods such as Wall 
& Melzack's "Gate Control Hypothesis" ( cited by Jessell & Kelly, 
1991) and due to neurotransmitter involvement through 
supraspinal modulation of nociceptive transmission. 
In the "Gate Control Hypothesis" the sensation of pam 1s 
modulated as follows. Activation of Type C un-myelinated 
afferents results in activity of the projection neurons, which are 
responsible for the sensation of pain. However, simultaneous 
activation of Aa/A~ myelinated non-nociceptive afferents also 
occurs, which results in suppression of the activity of these 
projection neurons by activation of inhibitory neurons. 
Regarding supraspinal modulation of nociceptive action, Jessell & 
Kelly, ( 1991) indicate a number of points. Firstly, direct 
administration of 5-HT or norepinephrine to the spinal cord 
produces analgesia. Secondly, serotonin [5-HT] is a very common 
neurotransmitter, with norepinephrine being the neurotransmitter 
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used in a descending pathway from the pons. These points are of 
particular interest when one considers that both 5-HT and 
norepinephrine can be elevated in individuals with CFS or OTS. 
The phenomenon of DOMS, which is experienced by most people 
at some time, was first studied by Theodore Hough in the early part 
of the 20th century. Hough, (1902, p. 76) states: "When an 
untrained muscle makes a series of contractions against a strong 
spring, a soreness frequently results which cannot be regarded as a 
phenomenon of pure fatigue". In his study Hough outlined how 
pain came on eight to ten hours after extensive exercise and did not 
abate for some four to seven days. Hough was describing what we 
now know as DOMS. 
DOMS can be described as a "sensation of discomfort or pain in 
the skeletal muscles following unaccustomed muscular exertion" 
(Armstrong, 1984, p., 529), that only occurs after the first or 
second bout of novel exercise (Byrnes & Clarkson, 1986 ). The time 
course ofDOMS is from 1 to 7 days with the first phase being the 
development of a sensation of stiffness and painful skeletal muscles 
in 24 to 72 hours following novel exercise, that can result in a 
reduction in both voluntary effort and the contractile capacity of 
the muscle, which usually subsides within 5 to 7 days post-exercise 
(Armstrong, 1984 ). The aetiology of DOMS is unclear though it is 
related to over-use of the muscle concerned and is thought to occur 
as a result of high-tension structural damage, though as Byrnes & 
Clarkson, ( 1986, p. 60 5) state: "Damage in itself: however, will not 
always result in pain. There are numerous myopathies such as 
muscular dystrophies, myotonic disorders and most congenital 
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myopathies in which muscle damage is evident but no pain is 
found". Lastly, whilst DOMS follows a similar time course as CK 
release in novel exercise there is no significant relationship between 
DOMS and CK release (Byrnes, Clarkson & Katch, 1985), rather 
the mechanism behind DOMS is thought to involve the 
accumulation of the histamine, kinins and potassium in the 
interstitium in the area of group IV un-myelinated afferent fibres 
(Armstrong, 1984 ). 
Table 2.6 
Some of the naturally occurring agents that activate or sensitise 
nociceptors. 
Substance 
1. Potassium 
2. 5-HT 
3. Bradykin 
4. Histamine 
5. Prostaglandins 
6. Leukotrienes 
7. Substance P 
Source 
Damaged cells 
Platelets 
Plasma kiniriogen 
Mast cells 
Arachidonic acid-
damaged cells 
Arachidonic acid-
damaged cells 
Primary afferent 
Enzyme involvement 
Tryptophan hydroxylase 
Kallikrien 
Cyclo-oxygenase 
5-Lipoxygenase 
Substances 1 - 4 activates primary, and 5 - 7 sensitise primary 
afferent fibres 
(Modified from Jessell & Kelly, 1991, p. 387). 
43 
2.3.7 Morphological Changes & Time Course of Recovery. 
Morphology, a term which is sometime used synonymously with 
anatomy, is the study of the structure of living organisms (Martin, 
1992). Whereas sub-cellular Z-band disruption is the major 
morphological change that occurs in skeletal muscle following 
eccentric exercise, no changes are evident after concentric exercise 
when the muscle is actively shortened (Newham, McPhail, Mills & 
Edwards, 1983 ). 
A brief review of some research undertaken into human muscle 
damage follows. Friden, Sjostrom, Ekblom, (1981) conducted 
research into delayed onset muscle damage (DOMD) via electron 
microscopy and histology on muscle biopsies taken from human 
soleus 2 weeks prior to, and 2 & 7 days post an eccentrically-
induced damage bout. They found no cellular level changes, 
determined by the absence of ischaemic fibre necrosis or fibre 
rupture. However, sub-cellular morphological changes were 
evidenced by frequent focal disturbances originating from Z-line 
disruption, being most evident 2 days post-exercise by a factor of 3 
: 1 when compared to pre-damage and 7 day post-damage muscle 
biopsies. Later research (Newham, et al., 1983) showed that the Z-
line disruption that occurs following eccentric exercise does not 
occur following concentric exercise, and unlike Friden et al., 
( 1981 ), they concluded that sub-cellular damage continues to 
develop after 2 days post-damage and not during the exercise 
period as previously thought. Jone~, Newham, Round, & Tolfree, 
( 1986) conducted a morphological study into eccentrically-induced 
muscle damage with muscle biopsies being taken at a time when 
CK response was expected to peak (4 to 8 days post-damage), 14 
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days post-damage, and 20 days post-damage. The biopsies taken 
when CK was expected to be at its peak generally show little 
morphological changes, however the biopsies taken 14 days post-
damage generally show small degenerating fibres, increased acid 
phosphatase activity, increased cellular infiltration, and 
regenerating fibres, with the Type 2 fibres being more severely 
affected than Type I fibres. The biopsy taken on day 20 showed 
muscle that was predominantly recovered or recovering. This led 
Jones et al., ( 1986) to conclude several things. Firstly, whilst CK is 
a marker for muscle damage it cannot be used to judge severity of 
damage as CK had returned to normal by approximately day 8 
post-damage however the peak of myofibre damage had not been 
reached and would not occur until about day 14 post-damage. 
Secondly, cellular infiltration was seen as a response to damage 
and not the cause, with the increase in acid phosphatase activity 
indicating that macrophages make up the majority of infiltrators. 
2.3.8 Conclusion. 
High force exercise results in a degree of skeletal muscle damage. 
This damage is more evident from exercise involving eccentric 
contractions, and can be determined by various factors including: 
a) force characteristics; b) cellular enzyme efllux, c) DOMS, and d) 
morphology. Whilst damage is involved in altering each of these 
parameters, they do not follow the same time course of change, 
consequently causal relationships between any two parameters, 
such as CK release and DOMS cannot necessarily be drawn. 
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2.4 Methodological Rationale 
Eccentric contractions result in the most noticeable damage to 
muscle (Ebbling & Clarkson, 1989) and thus are commonly used 
in studies of muscle damage and regeneration. The histological and 
immunocytological evidence suggests that eccentric damage is a 
useful research parallel to the immunological actions that occur in 
inflammatory myopathies ( Jones, et al., 1986; Jones & Round, 
1993) and which may occur with CFS. The use of 20 : 50 Hz 
tetanic stimulation will indicate the presence of damage at the EDF 
of the subjects, and thus provide evidence as to the state of the 
contractile properties of the muscle. Further, in conjunction with 
muscular force characteristics, biochemical indicators of gross 
damage, such as CK LDH, AST and myoglobin, are used to 
determine that skeletal muscle damage has actually taken place 
(Atwell, McNaughton, Gorringe, and Kaufman, 1991). In this 
research serum CK alone was used as the biochemical determinant 
for the following reasons: a) The muscle specific isoenzyme 
CKMM represents 98% of all CKMM found in the body (Painter, 
Cope, & Smith, 1994); b) it is only this isoenzyme that will change 
as a result of skeletal muscle damage; c) it is the most common 
method used by other researchers, and; d) the other enzymes offer 
no other advantages. In conclusion, serum CK is consistently found 
to be within the normal range (Table 3) in persons diagnosed with 
PVFS (Edwards, et al., 1991 ), and is thought to be elevated in 
persons with OTS only as a result of acute training overload (Fry, 
et al., 1991 b ). It then follows that it is reasonable to utilise these 
factors, as any elevation of serum CK in the subjects will be as a 
result of eccentrically induced muscle damage, and the time taken 
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for CK to return to normal ranges will indicate the time course of 
the degenerative stage during the recovery from this damage. 
2.5 Summary & Conclusion 
CFS and OTS are complex and debilitating conditions that have 
many similar symptoms, in particular profound fatigue and 
myalgia. The similarities in symptoms has led many researchers 
(Eichner, 1990; Fitzgerald, 1991; Fry et al., 1991a, 1991b; Gross, 
1992; Keast & Morton, 1992; Lehmann, et al., 1993; Parker, 1990; 
Parker & Brukner, 1994) to feel that OTS may be a sub-condition 
of CFS. The presence of myalgia in CFS that is unrelated to 
ongoing damage, unlike myalgia that occurs with inflammatory 
myopathies (Jones & Round, 1993), it is possible that damage and 
recovery characteristics of skeletal muscle in patients with CFS 
(including OTS) are affected by having a lower "threshold" to 
damage and thus may be damaged easier, and if the immune 
system is depressed may be slower to repair. Early diagnosis and 
knowledge of a muscular site of action in CFS and thus OTS 
increases the possibility of prevention in CFS/OTS and a further 
step in the elucidation of this disease, making a diagnosis more 
positive and enabling overtraining to be objectively discovered prior 
to its catastrophic phase. 
2.6 Theoretical Framework 
Through the use of eccentric muscle damage and by monitoring 
markers of the damage, such as intracellular proteins, force 
characteristics, and the time course of recovery, it is proposed that 
any differences in muscle regeneration dynamics between subjects 
with CFS/OTS and subjects without symptoms of CFS or OTS will 
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be defined. A diagrammatical representation of the theoretical 
framework of this thesis is shown in Figure 2.7. 
Changes in 
Serum CK 
High Force 
Eccentric Exercise 
+ 
_..------ CFS 
Skeletal Muscle~ 
Control 
Changes in 
Isometric 
Force 
Changes in Changes in DOMS 
Dynamic LFF 
Force 
Figure 2. 7. Theoretical framework of the thesis. 
48 
CHAPTER3 
METHODOLOGY 
3 .1 Design of the Study 
The research utilises quasi-experimental design of an untreated 
control group with pre-test and post test (Bums and Grove, 1993). 
A diagrammatical representation of the design is shown in Table 
3.1. 
Table 3.1 
Untreated control group with pre-test and post-test 
Subjects Pre-test 
1 - CFS patients yes 
2 - Healthy' Controls yes 
3 - Healthy Controls yes 
3 .2 Subject Sample 
Intervention Post-test Number 
damage 
damage 
control 
yes 
yes 
yes 
n=8 
n = 10 
n=7 
Recruitment of 25 subjects was undertaken. From these 25 subjects 
three experimental groups were formed of; Chronic Fatigue 
Syndrome (CFS)+ eccentric damage n = 8, Control Damage (CD) 
+ eccentric damage n = 10, and Control (ND)+ no-damage n = 7, 
as shown in Table 3.1. 
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The subjects of the study were a convenience sample selected via 
responses from an advertisement (Appendix B) placed in the local 
press for volunteer subjects who had been diagnosed as suffering 
from CFS or PVFS, and from Edith Cowan University student and 
staff response to a flyer distribution (Appendix C). Though the 
subjects are a convenience sample, the subjects who volunteered 
for the control groups were randomly assigned to CD and ND 
groups. 
Subjects that presented with CFS confirmed that they had been 
diagnosed with CFS, or as with CFS3 Fibromyalgia, by a General 
Practitioner (GP) or Specialist. In addition CFS subjects were 
requested to voluntarily complete an additional questionnaire 
(Appendix D) regarding their illness that provided information on: 
a) the longevity of their CFS; b) whether heavy bouts of exercise 
were implicated in their CFS; c) the presence or not of myalgia, 
and; d) what, if any medications were being taken by the subject, 
so that known effects of medications being taken could be 
accounted for. 
3 .3 Time Course of Data Collection 
The commencement of data collection was staggered over a 7 week 
period. This was in line with subject response, and to allow 
sufficient time for each subject to attend on 11 occasions over the 4 
week time course of the study . Consequently the time course of the 
data collection was a 11 week period with key dates shown below; 
1. 4.10.94 commencement of pilot study 
2. 11.10.94 commencement of actual study 
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3. 7 .11. 94 completion of pilot study 
4. 12.12.94 completion of actual study 
3.3.1 Pilot Study. 
Due to the possibility of a hyper-immunological response following 
the eccentric damage bout in the patients with CFS, a pilot study 
was undertaken with a subject diagnosed with PVFS so as to 
establish what minimum, exercised caused, damage bout protocol 
was required. The damage bout of the pilot study consisted of 2 x 
10, & 1 x 5 sets of maximal isokinetic eccentric contractions of the 
non-dominant forearm flexors at 90°sec-1, with the limb passively 
returning at a velocity of 15°sec-l, and a 1 minute rest break 
between each set giving a work-rest ratio of 1 : 4. The damage bout 
protocol for the main study was subsequently amended to 7 x 5 
sets of maximal isokinetic eccentric contractions at 90°sec-l, with 
the limb passively returning at a velocity of 15°sec-l, and a 2 
minute rest break between each set. The 1 : 4 work-rest ratio, with 
2 minute rest breaks between sets, was adopted in order to 
minimise fatigue and enable the subjects to perform the isokinetic 
eccentric and concentric tests in a fatigue free state. 
3 .4 Instruments 
The instruments used in data collection were as follows: 
Cybex 6000 Isokinetic dynamometer (Cybex INC, N.Y.); 
Force Chair and restraining straps; 
Tensiometer-strain gauge (fixed length); 
Goniometer; 
Preacher bench ( 45°); 
IBM Microprocessor; 
Digitimer Stimulator DS7; 
Thandor 170C pulse generator; 
Tubigrip bandage; 
Carbon compound electrode pads (3 x 6 cm); 
Electrode get 
Spectrophotometer (Reflotron); 
Isotonic saline; 
Eppendorf 5 ml tubes; 
Micro pipette; 
Medi swabs; 
Cotton wool balls; 
CK reagent carrier strips; 
Data test sheet; 
Pain proforma; and 
CFS information questionnaire. 
3.4.l Instrument Reliability. 
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Prior and post all of the testing sessions conducted over the 4 week 
period of the research, all instruments in use, where necessary ( ie 
Cybex, tensiometer, spectrophotometer), were calibrated for 
measurement. The calibration for the Cybex and spectrophotometer 
involved internal systems, whereas the tensiometer required manual 
calibration. Procedures and results of the tensiometer calibration 
are shown in Appendix E. 
The Cybex 6000 (Cybex, INC, N.Y.) is software driven and has a 
published system error of < I o/o for force, angle and angular 
velocity. Research on previous models (Sapega, Nicholas, Sokolow, 
& Saraniti, 1982) has shown Cybex error to be ± 1 °/o at full scale 
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( 488Nm). Measurement of each muscular contraction on the Cybex 
should be fatigue free and exhibit a coefficient of variance of < So/o 
between repeated measurements. The subjects were seated on the 
preachers bench and located adjacent to the Cybex in the same 
position for every testing session by recording, and emulating 
subject position at pre-test, positioning being the major cause of 
error in isokinetic dynamometry. 
The force chair and tensiometer ( strain gauge) were used to obtain 
maximal isometric forces and percutaneous isometric tetanic 
stimulation ratios. The subject was secured in the force chair in the 
same position for each test, this was achieved by recording the 
subject position at pre-test and ensuring that same positioning for 
all subsequent tests. The strain gauge was calibrated on a weekly 
basis, with an error of< 1 % (Appendix E). 
Dual plasma CK levels were measured on a Reflotron 
spectrophotometer (Boehringer & Mannheim) calibrated by 
reagent strip and with a published accuracy of± 5°/o within a range 
of; 9.8 - ca. 600 International Units/Litre (U/1) (25°C), 16.1 - ca. 
900 U/1 (30°C), 24 - ca. 1400 U/1 (37°C). For [CK] > 1400 U/1 
serial dilution with isotonic saline are required, where A = XAM 
[ AM = measured activity; A = plasma activity; and X = dilution 
factor]. 
3.4.2 Instrument Validity. 
The validity of isokinetic dynamometry conducted in vivo 1s 
reduced due to activation of stabilising muscles, the use of a 
preachers bench will help to isolate the forearm flexors (see Figure 
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3 .3) to some extent and the results will be as valid as possible with 
peak torque, total and peak work being least affected (Kannus, 
1994). 
The subject was restrained in the force chair (Figure 3.1) with 
sideways movement reduced as much as possible, though as with 
Cybex some stabilising musculature would be activated. The strain 
gauge which is of full bridge manufacture with dual 4 x 120 ohm 
resistance, was calibrated on a weekly basis with known weights 
and returned a error of< 1 o/o. 
CK activity falls in serum stored at; + 4°C : 2% after 7 days, +25° 
C : 2% after 24 hours. Chemical reagents on the carrier strip used 
to quantify CK levels are specific to all CK's (Braun, H., P ., 
Deneke, U., & Rittersdor( W. 1987). 
3.5 Testing Protocols 
3.5.1 Training. 
To avoid any anomalies due to an unawareness of expectations, 
prior to testing all the subjects ( control & experimental) were 
familiarised with the equipment and procedures used in the 
research. 
3. 5 .2 Serum Crea tine Kinase. 
Plasma CK concentration was established as follows: a) 30 µL 
mixed venous blood samples were taken following lancet finger 
prick from the index finger of the non-dominant hand, in 
accordance with the protocols for taking blood samples outlined by 
Minikin, ( 1991 ). b) The blood was then placed on to the red zone 
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of the reagent strip, ensuring that the pipette did not touch the 
reagent strip. c) The reagent strip was then placed into the 
spectrophotometer for analysis (Appendix A for assay protocol). d) 
As the need arose (CK> 1500 UI/L) the spectrophotometer would 
return a Dilute message, in this case a fresh sample of blood was 
then taken and serial diluted with a set quantity of isotonic saline 
with a zero concentration of CK, 30 µL samples of the diluted 
mixture was then placed on to the red zone of the reagent strip, 
again ensuring that the pipette did not touch the reagent strip. This 
whole process, including serial dilution as required was completed 
in less than 3 minutes per test. 
3.5.3 Isometric Strength. 
Isometric strength of the non-dominant forearm flexors, as 
measured by peak force was determined by 1 isometric MVC of 5 
seconds duration (Sale, 1991) as follows: a) The non-dominant 
arm was held in the sagittal plane, with approximately 90° of 
flexion at the elbow with the humerus held horizontally. The angle 
of flexion of the elbow was then measured by goniometer and 
recorded onto a test-sheet (Appendix F) so as to enable subsequent 
isometric MVC's testing to be undertaken at the same degree of 
flexion as at pre-test. b) A fixed length tensiometer was attached 
to the wrist ( distal styloids ), and a pre-set weight was placed at the 
same site so as to remove any slack from the tensiometer (see 
Figure 3.1). c) The subjects completed isometric MVC's and peak 
forces were measured from a strain gauge force transducer utilising 
an analog to digital converter in an IBM PC and using a Status-30 
(Version 2.07) computer software package, results were then 
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r e c o r d e d  a n d  t r a n s p o s e d  o n t o  t e s t  s h e e t  a s  w e l l  a s  E x c e l  5  
s p r e a d s h e e t  f o r  l a t e r  a n a l y s i s .  
F i g u r e  3  . 1 .  S u b j e c t  p o s i t i o n i n g  w i t h i n  t h e  f o r c e  c h a i r .  
3 . 5 . 4  L o w  F r e q u e n c y  F a t i g u e .  
L o w  f r e q u e n c y  f a t i g u e  ( 2 0  :  5 0 H z  r a t i o )  o f  t h e  b i c e p s  b r a c h i i  w a s  
m e a s u r e d  w i t h  t h e  s u b j e c t  s i t t i n g  i n  t h e  f o r c e  c h a i r  (  s e e  s e c t i o n  
3 . 5 . 3 ) .  T h i s  w a s  c a r r i e d  o u t  a t  t h e  s a m e  g e n e r a l  t i m e  t h a t  t h e  
i s o m e t r i c  f o r c e s  w e r e  t e s t e d  a n d  w a s  d e t e r m i n e d  b y  c a r r y i n g  o u t  4  
t e t a n i c  s t i m u l a t e d  i s o m e t r i c  c o n t r a c t i o n s  a t  e a c h  f r e q u e n c y  (  4  x  
2 0 H z ,  4  x  5 0 H z ) .  T h e  f r e q u e n c y  o f  s t i m u l a t i o n  w a s  c o n t r o l l e d  b y  a  
T h a n d o r  1 7 0 C  p u l s e  g e n e r a t o r .  T h e  s t i m u l a t i n g  p u l s e s  w e r e  
p r o d u c e d  b y  a  D i g i t i m e r  S t i m u l a t o r  ( D S 7 ) ,  w i t h  a  p u l s e  w i d t h  s e t  
a t  5 0  m i c r o s e c o n d s .  T h e  i n t r a m u s c u l a r  n e r v e s  w e r e  p e r c u t a n e o u s l y  
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s t i m u l a t e d  b y  2  c a r b o n  c o m p o u n d  e l e c t r o d e s  ( 3  x  6  c m ) ,  s m e a r e d  
w i t h  e l e c t r o d e  g e l  a n d  t h e n  p l a c e d  a c r o s s  t h e  m u s c l e  b e l l y ,  a n d  
h e l d  i n  p l a c e  b y  a  l e n g t h  o f  t u b i g r i p  ( F i g u r e  3 . 2 ) .  
F i g u r e  3 . 2 .  P o s i t i o n i n g  o f  e l e c t r o d e s  f o r  2 0 : 5 0  H z  s t i m u l a t i o n  
P r i o r  t o  t h e  2 0  :  5 0  H z  s t i m u l a t i o n ,  a m p e r a g e  t h r e s h o l d  t h a t  t h e  
s u b j e c t  c o u l d  e n d u r e  w a s  e s t a b l i s h e d  a s  f o l l o w s :  a )  1  H z  t w i t c h e s  
w e r e  g i v e n ,  e v e r y  5  s e c o n d s  w i t h  t h e  a m p e r a g e  b e i n g  i n c r e a s e d  b y  
2 5 / 1 0 0 0  o f  a n  a m p  e a c h  t w i t c h .  b )  T h e  c u r r e n t  w a s  i n c r e a s e d  u n t i l  
t h e  s u b j e c t  i n d i c a t e d  t h a t  t h e  d i s c o m f o r t  w a s  b a r e l y  t o l e r a b l e .  c )  A t  
t h i s  t i m e  t h e  a m p e r a g e  w a s  r e d u c e d  b y  5 0 %  a n d  2 0  :  5 0  H z  
p e r c u t a n e o u s  s t i m u l a t i o n s  w e r e  g i v e n  a n d  t h e  s u b j e c t  q u e s t i o n e d  a s  
t o  t h e  c o m f o r t  l e v e l  o f  t h e  s t i m u l a t i o n .  d )  T r i a l  2 0  :  5 0  H z  
s t i m u l a t i o n s  w e r e  t h e n  g i v e n  t o  t h e  s u b j e c t  w i t h  t h e  l e v e l  o f  
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amperage being increased by 25/1000th of an amp per test until the 
subject indicated the level of maximal tolerance. e) For 
percutaneous stimulation to be effective at least 10°/o and 
preferably 30°/o of the isometric MVC was required. f) The pre-test 
amperage level was used during subsequent testing, though it was 
found with a majority of CFS subjects that additional amperage 
was required to elicit sufficient muscle contraction ( see Chapter 4 
on results). 
3.5.5 Isokinetic Concentric Force. 
Dynamic forces measured were; isokinetic concentric peak torque 
(PT) in Newton metres (Nm) that was reached in any of the 3 
MVC's, and average peak torque (AT) in Nm, of the 3 x 1 sets of 
MVC's (Sale, 1991). Measurements were taken from the 3 
isokinetic concentric MVC's of the forearm flexors at an angular 
velocity of l 50°sec-I using Cybex 6000 as follows: 
a) With the shoulder fixed at 45° flexion by utilisation of the 
preacher bench, the dynamometer axle was positioned at the centre 
of rotation of the elbow, and the lever arm attached to the wrist 
( distal styloids ). 
b) Three (3) concentric MVC's were made through a range 
of motion (ROM) of 130° at an angular velocity of l 50°sec-I 
(Figure 3 .3) c) All force signals were raw signals, digitised and 
recorded in "real time" onto an IBM PC. 
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F i g u r e  3 . 3 .  S u b j e c t  p o s i t i o n i n g  f o r  d y n a m i c  f o r c e  m e a s u r e m e n t ,  
a n d  d a m a g e  p r o t o c o l .  
3 . 5 . 6  D e l a y e d  O n s e t  M u s c l e  S o r e n e s s  ( D O M S ) .  
P a i n  w a s  d e t e r m i n e d  b y  p a l p a t i o n  o f  t h e  d a m a g e d  b i c e p s  b r a c h i i  
w i t h  a  O  - 1 0  r e s p o n s e  a s  t o  t h e  s u b j e c t i v e  l e v e l  o f  p a i n  b e i n g  g i v e n  
b y  t h e  s u b j e c t ,  w i t h  O  =  n o  p a i n ,  a n d  1 0  =  v e r y ,  v e r y  p a i n f u l .  T h e  
l o c a t i o n  o f  t h e  p a i n  w a s  r e c o r d e d  o n t o  a  g r i d  p r o f o r m a  ( A p p e n d i x  
G )  a n d  t h e  r e s p o n s e  r e c o r d e d  o n t o  E x c e l  5  s p r e a d s h e e t .  
3 . 5 . 7  D a m a g e  P r o t o c o l .  
A f t e r  5  m i n u t e s  t o  a l l o w  f o r  r e c o v e r y  f r o m  a n y  f a t i g u e  t h a t  m a y  
h a v e  o c c u r r e d  a s  a  r e s u l t  o n  i s o m e t r i c  a n d  c o n c e n t r i c  t e s t s ,  s u b j e c t s  
f r o m  t h e  C F S  a n d  C D  g r o u p s  u n d e r w e n t  m u s c l e  d a m a g e  b y  
c o m p l e t i n g  3 5  m a x i m a l  v o l u n t a r y  i s o k i n e t i c  e c c e n t r i c  c o n t r a c t i o n s ,  
a t  9 0 ° s e c · l .  T o  m i n i m i s e  f a t i g u e  a n d  e n a b l e  s u b j e c t s  t o  c o n s i s t e n t l y  
p r o d u c e  h i g h  f o r c e s  t h e  l i m b  w a s  p a s s i v e l y  r e t u r n e d  a t  a  v e l o c i t y  o f  
l  5 ° s e c · l ,  g i v i n g  a  w o r k - r e s t  r a t i o  o f  1  :  4 ,  a n d  t h e  c o n t r a c t i o n s  w e r e  
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divided into 7 sets of 5 with a 2 minute recovery between sets 
(Figure 3.3). 
3.5.8 Testing Schedule. 
Measurements of force were conducted pre-damage and on day + 
1, + 2, + 4, + 6, + 8, + 12 and then every four days for 4 weeks. 
LFF and Pain were measured at every testing session until they had 
returned to base line ( approximated in Figure 3 .4 ), and again at 
post-test 28 days post-damage. Serum CK was measured at every 
testing session. The majority of subjects had not fully recovered 
isometric or dynamic forces by the scheduled end of data 
collection, and some isometric and dynamic force data was 
collected after this point. This is discussed at length in Chapters 4 
&5. 
Pre-Test + 1 +2 +4 +6 +8 + 12 + 16 +20 +24 +28 
CK * 
Pain * 
LFF * 
Isometric * 
Forces 
Dynamic 
Forces 
* 
Eccentric * 
Forces 
* * * * * * * * * 
* * * * * 
* * * * * * * * 
* * * * * * 
* * * * * * 
Figure 3.4: Testing schedule matrix 
* 
* 
* 
* 
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3.6 Data Analysis 
For convenience the hypotheses being tested are reproduced below. 
1. After damage, the muscle force characteristics of subjects 
with CFS will be different from the CD group. 
2. After damage, the contractile properties of skeletal muscle 
as determined by the level of low frequency fatigue, will 
differ in subjects with CFS when compared to the CD group 
3. The time course of serum CK efflux, and the serum CK 
concentration in subjects with CFS will be different from the 
CD group. 
4. The time course of delayed onset muscle soreness (DOMS) 
during recovery in subjects with CFS will be different from 
the CD group. 
5. The degree of DOMS in subjects with CFS will be different 
from the CD group. 
Data analysis was conducted using Statistical Package for Social 
Sciences (SPSS) for Windows Version 6.0. Hypothesis 1, 2 & part 
of 3 were analysed by repeated measures two way analysis of 
variance (ANOVA) with group x time interactions used to detect 
any significant difference benveen the groups and their response 
over time. Simple contrasts were used if results were significant. 
Part of hypothesis 3 and hypothesis 4 & 5 were analysed by 
Students independent t-test. In all cases the probability level at 
which significance difference was accepted was set to < 0.05. 
Throughout the time course of the data collection, either due to 
illness of subjects or instrument malfunction, some data points 
were missed. Subsequent procedures of using prior knowledge or 
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mean values for the treatment of missing data points were adopted 
(Tabachnick & Fidell, 1989). All raw data is shown in Appendix 
H. Results are described in text quoting Q values only, F values and 
full statistical findings are shown in Appendix K. 
3.7 Limitations 
1. The level of muscle pain is subjective. 
2. Due to repeated testing it is possible that some training effect 
may occur. 
3. The presence of neuropsychiatric dysfunction, and prescribed 
drugs in CFS subjects may result in less than maximal efforts 
in the testing and damage sessions. 
4. Total CK is measured, not CKMM specifically. 
3.8 Assumptions 
1. The subjects diagnosed as suffering from CFS, actually have 
CFS. 
2. The subjects will perform the eccentric, isometric and 
concentric tests to the best of their ability. 
3. That the subjects will not alter their levels of activity 
throughout the period of data collection. 
4. That changes in total CK will .predominantly come from 
skeletal muscle. 
3.9 Ethical Considerations 
In healthy people the damage that occurs to muscle as a result of 
exercise is a fact of life. On evety occasion a muscle is contracted it 
is likely that some micro-damage occurs. In this study the subjects 
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perceived damage as delayed onset muscle soreness (DOMS), the 
details of which is covered in Chapter 4 & 5. 
This study attempts to ascertain the time course of recovery from 
experimentally induced muscle damage in people diagnosed with 
CFS by measuring force and pain. The subjects were able to 
withdraw from the study at any time without prejudice. All of the 
CFS subjects completed an additional questionnaire regarding their 
illness (Appendix D). The University policy for the conduct of 
ethical research involving humans (Committee for the Conduct of 
Ethical Research, 1994) was strictly adhered to and all of the 
subjects were made fully aware of any potential risks involved in 
the study, and informed consent (Appendix I) was obtained. The 
names and addresses of the subjects were kept confidential, with 
subjects only being identified by subject number, with master list 
and control sheets kept under lock and key by the principal 
investigators. 
63 
CHAPTER4 
RESULTS 
4.1 Physiological Data 
The physiological aspects of subjects from the three groups are as 
follows, Chronic Fatigue Syndrome (CFS) + eccentric damage 
(Table 4.1 ), Control Damage (CD) + eccentric damage (Table 4.2) 
and Control (ND)+ no-damage) (Table 4.3). 
Table 4.1 
Physiological Qarameters of subjects diagnosed with CFS (n = 8}. 
Subject Age Gender 
CFSl 29.5 
CFS2 48.6 
*CFS3 48.2 
CFS4 41.8 
CFS5 36.8 
CFS6 16.4 
CFS7 45.1 
CFS8 24.0 
Mean 36.3 
± SD 11.9 
Male 
Male 
Female 
Male 
Female 
Female 
Female 
Male 
Mass Height 
(Kg) (cm) 
63.9 169 
65.6 168 
130.0 155 
89.0 179 
48.7 157 
62.0 166 
59.6 161 
79.0 193 
74.7 168.4 
25.5 12.3 
* Subject diagnosed with fibromyalgia 
Iso. 
Race Diagnosed MVC 
Cauc. 1993 
Cauc. 1992 
Cauc. 1987 
Cauc. 1993 
Cauc. 1994 
Cauc. 1991 
Cauc. 1986 
Cauc. 1993 
(N) 
165 
214 
222 
329 
174 
175 
189 
237 
213 
53 
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4 .1.1 Additional Data CFS Subjects. 
Of the 8 CFS subjects, 2 (CFS2 & CFS5) indicated that they 
regularly underwent heavy training bouts, with CFS2 training and 
participating in marathons, and CFS3 training for triathalons. Due 
to the high volumes of training known to occur in these sports, 
overtraining cannot be discarded from an involvement in the 
pathogenesis of CFS in these two subjects. CFS3 also indicated a 
overtraining diagnosis in the additional questionnaire completed, 
however due to the physiological make up of the individual, the 
presence of the "Modem" or parasympathetic form of OTS is 
questionable. 
Six of the subjects were taking some form of supplement with 
multivitamin, iron, calcium, vitamin C and glutamine supplements 
being taken. Three subjects were under current prescription 
medications: a) CFS2 Keflex, antibiotic for a urinary tract infection 
(UTI); b) CFS4 Anatranil, anti-depressant, and; c) CFS7 Aropax 
20, microgynon 50. 
Five of the subjects (CFSl, CFS2, CFS3, CFS4, & CFS7) indicated 
that they do suffer from CFS induced myalgia in the limbs from 
time to time but all indicated that at the time of undergoing the 
eccentrically-induced damage bout none of these subjects was 
suffering from the effects of myalgia in the upper limbs. 
Table 4.2 
Physiological Qarameters of CD subjects (n = 10). 
Subject 
CDl 
CD2 
CD3 
CD4 
CDS 
CD6 
CD7 
CD8 
CD9 
CD10 
Mean 
±SD 
Age 
21.3 
26.3 
29.8 
27.3 
24.8 
19.4 
31.8 
19.0 
37.3 
35.3 
27.2 
6.4 
Gender 
Female 
Male 
Male 
Female 
Female 
Female 
Male 
Male 
Female 
Male 
Mass Height 
(Kg) (cm) 
58.7 162 
82.2 188 
81.6 184 
60.7 163 
56.2 159 
61.3 170 
71.6 176 
95.0 185 
57.8 166 
83.3 171 
70.8 172.4 
13.8 10.4 
Race 
Cauc. 
Cauc. 
Cauc. 
Cauc. 
Cauc. 
Cauc. 
Cauc. 
Cauc. 
Cauc. 
Cauc. 
Iso. 
MVC 
(N) 
220 
282 
368 
229 
210 
146 
243 
305 
236 
302 
254 
62 
65 
Table 4.3 
Physiological Qarameters ofND subjects (n = 7}. 
Subject 
NDl 
ND2 
ND3 
ND4 
ND5 
ND6 
ND7 
Mean 
± SD 
Age 
35.4 
26.0 
30.6 
22.3 
22.2 
23.5 
25.5 
26.5 
4.9 
Gender 
Female 
Female 
Male 
Male 
Female 
Male 
Male 
4.2 Data Exclusion 
Mass Height Race 
(Kg) (cm) 
52.8 163 Cauc. 
65.4 178 Cauc. 
66.5 170 Cauc. 
67.3 177 Cauc. 
53.7 162 Asian 
81.6 185 Cauc. 
73.3 176 Asian 
65.8 173.0 
10.2 8.4 
Iso 
MVC 
(N) 
187 
207 
312 
367 
207 
329 
287 
271 
70 
66 
Of the 25 subjects, all data was excluded from analysis for 3 
subjects (CFSl, CFS3, & ND2) and partial data from 2 subjects 
(CFS5 & CD9) for the following reasons. 
Subject CFSl took part in the pilot study and as such received a 
different damage protocol. Consequently analysis of any data 
obtained from this subjects would be inappropriate. Subject CFS3 
presented with fibromyalgia, and though individuals with 
fibromyalgia are considered to be no more susceptible to 
eccentrically induced muscle damage than are healthy people 
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( Jubrias, Bennett, & Klug, 1994 ), this disease has many shared 
symptoms with CFS including myalgia and fatigue, and is so 
similar that is considered to overlap with CFS (Goldenberg, 1994 ). 
AB a consequence of the similarities of CFS to fibromyalgia this 
subject was subsequently accepted for the study, however, CFS3 
failed to damage following eccentric bout, as illustrated by CK and 
force analysis. Serum CK did not exceed 86.1 (UI/L) throughout 
the time course of the study, and isometric force which although 
reduced to 93.So/o of pre-test values 4 days post damage, reached 
113.5% of pre-test values by 8 days post damage. ND2 failed to 
attend for any sessions after pre-test. 
CFSS & CD9 both withdrew from the study due to illness 16 days 
post damage, far enough advanced to have returned to base line in 
LFF, DOMS and CK, though dynamic and isometric forces had 
not. Consequently, CK, DOMS and LFF were used in data analysis 
and force data excluded. 
4.3 Isokinetic Eccentric Torque 
Though not strictly a post damage test, it became evident during 
data collection that the level of eccentric torque produced by the 
CFS group reduced at a faster rate, and reduced further, than the 
control-damage group. This was evidenced by the CFS group 
torque output declining to 59 .1 % ( ± 1. 8o/o SEM) in the 7th set of 
the mean fresh value (1st set), compared to a mean 84.8°/o (± 3.5% 
SEM) in the 7th set in the CD group (Figure 4.1 ). Data was 
normalised to minimise individual variance and analysed by 
Students independent t-test. The results revealed a significant 
difference between the CFS and CD groups during the 3rd through 
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to the 7th set of eccentric contractions, with p < 0.05 in the 3rd set 
and p < 0.001 in the 4th to the 7th sets. 
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Figure 4.1. a) Isokinetic eccentric torque (normalised to pre-test) 
produced during damage bout, 7 sets of 5 maximal contractions at 
90° /sec -1. Values (means± SEM) are expressed in percentages of 
pre-test. Significant difference between CFS and CD groups p < 
0.05 (3rd set), p < 0.001 (4-7th sets). b) Isometric eccentric torque 
(NM) raw data. Values (means± SEM) are expressed in NM. 
* Indicates significant p < 0.05 
** Indicates significant P < 0.001 
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4.4 Serum Creatine Kinase 
Hypothesis 3 proposed that the time course of CK efflux and the 
concentration of serum CK would be different between the CFS 
and CD groups. This hypothesis was partially satisfied, in that, the 
serum CK concentration was significantly different, whilst the time 
course for CK efflux did not differ. Serum creatine kinase efflux 
peaked in the CFS & CD groups 4 days post damage with a peak 
mean of 8388 ± SEM 1224 (UI/L) in the CFS group and a peak 
mean of 2583 ± SEM 753 (UI/L) in the CD group. As expected the 
ND group serum CK levels remained constant. Serum CK levels 
began to diminish after day 4, returning to normal levels ir.i the CFS 
& CD groups by 12 days post-damage. 
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Figure 4.2. Serum creatine kinase values over the time course of the 
study. Values (means± SEM) are expressed in UI/L. Between 
subjects effects, significant difference between CFS and CD groups 
Q < 0.01, CFS and ND groups, Q < 0.001, 
* Indicates a significant difference between CFS and CD, as well 
as CFS and ND groups. 
** Indicates a significant difference between CFS and ND groups. 
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Following eccentric damage, serum CK was significantly higher in 
the CFS group (Figure 4.2) when compared to both control groups 
(.Q < 0.001), with simple comparison showing significant difference 
between CFS and CD groups (.Q < 0.01), CFS and ND groups (.Q < 
0.001). Within subject events with time as main the effect (.Q < 
0.001), and interaction (.Q < 0.001). There was no significant 
difference in the time course of CK efflux between the CFS and CD 
groups (Figure 4.3). 
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Figure 4.3. Time course of serum CK efflux, following eccentric 
damage bout, normalised to peak values. Values (means± SEM) 
are expressed in percentages of peak values. NS between CFS and 
CD groups. 
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4.5 Low Frequency Fatigue (LFF) 
Hypothesis 2 which proposed that, after damage, the level of LFF 
would differ, between the CFS and CD groups, was fully satisfied. 
The ratio of CFS group (immediately after the damage bout) fell to 
25.8o/o (± 11.8% SEM) of pre-test values compared to 38°/o (± 
9.2% SEM) for CD and 90.6% (± 3.7% SEM) for the ND group 
( who had only completed the concentric protocols). Refer to 
Figures 4.4 & 4.5. 
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Figure 4.4. Low frequency fatigue, 20 : 50 Hz ratios from biceps 
brachii. Values (mean± SEM ) are expressed in 20:50 Hz ratios. 
Between subjects effects, significant difference between CFS and 
CD groups, Q < 0.001, CFS and ND groups Q < 0.001, interaction 
.Q < 0.001. 
* Indicates a significant difference between CFS and CD, as well 
as CFS and ND groups. 
** Indicates a significant difference between CFS and ND groups. 
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Figure 4.5. Normalised low frequency fatigue, 20 : 50 Hz ratios 
from biceps brachii. Values (mean ± SEM) are expressed in 
percentages of initial values. Between subjects effects. significant 
difference between CFS and CD groups, 12. < 0.001, CFS and ND 
groups Q < 0.001, interaction 12. < 0.001. 
* Indicates a significant difference between CFS and CD, as well 
as CFS and ND groups. 
** Indicates a significant difference between CFS and ND groups. 
The CD group began recovery after 1 day with an increase to 
62.3% (± 8.2°/o SEM) of pre-test values 2 days post damage, which 
continued to rise to 87.8% (± 4.4% SEM) 4 days post-damage, 
93.0% (± 6.4% SEM) 6 days post-damage, from this time the 20 : 
50 Hz ratio remained relatively constant during remaining tests (8 
. 
& 12 days post damage) with a ratio of 97.8% (± 2.9°/o SEM) 28 
days post damage. Conversely the CFS group ratio continued to fall 
with 19.5% (± 14.2% SEM) of pre-test values 2 days post-damage, 
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12.7% (± 17.0% SEM) 4 days post damage, followed then by a 
gradual rise till a ratio of 85.6o/o (± 18.8% SEM) of pre-test values 
being reached 12 days post-damage, increasing to 107.5% (± 3.8°/o 
SEM) 28 days post damage. For an illustration of this reduced 
20:50 ratio in CFS subjects compared to CD subjects refer to 
Figures 4.6 & 4.7. Further examples showing 20:50 Hz ratio of2 x 
CFS, 2 x CD, 1 x ND subjects, over the time course of the research, 
are shown in Appendix J. 
It was necessary to increase the amperage of some subjects, post-
damage, to elicit sufficient contractile response, particularly in the 
CFS group where 5 of the 6 subjects required increased levels of 
stimulation compared to 1 of 10 subjects in the CD group. 
The LFF ratio (Figure 4.4 & 4.5) was significantly lower in the 
CFS group when compared to a control group (Q < 0.001). With a 
simple comparison showing significant difference between CFS 
and CD groups (Q < 0.001), and CFS and ND groups (Q < 0.001). 
Within subject analysis whereby time was the main effect (Q < 
0.001), and interaction (Q < 0.001). Data was analysed on mean 
figures (Figure 4.4), and normalised for presentation (Figure 4.5). 
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Figure 4.6. Isometric MVC and 20 Hz and 50 Hz percutaneous 
stimulation trace of CFS subject 8 days post damage, stimulation 
was given at 400 volts, square wave with 50 ms pulse width, at 
0.650 amps. 
* indicates 20Hz stimulations 
** indicates 50Hz stimulations 
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Figure 4. 7. Isometric MVC and 20 Hz and 50 Hz percutaneous 
stimulation trace of CD subject 8 days post damage, stimulation 
was given at 400 volts, square wave with 50 ms pulse width, at 
0.275 amps. 
* indicates 20Hz stimulations 
** indicates 50Hz stimulations 
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4.6 Isometric and Isokinetic Concentric Force 
Hypothesis 1 which proposed that, following damage, the muscle 
force characteristics of CFS subjects would differ from the CD 
group, was tested by isometric and isokinetic concentric force 
measurements, and was fully supported by the results. Prior to 
analysis measurements were normalised so as to minimise 
individual variance and gender differences. 
4.6.1 Isometric Force. 
Isometric forces in the CFS group fell to 57.7% (± 4.1 % SEM) of 
pre-test values 4 days post-damage compared to 82.4% (± 3.0% 
SEM) in the CD group and 97.9% (± 4.3o/o SEM) of the ND group. 
By 28 days the CFS group had recovered to 86.7~/o (± 3.7% SEM), 
the CD group 96.1 % (± 2.9% SEM) of pre-test values, and the ND 
damage group exhibited 104.9% (± 6.3% SEM) of pre-test values 
(Table 4.4). 
Two subjects from the ND group (ND4 & ND6) were at the time of 
the study undergoing upper body strength training, which in 
conjunction with any learning curve on the apparatus may account 
for the increase in isometric force to above pre-test values from 8 
days after pre-test. Similarly the strongest subject from the CD 
group (CD3) in post-test isometric MVC reached 88.5% of pre-test 
values, after peaking at 96.2% of pre-test values 12 days post-
damage. As this subject ceased previously undertaken upper body 
strength training two weeks after the pre-test damage bout, the 
resulting decrements in isometric MVC would not be accounted for 
by the damage bout alone. 
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The isometric force, following eccentric damage was significantly 
lower in the CFS group (Figure 4.8), when compared to a control 
group (Q < 0.001), with simple comparison showing a significant 
difference between CFS and CD groups (Q < 0.01) and CFS and 
ND groups (Q < 0.001). Within subject effect with time as major 
effect (Q < 0.001), and interaction (Q < 0.001). The raw data 
(Appendix H) has been normalised for presentation (Figure 4.8). 
Refer also to Table 4.4 for a percentage summary of dynamic and 
isometric force attained over the time course of data collection. 
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Figure 4.8. Normalised isometric MVC's of forearm flexors at 
approx 90° elbow flexion, pre-damage and then every 4 days for 28 
days following eccentrically induced damage. Values (means ± 
SEM) are expressed in percentages of pre-test. Between subjects 
effects, significant difference between CFS and CD groups Q < 
0.01, CFS and ND groups Q < 0.001. Within subject effects, 
whereby time was main effect Q < 0.001, interaction Q < 0.001. 
* Indicates a significant difference between CFS and CD, as well 
as CFS and ND groups. 
** Indicates a significant difference between CFS and ND groups. 
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4.6.2 Isokinetic Concentric Force 
Concentric force measurements, which were determined by using 
parameters of the non angle specific peak torque (PT) with average 
torque representing an average of the PT reached in all three sets. 
Results of these measurements are in the form of normalised pre-
test values and individually discussed in sub-sections 4.6.2.1 and 
4.6.2.2. The matters raised about subjects ND4, ND6, & CD3 in 
chapter 4.6.1 should also be considered when interpreting 
isokinetic concentric force results. 
4.6.2.1 Peak Torque (PT). 
PT values of the CFS group reduced to 53.9o/o (± 6.9% SEM) 4 
days post-damage, continued to fall to 53.3o/o (± 7.7% SEM) 8 
days post damage with a further drop to 52.1 % (± 6.7°/o SEM) of 
pre-test values 12 days post-damage. PT slowly recovered after this 
point to 77 .9% (± 6.7% SEM) of pre-test values at the end of data 
collection 28 days post-damage. On the other hand PT of the CD 
group reduced to 79.2% (± 3.7% SEM) 4 days post-damage (it is 
worth noting that CFS group only attained this approximate value 
at post-test) then slowly recovered to 89.3% (± 1.5% SEM) of pre-
test values at post-test 28 days later. PT of the ND group 
maintained± 4.2~'o of pre-test values (Table 4.4 & Figure 4.9). 
PT, following eccentric damage was significantly lower in the CFS 
group (Figure 4.9), when compared to a control group (.Q < 0.001), 
with simple comparison showing a significant difference between 
CFS and CD groups (.Q < 0.01) and CFS and ND groups (.Q < 
0.001 ). Within subject effect with time as major effect (.Q < 0.001 ), 
and interaction (.Q < 0.001). The raw data (Appendix H) has been 
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normalised for presentation (Figure 4.9). Refer also to Table 4.4 for 
a percentage summary of dynamic and isometric force attained 
over the time course of data collection. 
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Figure 4.9. Normalised isokinetic concentric peak torque that was 
attained in the 3xl contractions at 150° /sec -1 measured at pre-
damage, and then every four days post-damage for 28 days. Values 
(means± SEM) are expressed in percentages of pre-test. Between 
subjects effects, significant difference between CFS and CD groups 
Q < 0.01, CFS and ND groups Q < 0.001. Within subject effects, 
whereby time was main effect Q < 0.001, interaction Q < 0.001. 
* Indicates a significant difference between CFS and CD, as well 
as CFS and ND groups. 
** Indicates a significant difference between CFS and ND groups. 
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4.6.2.2 Average Torque (AT). 
AT results were similar to PT with an initial fall to 53.0% (± 6.5% 
SEM) 4 days post-damage in the CFS group compared to 79.5% (± 
4.1 % SEM) 4 days post-damage in the CD group. There was a 
slight recovery of AT in the CFS group 8 days post-damage (54.6% 
± 7.3% SEM)) followed by a further drop in AT 12 days post-
damage (54.0°10 ± 6.5% SEM)), followed by a slow recovery of AT 
peaking at 77.0% (± 5.5% SEM) 28 days post-damage. Which, as 
with PT, was the same level of force loss attained by the CD group 
4 days post-damage. The ND damage group as expected 
maintained pre-test values ( ± 5 .1 °/o ). Refer to Table 4.4 & Figure 
4.10. 
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Figure 4.10. Normalised isokinetic concentric average torque, 
average of the 3xl contractions at 150° /sec ·1 measured at pre-
damage, and then every four days post-damage for 28 days. Values 
( means ± SEM) are expressed in percentages of pre-test. Between 
subjects effects, significant difference between CFS and CD groups 
Q < 0.001, CFS and ND groups Q < 0.001. Within subject effects, 
whereby time was main effect Q < 0.001, interaction Q < 0.001. 
* Indicates a significant difference between CFS and CD, as well 
as CFS and ND groups. 
** Indicates a significant difference between CFS and ND groups. 
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AT, following eccentric damage was significantly lower in the CFS 
group (Figure 4.10), when compared to a control group (Q < 
0.001 ), with simple comparison showing a significant difference 
between CFS and CD groups (Q < 0.001) and CFS and ND groups 
(Q < 0.001 ). Within subject effect with time as major effect (Q < 
0.001), and interaction (Q < 0.001). The raw data (Appendix H) 
has been normalised for presentation (Figure 4.10). Refer also to 
Table 4.4 for a percentage summary of dynamic and isometric 
force attained over the time course of data collection. 
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Table 4.4. 
Summary of isometric (MVC) and concentric results (PT & AT) at 
pre-test then every four days for 28 days from the CFS (n=5), CD 
(n=9) & ND (n=6) groups, normalised values± SEM in brackets. 
Test Isometric Peak Torque Average Torque 
CFS CD ND CFS CD ND CFS CD ND 
Pre- 100 100 100 100 100 100 100 100 100 
test ( 0) ( 0) ( 0) ( 0) ( 0) ( 0) ( 0) ( 0) ( 0) 
+4 57.7 82.4 97.9 53.9 79.2 97.4 53.0 79.5 98.7 
(4.1) (3.0) (4.3) (6.9) (3.7) (4.1) (6.5) (4.1) (4.4) 
+ 8 65.7 87.7 105.6 53.3 80.3 95.8 54.6 82.6 94.9 
(2.9) (2.6) (3.8) (7.7) (3.6) (2.8) (7.3) (3.0) (2.8) 
+ 12 71.4 88.2 106.2 52.1 82.9 97.4 54.0 82.9 99.0 
(5.5) (1.9) (4.3) (6.7) (2.7) (5.6) (6.5) (3.1) (4.7) 
+ 16 76.0 91.8 109.2 64.4 83.2 95.8 62.7 84.5 97.3 
(6.4) (2.8) (3.0) (9.2) (3.1) (2.3) (9.8) (3.3) (2.3) 
+ 20 76.4 93.4 110.6 69.3 86.l 100.0 67.6 87.3 100.4 
(6.7) (2.8) (4.2) (6.3) (3.3) (4.2) (7.3) (3.3) (3.2) 
+ 24 83.6 95.1 106.6 73.0 87.5 99.7 69.5 88.7 100.2 
(6.1) (2.2) (5.3) (6.7) (2.9) (3.4) (6.2) (2.6) (2.7) 
+ 28 86.7 96.1 104.9 77.9 89.3 96.3 77.0 91.3 99.2 
(3.7) (2.9) (6.3) (6.7) (1.5) (2.9) (5.5) (2.6) (3.1) 
82 
4.8 Delayed Onset Muscle Soreness 
Hypothesis 4 which proposed that the time course of DOMS would 
be different between the CFS and CD groups was rejected, for the 
following reasons. The time course of DOMS, determined by the 
number of sites, where pain was indicated by the subject during 
palpation of the damaged biceps brachii (Figure 4.11, see also 
Appendix E), was similar in both CFS and CD groups. DOMS was 
felt at a mean of 8.3 (± 3.2 SEM) sites in the CFS group and 9.7 (± 
1.8 SEM) sites in the CD group on after 1 day, with a peak of CFS 
group 19.5 (± 1.6 SEM) and CD group 19.4 (± 1.5 SEM) 2 days 
post-damage. D01\1S in terms of location then subsided_ and was 
totally gone by day 8 in all subjects. Statistical analysis using 
Students independent t-test showed that there was no significant 
difference in the time course of DOMS, between the CFS group 
and the CD group. This homogeneity of DOMS time course can be 
clearly seen in Figure 4.11. 
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Figure 4.11. Number of indicated sites (m~e-cimum 30) of DOMS in 
the biceps brachii of CFS and CD subjects following eccentric 
damage bout. Values (means± SEM) are expressed in the average 
number of sites. NS between groups. 
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The degree of DOMS was represented by the mean score of the 
intensity, rated between O (no pain) and 10 (very, very painful), of 
pain at the sites as indicated by the subjects during palpation. 
Figure 4.12 shows that the intensity of DOMS was less in the CFS 
group with a mean peak of 2.5 (± 0.7 SEM) occurring 2 days post-
damage in the CFS group, and 4.3 (± 0.7 SEM) occurring 4 days 
post-damage in the CD group. Statistical analysis using 
independent samples T-test shows that the degree of DOMS was 
significantly less 6 days post-damage in the CFS group when 
compared to the <;::D group (.Q < 0.05). Therefore, the results 
attained supported hypothesis 5 which proposes that the degree of 
DOMS following eccentric damage, between the CFS and CD 
groups would differ. 
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Figure 4.12. Intensity of DOMS as given by the average value from 
all sites tested, each site attributed a value of between O - 10 (0 = 
no pain, 10 = very, very, painful). Values (means ± SEM) 
expressed as an average. Asterisk indicates significant difference 
between CFS and CD groups at 6 days post-damage, .Q < 0.05. 
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4.9 Summary 
The results gained in this research, as they occurred in a general 
chronological order showed: a) A significant reduction of isokinetic 
eccentric torque produced by the CFS group. b) a LFF ratio which 
was significantly lower, and retained for a longer period in the CFS 
group. c) DOMS, with the only difference being in the intensity of 
DOMS in the CFS group, which perhaps surprisingly was 
significantly lower. d) Serum CK activity, whereby the CFS groups 
had significantly higher serum concentration as a result of 
eccentrically induced damage. e) Isometric and isokinetic 
concentric force measurements (PT & AT) force which were 
significantly reduced as a result of the damage in the CFS group. 
CHAPTERS 
DISCUSSION 
5.1 Introduction 
The purposes of this study are to establish whether differences 
exist in muscle force and damage characteristics, in the short 
term, following eccentrically induced muscle damage, between 
subjects diagnosed with CFS (inclusive of subjects diagnosed 
with OTS), and healthy individuals, and to determine the time 
course of recovery from this damage. 
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Differences occumng m CFS include; a greater reduction in 
isometric and isokinetic concentric force output, an increased 
serum CK activity, a greater decrease 20:50 Hz ratio, and a lower 
intensity of DOMS. 
5 .2 Isokinetic Eccentric T orgue 
The reduction in the amount of eccentric torque absorbed in the 
CFS group compared to the CD group is of special interest. 
Previous research (Kent-Braun, et al., 1993; Lloyd, et al., 1988; 
Stokes et al., 1988) has found that CFS skeletal muscle is no more 
fatigable than skeletal muscle of healthy controls. This then begs 
the questions: Is the greater relative reduction in eccentric force 
absorbed by the CFS group due to eccentrically induced damage? 
Does this infer that CFS skeletal muscle has a lower "threshold" for 
damage? Is the reduction due to central and, or peripheral fatigue? 
Or a combination of fatigue and damage? 
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Jones & Round ( 1993) indicate that in healthy fatigued skeletal 
muscle ATP levels are not significantly reduced, and therefore 
muscle ATP is not considered to be a major factor in fatigue. On 
the other hand research by Wong et al., (1992) using 31P NMR 
spectroscopy found that the level of ATP in skeletal muscle of 
patients with CFS was significantly lower at peak exercise levels, 
than that of healthy controls. They inferred that this finding is 
indicative of some oxidative metabolism defect, and as such 
glycolysis was accelerated in CFS patients. 
In conclusion whether muscle ATP is involved, and to what degree 
it is involved is a matter for conjecture for the following reasons: a) 
Eccentric exercise requires less ATP than concentric exercise; b) It 
is unknown whether the reduced level of ATP that occurred in the 
Wong et al., (1992) study would occur in the damage protocol 
adopted in this study. Electromyography (EMG) would have 
provided some evidence as to whether the reduction in eccentric 
force absorbed was due to central fatigue, damage at crossbridge 
attachments, or at the EDF ( see Chapter 5 .3 ). 
5.3 Low Frequency Fatigue 
Low frequency fatigue (LFF) which results from damage occurring 
at the EDF (Figure 2.5), is not associated with DOMS or serum CK 
activity (Ebbling & Clarkson, 1989). LFF generally begins to 
recover 24 to 48 hours post-damage, as was observed with the CD 
group (Figure 4.4 and 4.5). However, this was not the case with 
CFS subjects, who appear to have a lower threshold for LFF, in 
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that, the degree of LFF following the damage is greater, and more 
prolonged in CFS subjects when compared to healthy controls. 
The differences in the 20:50 Hz response may be due to three 
possible causes. Firstly, whilst most of the subjects from CFS and 
CD groups were observed to have had a degree of swelling 
following damage, it is possible that the oedema may disperse from 
the muscle of CFS subjects more slowly, reducing conductivity 
during the percutaneous stimulation process. Therefore, a greater 
proportion of the electric discharge was absorbed by the oedema 
rather than the muscle. However, the intensity of DOMS observed 
in the CFS and CD groups does not support this notion, in that, if 
the oedema was to disperse more slowly it would be reasonable to 
conclude that the intensity of DOMS would be higher in the CFS 
group when compared to the CD group (Chapter 5.4) as the level 
of oedema and serum CK concentration are implicated in the 
intensity ofDOMS (Clarkson, et al., 1992~ Jones & Round, 1993). 
Secondly, practical difficulties in percutaneous stimulation due to 
the placement of electrodes. However, the range in size of the 
biceps brachii across the groups was similar, and electrodes and gel 
were used universally, therefore whilst some practical error may 
have occurred, it was minimised by careful placement and it is 
unlikely to account for the marked difference between the groups. 
Thirdly, there was a greater degree of damage at the EDF. 
Certainly the absolute forces produced by the 20 : 50 Hz 
stimulations in the CFS group immediately following eccentric 
damage, through to day 8, were less than those produced by the 
corresponding stimulations of the CD group. This reduced absolute 
force production does support the notion that there is a greater 
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degree of damage at the EDF. Refer to Figures 4.6 & 4.7 (see also 
Appendix J). 
5 .4 Delayed Onset Muscle Soreness 
It is apparent from the results that DOMS in subjects with CFS is 
activated in much the same way as with healthy subjects. This is 
evidenced by the observation that little difference was noticed in 
the time course and movement of DOMS within the CFS and the 
CD groups. Therefore it would seem that the chemical activation of 
nociceptors, and removal of these chemicals, function normally in 
subjects with CFS. 
More surprisingly perhaps, was the difference in the perceived 
intensity of DOMS, whereby the intensity of DOMS in CFS 
subjects was significantly less than with the CD group. This result 
was in some ways unexpected as the intensity of DOMS is linked 
to serum CK concentrations whereby low (peak <500 U.L-1) CK 
responders to eccentric damage had significantly less pain than 
medium (peak 500 - 2000 U.L-1) or high (peak > 2000 U.L-1) 
responders (Clarkson et al., 1992). In this study the means of both 
groups had a peak> 2000 U.L·1 and similar pain intensities would 
have been expected. Furthermore, as hypochondria and histrionics 
amongst CFS sufferers has been reported (Parker, 1990; Wessely 
& Thomas, 1990) lower levels of pain may have been described as 
more severe by these individuals. 
However, as previously stated this was not supported by the 
evidence, which instead supports the notion of a higher threshold 
of pain as evidenced by a lower intensity of pain for a greater 
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amount of damage (see Chapter 5.5). What is not clear is whether 
the myalgia sometimes reported by CFS sufferers is of the same 
intensity as eccentrically-induced DOMS, and whether the 
observed lower intensity of DOMS in the CFS subjects was 
perhaps due the modulation of pain receptors. 
5.5 Serum Creatine Kinase 
The greater concentration of serum CK in the CFS group following 
damage when compared to the control groups is of particular 
interest, indicating a greater degree of eccentrically induced 
damage. Whilst it is accepted that serum CK activity is "a useful 
tool for the detection of muscle damage, since it is generally 
considered to be highly sensitive and relatively specific to muscle" 
(Dioszeghy & Mechler, 1988, p. 175), doubt remains about the 
concentration of serum CK being used as a determinant of the 
amount of damage due to the large inter-subject & gender 
differences reported in serum CK efflux (Ebbling & Clarkson, 
1989 ). Evans & Gannon, ( 1991, p. 104) state: "It is likely that 
postexercise rise in circulating CK activity is a manifestation of 
skeletal muscle damage but not a direct indicator of it". 
Therefore whilst it is interesting that mean peak of serum CK 
activity was significantly higher in the CFS group than the CD 
group perhaps of more interest is the possible cause of the higher 
level, and the ramifications for CFS patients. Research (Clarkson, 
et al., 1992) has shown that moderate (peak 500 - 2000 U.L-1) and 
high (peak> 2000 U.L-1) CK responders to eccentric damage had a 
significantly greater reduction in isometric force than low 
responders (peak <500 U.L-1). Therefore, the higher serum 
90 
concentration of CK that was evident in the CFS group (8388 ± 
SEM 1224 U.L-1) than the CD group (2583 ± SEM 753 U.L-1) in 
this study can be linked to the greater loss in isometric force that 
also occurred in the CFS group. Furthermore, the reduced absolute 
forces from 20:50 Hz stimulation that were produced in the CFS 
group when compared to the CD group (Figure 4.4 & 4.5), in 
conjunction with the increased serum CK concentration may 
indicate greater muscle damage in the CFS group. 
5.6 Isometric Strength and Isokinetic Concentric Force 
Both isometric and isokinetic concentric force measurements were 
shown to be significantly reduced in the CFS group. It is unlikely 
that peripheral fatigue is an issue with the changes that occurred in 
isokinetic concentric force following damage, as these tests only 
involved 3 x 1 MVC's at l 50°/sec·1 with a rest of 60 seconds 
between each contraction. Therefore, phospho-creatine 
regeneration which has a half time of 20 seconds would have been 
sufficient for maximal ATP usage by the contractile apparatus. 
Similarly, isometric testing which only contained one 5 second 
MVC is unlikely to be subject to peripheral fatigue. Therefore it is 
reasonable to conclude that the reduction in forces in the isometric 
and isokinetic tests was due to actual muscle damage and possibly 
an inhibitory effect of pain in conjunction with the perception of 
effort. This however does not explain the difference between the 
CD and CFS groups, and in conjunction with the changes that 
occurred with LFF it is possible that some secondary immune 
response occurred that resulted in a greater degree of damage to 
muscle tissue that resulted in a longer lasting force and strength 
loss in the CFS subjects. 
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CHAPTER6 
SUMMARY 
In the series of events that occurred following eccentric damage, 
most of the parameters used to measure these events differed 
between CFS subjects and healthy individuals, with only the degree 
of DOMS in both damaged CFS and CD groups showing no 
difference. A summary of the findings of the hypotheses being 
tested in this research follows. 
Hypothesis 1 ( after damage, muscle force characteristics of 
subjects with CFS will be different from the Control Damage (CD) 
group) was fully proved with isometric muscle force characteristics 
along with dynamic force differences being significantly different 
between the groups after the damage. Hypothesis 2 ( after damage, 
the contractile properties of skeletal muscle as determined by the 
level of low frequency fatigue (LFF), will differ in subjects with 
CFS when compared to the CD group) was satisfactorily proven by 
LFF in CFS patients having significantly greater depth, and lasting 
longer. Hypothesis 3 (the time course of serum CK efflux, and the 
serum CK concentration in subjects with CFS will be different from 
the CD group) was partially proved, in so far as the serum 
concentration of CK was significantly higher in CFS patients 
following the damage bout, however the time course of the 
increased serum CK activity was no different from the control 
group. Hypothesis 4 (the time course of delayed onset muscle 
soreness (DOMS) during recovery in subjects with CFS will be 
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different from the CD group) was not proved, in that the time 
course of DOMS in the two damaged groups did not differ. Lastly, 
hypothesis 5 (the degree of DOMS in subjects with CFS will be 
different from the CD group) was proved, in that, the degree of 
DOMS was significantly less in the CFS group when compared to 
the other damaged group. 
The evidence provided by the combination of higher serum CK 
activity, greater isometric and dynamic force losses, a longer lasting 
and greater depth of LFF, and a reduced sensitivity to DOMS, 
support the notion that CFS patients have a lower threshold of 
damage. Moreover, these data seems to indicate that a secondary 
immune response could be implicated in explanation of the 
possible aetiology of these differences. 
Finally, whilst it has been determined that there are differences 
between the CFS group and the CD group, these findings should be 
viewed with caution when applying causality, for the following 
reasons. The CD and ND controls groups by in large came from 
the Human Movement Department student body, and as such it is 
likely that they are not representative of the population that the 
CFS group was drawn from. In that, they are generally younger, 
weigh less, and by the nature of their studies, probably have a 
higher cardio-vascular fitness level. Similarly, the greater degree of 
damage that seems to have occurred in the CFS group could be due 
to the CFS condition per se, or in some cases it could be due to 
deconditioning that commonly occurs in CFS. 
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6.1 Recommendations For Future Research 
There is still much to learn in the effort to understand the aetiology, 
and, in establishing a simple diagnostic protocol for CFS. Firstly, 
further research is required into the primary and secondary 
immunological processes that are taking place in CFS subjects over 
the full damage-recovery time course. This study should also 
examine CK activity. Secondly, confirmation of the findings of 
delayed recovery from LFF needs to be examined, with perhaps a 
study involving direct nerve stimulation, thereby removing any 
problems associated with electrode positioning or from oedema. 
Finally, a comparative study between CFS and OTS subjects 
should be undertaken. All of these studies should wherever 
possible be age and sex matched. 
94 
REFERENCES 
Almekinders, L.C., & Almekinders, S.V. (1992). Immune 
functions in exercise-induced injuries. In Exercise and Disease, 
Watson, R.R., & Eisinger, M. (Eds.). (pp. 149-158). 
Boca Raton: CRC Press. 
Appell, H. J., Soares, J. M. C., & Duarte, J. A. R. (1992). Exercise, 
muscle damage and fatigue. Sports Medicine, ll (2), 108-115. 
Ann strong, R. B. ( 1984 ). Mechanisms of exercise-induced delayed 
onset muscular soreness: A brief review. Medicine and Science 
in Sports and Exercise, 1§.(6), 529-538. 
Armstrong, R. B. (1990). Initial events in exercise-induced 
muscular injury. Medicine and Science in Sports and Exercise, 
22(4), 429-435. 
Atwell, A., McNaughton, L., Gorringe, S., & Kaufman, D. (1991). 
The effects of multiple anaerobic exercise periods on levels of 
lactate, lactate dehydrogenase, creatine kinase, aspartate 
transaminase. The Australian Journal of Science and Medicine 
in Sport, 23(2), 32-36. 
95 
Behan, P. 0., & Behan, W. M. H. (1993). Chronic fatigue 
syndrome, what is it? In MacLeod, D. A. D. Maughan, R. J., 
Williams, C. Madeley, C. R., Sharp, J. C. M., & Nutton, R. W. 
(Eds.). Intermittent High Intensity Exercise (pp. 227 - 237). 
London : E. & F., N. Spon. 
Braun, H. P., Deneke, U., & Rittersdor( W. ( 1987). Test for 
the quantitative determination of CK (EC 2.7.3.2) in blood, 
serum or plasma with Reflotron®. Clinical Chemistry, 33, 988 
Burns, N., & Grove, S. K. (1993). The practice of nursing 
research conduct critique & utilization. (2nd ed.). Philadelphia 
: W. B. Saunders Company. 
Buchwald, D., & Komaroff, A.L. (1991). Review of laboratory 
findings for patients with chronic fatigue syndrome. Reviews of 
Infectious Diseases, U(Suppl. 1), S12-S18. 
Byrd, S.K. (1992). Alterations in the sarcoplasmic reticulum: A 
possible link to exercise-induced muscle damage. Medicine and 
Science in Sport and Exercise, 24(5), 531-536. 
Byrne, E. ( 1991 ). The chronic fatigue syndrome: A reappraisal 
and unifying hypothesis. Clinical and Experimental Neurology, 
~ 128-138. 
Byrnes, W. C., & Clarkson, P. M. (1986). Delayed onset 
muscle soreness and training. Clinics in Sports Medicine, .2_(3 ), 
605-614. 
1 
:I 
·I .,, 
I' 
96 
Byrnes, W. C., Clarkson, P. M., & Katch, F.I. (1985). 
Muscle soreness following resistance exercise with and without 
eccentric contractions. Research Quarterly for Exercise and 
Sport 56(3), 283-285. 
Cady, E.B., Jones, D.A., Lynn, J., & Newham, D.J. (1989). 
Changes in force and intracellular metabolites during fatigue of 
human skeletal muscle. Journal of Physiology, 418, 327-337. 
Clarkson, P.M., Nosaka, K., & Braun, B. (1992). Muscle function 
after exercise-induced muscle damage and rapid adaptation. 
Medicine and Science in Sports and Exercise, 24(5), 512-520. 
Committee for the Conduct of Ethical Research, ( 1994 ). 
Policy for the conduct of ethical research involving human 
subjects. Available Edith Cowan University: Perth, Western 
Australia. 
Dioszeghy, P., & Mechler, F. (1988). The significance of 
simultaneous estimation of serum creatine kinase and 
myoglobin in neuromuscular disease. Journal of Neurology, 
235, 174-176. 
Ebbling, C. B., & Clarkson, P. M. (1989). Exercise-induced 
muscle damage and adaptation. Sports Medicine, 1( 4 ), .208-
234. 
Ebbling, C.B., & Clarkson, P.M. ( 1990). Muscle adaptation prior 
to recovery following eccentric exercise. European Journal of 
Applied Physiology, 60, 26-31. 
Edwards, R.H. T., Newham, D. J., & Peters, T. J. (1991). 
Muscle biochemistry and pathophysiology in postviral fatigue 
syndrome. British Medical Bulletin, 47(4), 826-837. 
Eichner, E.R. ( 1991 ). Chronic fatigue and staleness. In Strauss, 
R.H. (Ed.), Sports Medicine, (2nd ed.), (pp. 207-220). 
Philadelphia : W. B. Saunders Company. 
Evans, W.J., & Gannon, J.G. (1991). The metabolic effects 
97 
of exercise-induced muscle damage. Exercise and Sport Science 
Reviews, 19, 99-125. 
Fairbanks, V.F., & Klee, G.G. (1994) Biochemical aspects 
ofhemotology. In Burtis, C. A., & Ashwood, E. A. (Eds.). 
( 1994 ). Tietz textbook of clinical chemistry. (2nd ed.) (pp. 
1974-2072). Philadelphia: W. B. Saunders Company. 
Fitzgerald, L. ( 1991 ). Overtraining increases the 
susceptibility to infection. International Journal of Sports 
Medicine, 12(Suppl. 1 ), S5-S8. 
Friden, J., Sjostrom, M., & Ekblom, B. (1981) A morphological 
study of delayed muscle soreness. Experientia, 37, 306-307. 
Friden, J., Sjostrom, M., & Ekblom, B. (1983). Myofibrillar 
damage following intense eccentric exercise in men. 
International Journal of Sports Medicine, 1(3 ), 170-176 
Fry, R. W., Morton, A. R., & Keast, D. (1991a). 
98 
Overtraining in athletes an update. Sports Medicine, 12(1 ), 32-
65. 
Fry, R. W., Morton, A. R., & Keast, D. (1991b). 
Overtraining syndrome and chronic fatigue syndrome part 1. 
New Zealand Journal of Sports Medicine, 19(3 ), 48-52. 
Fry, R. W., Morton, A. R., & Keast, D. (1991c). 
Overtraining syndrome and chronic fatigue syndrome part 2. 
New Zealand Journal of Sports Medicine, 19( 4 ), 76-77. 
Galasso, P.J., Litin, S.C., & O'Brien, J.F. (1993). The 
macroenzymes: A Review. Mayo Clinic Proceedings, 68( 4 ), 
349-354. 
Goldenberg, D.L. (1994 ). Fibromyalgia, chronic fatigue syndrome, 
and myofacial pain syndrome. Current Opinion in 
Rheumatology, .Q, 223-233. 
Gross, J.B. (1992). Chronic fatigue syndrome and the sports 
performer. Sports Health, 10(3), 25-26. 
99 
Horrobin, D.F. (1990). Post-viral fatigue syndrome, viral 
infections in atopic eczema, and essential fatty acids. Medical 
Hypotheses, J2, 211-217. 
Hough, T. (1902). Ergographic studies in muscular soreness. 
American Journal of Physiology, L 16-92. 
Jessell, T.M., & Kelly, D.D. (1991 ). Pain and analgesia. In Kandel, 
E.R., Schwartz, J.H., & Jessell, T. M. (Eds.). Principles of 
neural science (3rd ed.). New York: Elsevier. 
Jones, D. A., Newham, D. J., Round, D.A., & Tolfree, S.E.J. 
(1986). Experimental human muscle damage: Morphological 
changes in relation to other indices of damage. Journal of 
Physiology, 375, 435-448. 
Jones, D. A., Newham, D. J., & Torgan, C. (1989). 
Mechanical influences on long-lasting human muscle fatigue 
and delayed-onset pain. Journal of Physiology, 412, 415-427. 
Jones, D. A., & Round, J.M. (1993). Skeletal muscle in 
health and disease. Manchester : Manchester University Press. 
Jubrias, S.A., Bennett, R.M., & Klug, G.A. ( 1994 ). Increased 
incidence of a resonance in the phosphodiester region of 31 P 
nuclear magnetic resonance spectra in the skeletal muscle of 
fibromyalgia patients. Arthritis & Rheumatism, 37(6), 801-
807. 
100 
Kannus, P. (1994). Isokinetic evaluation of muscular 
performance: Implications for muscle testing and rehabilitation. 
International Journal of Sports Medicine, U(Suppl. 1), Sl l-
Sl8. 
Keast, D., & Morton, A.R. (1992). Long-term exercise and 
immune functions. In Exercise and Disease, Watson, R.R., & 
Eisinger, M. (Eds.). (pp. 89-120). Boca Raton: CRC Press. 
Kent-Braun, J.A., Sharma, K.R., Weiner, M.W., Massie, B., 
& Miller, R.G. (1993). Central basis of muscle fatigue in 
chronic fatigue syndrome. Neurology, 43, 125-131. 
Kirkendall, D.T. (1990). Mechanisms of peripheral fatigue. 
Medicine and Science in Sports and Exercise, 22 ( 4 ), 444-449 
Knochel, J.P. (1993). Mechanisms of rhabdomyolysis. Current 
Opinions in Rheumatology, ~(6), 725-731. 
Krupp, L.B., Mendelson, W. B., & Friedman, R. (1991). An 
overview of chronic fatigue syndrome. Journal of Clinical 
Psychiatry, 52(10), 403-410. 
LaPerriere, A., Antoni, M.H., Fletcher, M.A., & Schneiderman, N. 
(1992). Exercise and health maintenance in HIV. In Galantino 
(Ed.). (pp. 66-75) Clinical assessment and treatment of HIV. 
New York : McGraw-Hill, Inc. 
101 
LaPerriere, A., Ironson, G., Antoni, M.H., Schneiderman, N., 
Klimas, N., & Fletcher, M.A. (1994). Exercise and 
psychoneuroimmunology. Medicine and Science in Sports and 
Exercise, 26(2), 182-190. 
Lee, J. (1994). Roots of fatigue. New Scientist, 1926, 
21May, 1994, 1-4. 
Lehmann, M., Foster, C., & Keul, J. (1993). Overtraining in 
endurance athletes: A brief review. Medicine and Science in 
Sports and Exercise, 25(7), 854-862. 
Lehmann, M., Schnee, W., Scheu, R., Stockhausen, W., & 
Bachl, N. (1992). Decreased nocturnal catecholamine 
excretion: Parameter for an overtraining syndrome in athletes? 
International Journal of Sports Medicine, U(3), 236-242. 
Lieber, R.L., & Friden, J. (1993). Muscle damage is not a function 
of muscle force but active muscle strain. Journal of Applied 
Physiology, 74(2), 520-526. 
Lloyd, A.R., Gandevia, S.C., & Hales, J.P. (1991). Muscle 
performance, voluntary activation, twitch properties and 
perceived effort in normal subjects and patients with the 
chronic fatigue syndrome. Brain, 114, 85-98. 
102 
Lloyd, A.R., Hales, J.P., & Gandevia, S.C. (1988). Muscle 
Strength, endurance, and recovery in the post-infection fatigue 
syndrome. Journal ofNeurology, Neurosurgery, & Psychiatry, 
ll, 1316-1322. 
MacK.innon, L. T. ( 1994 ). Current challenges and future 
expectations in exercise immunology: back to the future. 
Medicine and Science in Sports and Exercise, 26(2), 191-194. 
MacK.innon, L.T., & Hooper, S. (1992). Overtraining: State of the 
art review No. 26. Excel,~ 3-12. 
Manfredi, T.G., Fielding, R.A., O'Reilly, K.P., Meredith, C.N., Lee, 
H.Y., & Evans, W.J. (1991). Plasma creatine kinase activity 
and exercise-induced muscle damage in older men. Medicine 
and Science in Sports and Exercise, 23(9), 1028-1034. 
Manu, P., Lane, T. J., & Matthews, D. A. (1992). The 
pathophysiology of chronic fatigue syndrome : Confirmations, 
contradictions, and conjectures. International Journal of 
Psychiatry in Medicine, 22( 4 ), 397-408. 
Martin, E.A. (Ed.). (1990). Concise Medical Dictionary (3rd ed.). 
Oxford: Oxford University Press. 
103 
McCluskey, D.R. (1993). Chronic fatigue syndrome and 
its effect on exercise capacity. In MacLeod, D. A. D. Maughan, 
R. J., Williams, C. Madeley, C.R., Sharp, J.C. M., & Nutton, 
R. W. (Eds.). Intermittent High Intensity Exercise (pp. 239-
249). London : E. & F., N. Spon. 
McGregor, N ., Butt, H.L., Zerbes, M., Dunstan, R.H., Roberts, 
T.K., & Klineberg, I.J. (1994, May). Chronic fatigue syndrome: 
A urinary biomarker. Paper presented at an international 
meeting on Chronic Fatigue Syndrome, Dublin, Ireland. 
Minikin, B. (1991 ). Laboratory standards assistance 
scheme- physiology. Requirements and recommended practices 
for laboratories conducting physiological and sports 
performance testing. Canberra : Australian Sports Commission. 
Moss, D.W., & Henderson, A.R. (1994). Enzymes. In 
Burtis, C. A., & Ashwood, E. A. (Eds.). ( 1994 ). Tietz textbook 
of clinical chemistry. (2nd ed.) (pp. 735-896). Philadelphia: 
W. B. Saunders Company. 
Newham, D. J., Jones, D. A., & Clarkson, P. M. (1987). 
Repeated high-force eccentric exercise: effects on muscle pain 
and damage. Journal of Applied Physiology, 63( 4 ), 1381-1386. 
Newham, D.J., Jones, D.A., Tolfree, S.E.J., & Edwards, R.H.T. 
(1986). Skeletal muscle damage: A study of isotope uptake, 
enzyme efflux and pain after stepping. European Journal of 
Applied Physiology, 55, 106-112. 
104 
Newham, D.J., McPhail, G., Mills, K.R., & Edwards, R.H.T. 
( 1983 ). Ultrastructural changes after concentric and eccentric 
contractions of human muscle. Journal of Neurological 
Sciences, fil., 109-122. 
Newham, D. J., Mills, K. R., Quigley, B. M., & Edwards, 
R. H. T. (1983 ). Pain and fatigue after concentric and eccentric 
muscle contractions. Clinical Science, 55-62. 
Newsholme, E.A., Blomstrand, E., McAndrew, N ., & 
Parry-Billings, M. (1992). Biochemical causes of fatigue and 
overtraining. In Endurance in sport: The encyclopaedia of 
sports medicine an IOC medical commission publication (pp. 
351-364 ). Oxford : Blackwell Scientific Publications. 
Nosaka, K., & Clarkson, P.M. (1992). Relationship between post-
exercise plasma CK elevation and muscle mass involved in the 
exercise. International Journal of Sports Medicine, 13(6), 471-
475. 
Nosaka, K., Clarkson, P.M., & Apple, F.S. (1992). Time 
course of serum protein changes after strenuous exercise of the 
forearm flexors. Journal of Laboratory and Clinical Medicine, 
119(2), 183-188. 
105 
O'Brien, M. ( 1993 ). Prevention of overtraining. In Sports injuries 
basic principles of prevention and care: Volume IV of the 
encyclopaedia of sports medicine an IOC medical commission 
publication (pp. 291-296). Oxford: Blackwell Scientific 
Publications. 
Painter, P.C., Cope, J.Y., & Smith, J.L. (1994 ). Appendix. 
In Burtis, C. A., & Ashwood, E. A. (Eds.). ( 1994 ). Tietz 
textbook of clinical chemistry. (2nd ed.) (pp. 2161-2218). 
Philadelphia : W. B. Saunders Company. 
Parker, S. (1990). Chronic fatigue syndrome and the athlete. In 
Sports Performance Through the Ages: Proceedings of 27th 
Annual ASMF Conference, 548-589. 
Parker, S., & Brukner, P. (1994). is your sportsperson 
suffering from chronic fatigue syndrome. Sport Health, 12(1), 
15-17. 
Parry-Billings, M., Budgett, R., Koutedakis, Y., Blomstrand, 
E., Brooks, S., Williams, C., Calder, S., Pilling, S., Baigrie, R., 
& Newsholme, E. A. (1992). Plasma amino acid concentrations 
in the overtraining syndrome: possible effects on the immune 
system. Medicine and Science in Sports and Exercise, 24( 12 ), 
1353-1358. 
106 
Parry-Billings, M., Matthews, V. J., Newsholme, E. A., 
Budgett, R., & Koutedakis, J. (1993). The overtraining 
syndrome: Some biochemical aspects. In MacLeod, D. A. D., 
Maughan, R. J. Williams, C., Madeley, C. R., Sharp, J. C. M., 
& Nutton, R. W. (Eds.). Intermittent High Intensity Exercise 
(pp. 215-225). London: E. & F., N. Spon. 
Poels, P.J.E., & Gabreels, F.J.M. (1993). Rhabdomyolysis: A 
review of the literature. Clinical Neurology and Neurosurgery, 
93(3), 175-192. 
Powers, S.K. & Howley, E.T. (1994). Exercise physiology: Theory 
and application to fitness and performance (2nd ed.). Dubuque, 
Iowa : WCB Brown & Benchmark. 
Rosano, T.G., & Kenny, M.A. (1977). A radioimmunoassay 
for human serum myoglobin. Method development and normal 
values. Clinical Chemistry, 23, 69-75. 
Rothwell, J. (1994). Control of human voluntary movement 
(2nd ed.). London : Chapman Hall. 
Sale, D. (1991) Testing strength and power. In MacD.ougall, 
J.D., Wenger, H.A., & Green, H.J. (Eds.). Physiological testing 
of the high-performance athlete (2nd ed.) (pp. 21-106). 
Champaign, Illinois : Human Kinetics Books. 
Sapega, A.A., Nicholas, J.A., Sokolow, D., & Saraniti, A. (1982) 
The nature of torque "overshoot" in Cybex isokinetic 
dynamometry. Medicine and Science in Sports and Exercise, 
14(5), 368-375. 
Sharp, C., & Parry-Billings, M. ( 1992) Can exercise damage 
your health. New Scientist, 1834, 15 August, 1992, 33-37. 
Soares, J.M.C., Duarte, J.A.R., Carvalho, J., & Appell, H.J. 
107 
( 1993 ). The possible role of intracellular Ca2+ accumulation for 
the development of immobilization atrophy. International 
Journal of Sports Medicine, 14(8), 437-439. 
Stokes, M.J., Cooper, R.G., & Edwards, R.H.T. (1988). 
Normal muscle strength and fatigability in patients with effort 
syndromes. British Medical Journal, 297, 1014-1017. 
Tabachnick B.G., & Fidell, L.S. ( 1989). Using multivariate 
statistics. (2nd ed.). California: Harper Collins Publishers. 
Weicker, H., & Werle, E. ( 1991 ). Interaction betweeen 
hormones and the immune system. International Journal of 
Sports Medicine, 12(Suppl. 1 ), S30-S37. 
Wessely, S., & Thomas, P.K. (1990). The chronic fatigue 
syndrome-myalgic encephalomyelitis or postviral fatigue. In 
Keynard, C. (Ed.). Recent Advances in Clinical Neurology, VI. 
London : Churchill Livingstone. 
White, T. A., & Esser, K., A. (1989). Satellite cell and growth 
factor involvement in skeletal muscle growth. Medicine and 
Science in Sports and Exercise, 21(5 Suppl.), S158-S163. 
108 
Wong, R., Lopaschuk, G., Zhu, G., Walker, D., Catellier, D., 
Burton, D., Teo, K., Collins-Nakai, R., & Montague, T. (1992). 
Skeletal muscle metabolism in the chronic fatigue syndrome: In 
vivo assessment by 31 P nuclear magnetic resonance 
spectroscopy. Chest, 102, 1716-1722. 
109 
Appendix A 
Biochemical Test Principles 
EC 2.6.1.1 Aspartate transaminase (AS1) 
It is not possible to directly monitor transaminase reactions, therefore the test principle 
used to determine AST levels is based upon quantifying the reduction of oxaloacetate 
(fanned by AST reaction) to malate in the presence of malate dehydrogenase (MD) 
2-0xogiutarate\ /L-AspartAl.e L-Malate ~ / NAD+ 
AST MD 
L-Glutamate / ~ Oxaloaeetate _-/ \ NADH 
Aminotransferase reaction 
(fonnation of oxaloacetate) 
Assay reaction 
Dehydrogenase reaction 
( quantification of oxaloacetate) 
Indicator reaction 
Moss & Henderson, (1994, p. 792) 
EC 2.7.3.2 Creatine Kinase (CK) 
CK activity is determined by the rate ofNADPH fonnation as illustrated below. 
a) 
CK 
Creatine phosphate + ADP ~ Creatine + ATP 
pH 6.7 
HK 
ATP + glucose ~ glucose-6-phosphate + ADP 
GPD 
Glucose-6-phosphate + NADp+ ~ 6-phosphogluconate + NADPH + H+ 
Moss & Henderson, (1994, p. 803) 
b) 
CK 
Creatine phosphate + ADP :::.::==~ Creatine + ATP 
GK 
Glycerol + ATP ~ glycerol-3-P + ADP 
GPO 
Glycerol-3-P + 0 2 ~ dihydroxyacetone phosphate + Hp2 
H202 + indicator (colourless) 
Braun, et al., (1987) 
POD 
~ dye + Hp 
110 
Appendix A 
Biochemical Test Principles 
Myoglobin 
Unable to distinguish between cardiac and skeletal muscle myoglobin, and is generally 
determined by radioimmunoassay, kits are available from Biomerica Inc. Newport Beach, 
CA (Fairbanks & Klee, 1994). The method development and nonnative values for 
radioinununoassay for humans is available from Rosano & Kenny, (1977). 
EC 1.1.1.27 Lactate Dehydrogenase (LD H) 
pyruvate is reduced to lactate in the presence of LDH, with the accompanying oxidation 
of NADH to NAD+ measuring the rate of absorption decrease at 339nm by 
spectrophotometer. 
CH3 
I LD 
H-C - 0 - H + NAD+ ~=pH;::;3=.3·==9.=c:3 ==..,,,_~ 
pH7.4-H 
C=O 
I 
o-
L-Lactate 
Moss & Henderson, (1994, p. 813) 
CH3 
I 
C=O+ NADH + H+ 
C=O 
I 
o-
Pyruvate 
:·.- ... 
TO BE PUBLISHED: 
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Newspaper Advertisement 
-
-
-
-
VOLUNTEERS 
WANTED 
Exercise physiology postgraduate researcher at Edith 
Cowan University's Joondalup Campus requires 
volunteers for a four-week muscle function study. The 
volunteers need to meet one of the following criteria: 
CRITERION 1: 
Preferably under 50 years of age and diagnosed with 
Chronic Fatigue Syndrome (CFS) or Post Viral Fatigue 
Syndrome 
CRITERION 2: 
Preferably under 50 years of age and in the opinion of 
the coach or athlete. has Overtraining Syndrome (OTS) 
or has been diagnosed as having OTS. 
Prospective volunteers would need to be able to attend 
the Exercise Physiology laboratory at the University's 
Joondalup Campus on 10 separate occasions over a 
four-week period to undergo muscle function testing. 
Interested parties should contact David Wright 
on telephone (09) - or after hours on 
(09)-
EDITH COWAN 
WEST AUSTRALIAN, SATURDAY, OCTOBER 22 
JOONDALUP TIMES, OCTOBER 28 
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Advertising Flyer 
Volunteers Wanted 
Introduction 
Chronic fatigue syndrome (CFS) and Overt.raining syndrome (OTS) are separate, 
complex conditions which are difficult to diagnose that have several similar debilitating 
effects, one of which is myalgia (muscle pain). This research is aimed at providing a 
diagnostic protocol for CFS and OTS. 
Subjects 
We require a total of 40 volunteer subjects for muscle damage-recovery research: 
• 10 subjects with CFS or Postviral Fatigue Syndrome (PVFS) 
• 10 subjects diagnosed with OTS, or believe they might be overtraining 
• 20 subjects without CFS, PVFS or OTS 
As a Volunteer Subject You Would: 
• Be able to attend the Exercise Physiology laboratory at Edith Cowan University 
(ECU) J oondalup campus on approximately ten occasions over a 4 week period, 
• Undergo one single bout of muscle damaging exercise on your non-dominant 
arm (biceps) which will probably result in some discomfort and reduced mobility 
m 
this arm for about 1 week, 
• Have blood samples taken on each test day, 
• Provide one urine sample, 
• Undergo strength tests both prior to and after the damaging bout, 
• Undergo non-voluntary stimulation of your biceps, 
• Undergo tests to determine the level and location of muscle pain, 
• As much as possible not change your exercise and diet patterns during this time. 
What You Can Expect Of Us 
• Be provided with a full briefing prior to, and after any test being undertaken, 
• Be treated in a respectful and informed manner. 
• Have your confidentiality respected, and 
• To respect your right to withdraw from the research at any time without question, 
Who To Contact 
Any questions or further information can be gained from David Wright on 4055553 or 
4781488 (AH) 
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Confidential 
Chronic Fatigue Syndrome (CFS)/ Overtraining Syndrome (OTS) 
Questionnaire 
Name: 
Date of Birth: 
Sex: 
Diagnosis: 
How long have you been diagnosed with CFS / OTS? 
Do you have any Post-Viral infection? if so what infection? 
If you have CFS has your condition occurred following heavy bouts of exercise? Please 
describe the level and type of activity undertaken. 
Do you presently suffer from muscle pain? If so please describe the nature and location 
of this pain. 
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Please list any prescription ~ or supplements you are currently taking. 
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Strain Gauge Calibration Procedures & Schedule. 
The aim of the calibration procedure was to convert the voltage response from the 
Status-30 program into newtons therefore it was necessary to establish the number of 
newtons per volt. 
Calibration of the strain gauge was completed using known weights, which were Cybex 
25 lb calibration weights. :tviass of these weights were confirmed to be 1) 11. 34 kg, 2) 
22.49 kg, 3) 34.02 kg by weighing each weight individually and together on high 
resolution scales. 
With the base line voltage set as near as possible to zero, the program was activated at a 
:frequency of 10 Hz for 1024 samples (102 seconds). During this time the known 
weights were hung from the strain gauge at 10 second intervals (10 sec 11.34 kg, 20 
sec 22.49 kg, & 30 sec 34.02 kg), a weight was then removed every ten seconds. 
Once the program completed its sampling, the voltage for each phase was measured 
and recorded, any base line voltage was subtracted from this figure and calculations 
made as to the number of Newtons per Volt, this conversion factor was entered into the 
program setup and details saved. 
The procedure of calibration was repeated so that the measurements in Newtons could 
be compared to the number of newtons of the known calibration weights. Calibration 
was conducted each week. 
:M:ass(kg) Newtons 
5/10/94 
11.34 
22.68 
34.02 
111.25 
222.49 
333.74 
Voltage 
0.2148 
0.4236 
0.6262 
Baseline 
0.0061 
0.0061 
0.0061 
Volts/Newtons 
0.00188 
0.00188 
0.00186 
Conversion factor 531.91 Newtons per volt, error< 1 °/o 
10/10/94 
11.34 
22.68 
34.02 
111.25 
222.49 
333.74 
0.2148 
0.4175 
0.6201 
0.0122 
0.0122 
0.0122 
0.00182 
0.00182 
0.00182 
Conversion factor 549.45 Newtons per volt, error< 1 o/o 
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Mass (kg) Newtons Voltage Baseline Volts/Newtons 
17/10/94 
11.34 111.25 0.2148 0.0122 0.00182 
22.68 222.49 0.4297 0.0122 0.00188 
34.02 333.74 0.6323 0.0122 0.00186 
Conversion factor 540.54 Newtons per volt, error< 1 % 
23/10/94 
11.34 111.25 0.2026 0.0 0.00182 
22.68 222.49 0.4053 0.00 0.00182 
34.02 333.74 0.6201 0.00 0.00186 
Conversion factor 545.46 Newtons per volt, error< 1 o/o 
31/10/94 
11.34 111.25 0.2026 0.00 0.00182 
22.68 222.49 0.4175 0.00 0.00188 
34.02 333.74 0.6201 0.00 0.00186 
Conversion factor 540.54 Newtons per volt, error< 1 % 
10/11/94 
11.34 111.25 0.2148 0.00 0.00193 
22.68 222.49 0.4175 0.00 0.00188 
34.02 333.74 0.6262 0.00 0.00188 
Conversion factor 529.1 Newtons per volt, error< 1 % 
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Mass (kg) Newtons Voltage 
19/11/94 
11.34 
22.68 
34.02 
111.25 
222.49 
333.74 
0.2148 
0.4175 
0.6262 
Baseline Volts/Newtons 
0.00 
0.00 
0.00 
0.00193 
0.00188 
0.00188 
Conversion factor 529.1 Newtons per volt, error< 1 % 
28/11/94 
11.34 
22.68 
34.02 
111.25 
222.49 
333.74 
0.2148 
0.4175 
0.6262 
0.0061 
0.0061 
0.0061 
0.00193 
0.00188 
0.00188 
Conversion factor 529 .1 Newtons per volt, error < 1 % 
5/12/94 
11.34 111.25 0.2148 0.00 0.00193 
22.68 222.49 0.4175 0.00 0.00188 
34.02 333.74 0.6262 0.00 0.00188 
Conversion factor 529.l Newtons per volt, error< 1 o/o 
12/12/94 
11.34 
22.68 
34.02 
111.25 
222.49 
333.74 
0.2026 
0.4175 
0.6201 
0.00 
0.00 
0.00 
0.00182 
0.00187 
0.00186 
Conversion factor 540.54 Newtons per volt, error< 1 % 
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Test Sheet 
General Information 
Name: Proximal 
DOB: 
Height: 
Sex: 
Mass: 
Distal 
Race: 
Cybex Arm: Cybex Height: 
CybexX: Cybex 0: 
Preacher Bench Height: Iso MVC Angle: 
Digitimer AMPS: Files: 
Test Data 
CK: 
MVCiso: 
Baseline 
20Hz: 
Baseline 
50Hz: 
BaselineD 
20: 50 
Pain: 
Concentric: 
Eccentric: 
Pain Proforma 
0 
10 
Proximal 
Distal 
Nopain 
Extremely painful 
X X 
X X 
X X 
X X 
X X 
X X 
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X X X 
X X X 
X X X 
X X X 
X X X 
X X X 
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Raw Data 
Physiological Data 
ICF1 \CF2 ICF3 CF4 iCFS ICF6 ICF7 ICF8 !CF9 CF10 )Mean !SD 
I----·- ' ' +-----~· --+---+----+------< 
~ge !
1
, 29.SJ 48.6! 48.2 41.81 36.81 16.4! 45.1: 24.0; ! 36.3! 11.9 
Ma~~~9L 63:~.L 65.61130.0 89.01 48.71 62.0J..._59.61 79.0t i 74.7! 25.5 
He!ghqcm) i 169\ 1681 155 1791 1571 166i 161 \ 192.5\ i 168.41 12.3 
Sex (Male=2) ! 2! 2! 1 2) 11 1 I 11 21 l 1 
Race icauc /cauc icauc cauc !cauc lcauc lcauc /cauc 1 i : 
Cy Arm ! 10 ! 5 l 3 8 i 3 I 4 i 4 i 11 \ , : 
19'.'.!'ex Ht i 13.751 6.00110.00! 6.00110.001 8.00! 8.001 16.001 i \ 
Cybex O I 30! 35! 341 331 33! 341 341 34! i 
CybexX i 65/ 71j 69/ 69! 711 11 O! 69/ i ! 
PBHeight I 2! 21 11 21 21 21 21 4! I I ! 
lso Angle i 66! 90! 88i 901 80! 881 83! 85! ! ! 83.8! 8.0 
Stimulation I 225/ 325i 2751 3001 2751 2001 275! 375! I I i 
.. ______ 1co1 JCD2 ~03 Jf04 j__CD5 _jCD6 _jCD7 \C08 )CD9 jCD10 \Mean jSO 
Age ! 21.3! 26.3! 29.81 27.3! 24.81 19.41 31.81 19.01 37.31 35.31 27.21 6.4 
~Mass (kg) ! 58.71 82.2l 81.61 60.7\ 56.2\ 61.31 71.6/ 95.0\ 57.8\ 83.31 70.81 13.8 
Heig_ht (cm) I 1621 188i 184i 1631 159 1 1701 1761 18Si 1661 171 I 172.4i 10.4 
Sex(Male=2) I 11 21 21 11 11 11 21 21 11 21 1 
Race icauc !cauc !cauc !cauc lcauc !cauc fcauc !cauc !cauc tcauc ! ! 
Cy Arm : 5 ! 8 i 8 i 1 / 3 i 31 5 i 8 \ 5 I 7 i 
Cybex Ht I 6.00i 6.001 8.251 6.00\ 13.75\ 6.501 6.00\ 18.00\ 9.00i 10.00\ 
Cybex O ! 321 32! 41 33) 61 O! 33! 33! 34! 33! , 
Cybex X i 69i 70i 39/ OI 36\ 351 71 I 701 701 701 1 
PB Height i 1 i 21 2i 1 i 21 1 i 11 4i 2! 2i ' 
lso AI!_gle i 65.I 82i 891 801 861 88\ 751 891 80! 80! 81.4: 
Stimulation i 250i 4001 300j 27Si 250! 250! 2751 3251 3001 250! 1 
1 
________ i_N_0_1. _lli_D2 !N03 iND4 !NOS iND6 iND7 !ND8 iND9 !ND10 !Mean iSD 
M~. I 35.4i 261 30.61 22.31 22.21 23.Si 25.5\ i I i 26.5: 
Mass (kg) j 52.81 65.41 66.5! 67.31 53.7! 81.6! 73.3! i ! I 65.8! 
Height (cm) I 153·1 1781 170! 1771 162! 185i 1761 i I i 173.0! 
Sex(Male=2) I 1! 1! 2i 2i 1i 21 2! i ! i · 
Race !cauc icauc lcauc icauc !asian lcauc lasian ! : i , : 
Cy Arm ! 5/ 7! 7! 81 3i 8) 41 1 l i 
Cybex Ht ! 8.00i 12.00i 6.00i 13.75i 14.75113.SOi 14.00i : i 1 
7.4 
4.9 
10.2 
8.4 
Cybex O ! 33! 33! 341 331 34! 33i 32\ : i ! , 
Cybex X : 68! 11 69\ 70! 69! 69i 71 [ ~--+-:---, -----1 
fB Height i 1 i 3: 2 ! 3 i 3 i 3: 3 t 1 : • 
lso Angle ! 73! 87[ 89\ 82! 871 90\ 84\ , : i 84.6i 5.8 
. ·· .···---····-·--r--·----··-·r--···-·-·-·· ···,----·- -·-i ·-···--··-- -r··-····· · ··; · ----····-- , ·-·-··· ----- -·;··--------:---·------i-----~---i·----·-· .---- ·· ··-
St1 mulat1on ! 250, 275! 350, 500; 225, 250i 275, , 1 1 ' 
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Raw Data 
Cone, Ecc 90 
Concentric ICF1 ICF2 lCF3 iCF4 ICFS ICF6 ICF7 ICF8 ICF9 ICF10 iMean 1Max iMin iSD 
~~k Tor_gu_e I 49! 43i 31 i 54! 16! 24! 19! 381 ! i 34! 54! 16i 14 I ' 
tve T.9.!:gue 44! 41! 29! s11 15[ 231 171 36i I I 32[ 51/ 15i 13 I I ' I 
Ave Power I 49\ 41 i 341 531 171 261 181 40! i i 35: 53! 171 13 ! 
Total Work ! 74! 591 51! 86! 231 33! 241 601 I ! 51) 86! 23! 23 I 
' Eccentric ICF1 iCF2 iCF3 jCF4 !CFS iCF6 ICF7 iCF8 iCF9 ICF10 !Mean !Max \Min iSD 
Peak Torque j 57i 651 421 83 28i 341 341 60i I i 501 831 281 19 
Ave Torque I 561 481 401 65 211 281 241 481 I I 411 65l 21\ 16 
Ave-Power I 581 48! 441 68, 191 30! 261 SO! I I 431 68! 19j 17 
Total Work i 89i 72i 67l 102 26i 391 35i 781 I I 63i 102i 261 27 i. 
Concentric ICD1 !CO2 ICD3 ICD4 iCD5 ICD6 iCD7 ICD8 ICD9 ICD10 fMean !Max !Min ISO 
Peak Torque ! 301 SOI 71 ! 33! 23! 28! 371 54141 I sol 42! 711 231 15 
Ave Torque I 291 471 71 I 31 231 2si 361 S3j 381 49j 401 71 ! 231 15 
;::ar~~~------l----~;1--- ~~ 1;~!--!~I-- ~;1----;;I···· :~r--~:+---:~1---- ~;r---- --:~~ 1;~1 ~;1 23 29 
Eccentric :co1 !CO2 iCD3 ICD4 !CDS [CD6 ICD7 ICD8 ICD9 /CD10 !Mean !Max /Min !SD 
PeakTor~e i 37[ 69[ 1061 461 35[ 281 so, 711 49! 691 56[ 1061 281 23 
Ave Torque I 321 611 961 401 28\ 241 481 621 431 621 501 961 241 21 
Ave Power I 32! 68! 105! 43! 26! 23/ 54! 691 461 661 53! 1051 231 25 ; 
Total Work I 46/ 971 1581 57i 491 36! 761 641 94i 781 1581 361 36 I 991 
Concentric iND1 !ND2 iND3 !ND4 iND5 JND6 \ND7 IND8 IND9 IND10 !Mean \Max \Min iSD 
Peak Torque I 271 451 61 ! 641 27! 72! 41 I I I I 48! 721 271 18 I 
2sl 
I 
62/ Ave Torque I 42t 58/ 271 701 41 I I ! I 461 701 25 17 ! I 
Ave Power i 42i 491 63! 74/ 221 79i 461 i ! i 54j 79i 22 20 I 
Total Work i 291 411 911 1041 341 1131 61 l I I I 68! 1131 29 35 I 
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Raw Data 
Eccentric Sets Data 
Set 1 
CF2 ICF4 ICFS CF6 ICF7 !CFS !Mean !Max iMin iSD I i ! 
651 83! 28 34! 34) 60! 50.7! 83i 28! 221 ! ! 
Set 2 56i 77i 24 33i 28i 571 45.81 77/ 24i 21 i I i 
Set 3 53i 71 I 20 31 ! 26.0i 54j 42.51 71 ! 20i 201 i i 
Set 4 46! 62! 19 271 22! 45! 36.8! 62! 19! 17! t j 
Set5 41 i 60\ 19 26\ 23\ 43! 35.3\ 60\ 19! 16\ ' ' 
Set6 37\ 521 18i 23i 19i 39i 31.3i 521 18/ 141 ! i 
Set 7 35J 491 18J 22! 19! 371 30.0! 491 18! 121 i I 
CD1 i CO2 I CD3 i CD4 / cos l CD6 i CD7 i CD8 ! cog ! CD10 ! Mean Max ! Min ! SD 
Set 1 35i 691 951 46i 35i 281 501 71 i 49i 691 54.71 951 28i 21 
Set2 371 651 1061 451 31) 241 501 661 421 621 52.81 1061 241 24 
Set 3 31 ! 61 ! 100! 38! 28/ 27! 49! 61 ! 46! 66! 50.7! 100! 27! 22 
Set4i 311 61i 96l 41! 28! 23\ 49! 57i 43\ 62! 49.1i 961 23! 21 
~:!~+----;~/---- ~~-/- ~~I- ;~J --;~1------;~f-- :~f -~~!----:;/- -~~+- :~:~!----~~I---;~~- ;~ 
Set 7 ! 30\ 53\ 96\ 39\ 23i 221 49\ 57\ 35! 60\ 46.4\ 961 22\ 22 
: 
1 
: i . 1 I! i ,
1 
1! ! Ii : ! I i I l l I ! 1 
i i l CF I CD i l I I ! CF ! CD ! l I i 
_ !CFS (rlCD (n ~SE !SE ! ! !CFS ((CD (riSE !SE ! ! i ! 
Set1 i 50.71 54.71 8.91 6.Si tset 1 i 100.01100.01 17.51 11.Bi : i i 
Set 2 i 45.8! 52.81 8.4i 7.4! !Set 2 I 90.3i 96.51 16.Si 13.51 i I 1 
Set 3 ! 42.51 50.7! 8.0! 7.01 !Set 3 ! 85.0I 92.6! 15.7/ 12.71 ! l ! 
Set 4 / 36.8/ 49.1 / 6.81 6.7/ !Set 4 i 72.51 89.7\ 13.4! 12.21 ! I ! 
SetSi 35.3i 48.1i 6.3! 6.51 iSetS i 69.6i 87.9i 12.4\ 11.8i 1 ! i 
Set6 I 31.31 45.61 5.5! 6.21 1Set6 I 61.71 83.3\ 10.81 11.31 ! I ! 
setT: 30.0j 46.4\ s.0 1.: 6.9j jSet 7 j 59.1 \ ~ 9.8\ 12.6\ \ \ ; 
! 1 1 , I 1 ! ! i 1 i l ! I 
\CF2 !CF4 ICFS iCF6 ICF7 !CFS isem I i ! i i i i 
Set 1 j 100! 100! 100) 100! 100! 100! 0.0! / I ! I ! 1 
Set2i 86.11 92.8! 85.71 97.1/ 82.41 95.0i 2.4! / ! i i ! i 
Set3i 81.51 85.Sj 71.4j 91.2! 76.51 90.0! 3.2i ; i i ! i i 
Set 4 i 70.8! 74.7! 67.9i 79.4! 64.71 75.0! 2.21 1 i l , i ! 
Sets! 63.1 i 72.31 67.91 76.Si 67.6/ 71.7! 1.9/ / ! 1 1 ' 
Set 6 i 56.9i 62.7i 64.3i 6_7.6i 55.91 65.0I 1.9j , i i i : 
Set?! 53.81 59.0I 64.31 64.7i 55.91 61.7! 1.8i \ i i , ' 
)CD1 !CO2 1;C03 \CD4 )CDS )CD6 jC07 )COB )CD9 !CD10 !sem \ 
Set 1 i 1001 1001 1001 100: 100: 1ooi 10oi 1ooi 100/ 100! o: : 
Set2 i 105.?j 94.2\111.61 97.8j 88.6i 85.?j 100.0j 93.0j 85.7[ 89.9j 2.71 : .... ___ __ 
set3T-aa~sr·aa·~-4!16K3rai·s1·-·-ao~orgs_·41-·g8_01--as~§i-93_9_J_9s.1!· ----2~sr ___ · , --- -
Set4 f 88.61 88.41101.1 ! 89.1 80.0I 82.1 ! 98.0! 80.3! 87.8i 89.91 2.2! 1 
~t 5 j 85.7! 87.Q.i 95.8! 82.6 77.1 i 82.1 i 94.0i 87.31__85.?i 88.4\ 1.7i : 
Set6 l 80.0I 82.61 93.7! 76.1 74.3! 85.71 90.0I 80.31 85.71 76.81 21 1 
Set7 ! 85.71 76.81101.1 ! 84.8 65.7! 78.6! 98.0ITo.3! 71.4! 87.0! 3.5! ! 
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AppendixH 
Raw Data 
Creatine Kinase Raw Data 
ICF2 _JfF4 iCFS iCF6 'CF7 ,CFS !Mean ;Max !M'm iSD i I I i i I I 
1-p""".r=-e-st-;-1--=ssT 111: 1s1 83! 53i 1061 as, 111: 531 211 , 1 1 i 1 
11 8631 2841 132• 112! 1291 1681 281i 8631 1121 2921 i : ! l i I 
21 25441 2228! 3541 249! 160! 6851 10371 2544; 1601 1065! I i i i I 
41 92401121201 ss2oi 5560! 44001 ssso1 8388! 121201 44001 2998! I i : • i ! 
6! s2011 4680i 3560i 21so1 1230! 37681 34371 s2011 12301 1499! I I I I ! i 
~i 1286i 902: 10201 602! 650.0I 19261 10641 19261 6021 491 i : I , i 1 
12i 111\ 1221 4241 1061 SOI 151 I 1771 424! so: 126! i ! I i 
16, 1331 s1: 100.oi 761 631 681 891 1331 631 261 i I I I I 
20: 129/ 1361 100.0: 671 63i 84! 97! 1361 63! 31 I i I i ! i i 
241 95i 991 100.0! 531 44! 121 J 851 121 l 441 301 I I I i I : 
28! 1891 68! 100.0! 66/ 381 861 91 I 1891 381 521 I I i i 
1CD1 !CO2 ,CD3 !CD4 1CD6 JCD6 ICD7 ICDS /CDS ;co10 !Mean !Max /Min SD I ! 
P-Test ! 101 ! 292! 1591 171 I 791 551 971 278! 641 132! 1431 292 55 841 ! 
11 · 1101 2041 245! 2221 1291 671 1291 240! 97, 2941 1741 294/ 67 761 I ! 
21 270! 2260/ 174) 81501475.00! 11101 332! 1321 4431 179/ 13531 8150 132 2476 1 i 
41 278013870.0\ 4QO.O! 78ool 5991 15481 49601 1040i 22801 4591 25831 78001 459 2379 I 
61 1300!-38701 4901 2040) 8621 3661 2456] 497! 1000.01 8841 1377! 38701 3661 1108 I 
al 7331 21s11 3881 s231 533
1
, 11s1 763! 135! ~831 s121 21s1 s2 608 1 
121 102134513681 1201 66, 127! 131 I- 1771 144! 2!ff1 187! 368 66 107 I ! 
161 86\ 2231 1~_!31 185\ 87\ 6~! 971 87\ 37' 256\ 1291 2561 37 731 I 
... -- ;~+--1:H 2i:.~n~~n:,---1~~:---· !~:1,-- -:~:--- ~f-::::11---g~1- --~ci~!----;~~f ---- ~+- ~~1- --- 1 : 281 4531 169! 1051 2731 881 44 841 61 ! 60.0 103! 1441 4531 441 1281 I i 
1----'-'-iN_D1 IND3 !ND4 JND§_IND6 fND7 !Mean _•Max .lM).!!._~:=_L __ ---1 I I I 
P-Test L~~_J_§~J___Jl~L-§.~i 369j 1581 200~1 661 1181 __ L_ I 
1 i 2041 133! 1671 80! 238, 165i 1651 238i 801 55! I I I i 
4i 1961 126! 2611 82i 166i 108! 156! 2611 821 65/ , i ! I 
21 2241 121 i 197t 113! 10! 102! 1381 224i 70 60i ! : 
' i I 
I I 
! i 
i i I 61 196.0i 96! 251 ! 701 1891 1071 1521 251 ! 701 71 i I I 
81 195! 121 i 266i 61 i 1881 831 1521 2661 611 781 i I I ! 
i I 
I i 
i 
I ! 
I ! 
12! 196i 120~1 50i 163; 188j 1451 1961 50! 54i I 
161 124, 11s: 210.01 s2I 160.ol 1411 1341 2101 s21 s21 I 
201 11~ 2oe.l~J soi 1541 3681 2031 3681 soi 1os1 I 
24/ 180.0/ 1091 2471 52.5! 175.0! 200.0/ 161 i 247/ 53! 691 ! i 
281 190! 96/ 24sr-"s5i 1931 53J 1391 245/ 531 81 ! I I 
I I i ! I ! 1 i ! I i I I ! ; 
I I • ICFS !CO JNO l i i _ __j _____ __j_ I ! I ! 
lcFs (n!CD (n ~ND (n ~se lse ise I ICFS (niCD (n =lcfse ,cdse i I I I i 
P-Test ! 88! 1431 2001 8.7, 26.51 48.1 IP-Test! 1 i 51 0.12! 3.45i 1 1 : I i 
11 2s1, 1741 1651 119.0! 24.1• 22.41 11 3! 7! 1.461 8.131 I I i i ; 
2! 10371 1353i 1381 434.7j 782.8! 24.31 2! 12/ 52! 4.92! 9.87! I ; i ' I 
41 83881 2583i 156! 1223.71 752.81 26.71 4! 100j 100.l__.!!:OOLJ~ l i ! i 
61 343.71 1377! 1si1 611.sl 350.si 28.8! 61 40L __ s~.621 10.211 i I I i 
Si 1064! 572i 152! 200.41 192.21 31.71 Si 131 221 1.361 8.40/ 1 i l ! ! 
_ __J1j 177j__187J__145i ____ 5L3/_33.9i_22.01 ___ 121 ____ 2: ... 7l 3.42i 7.141 I I I I : 
161 89i 1291 1341 10.61 23.1 i 21.31 16! 11 5L.QJ1! 3.721 i i j ! j 
20J 97'. 140\ 2031__!2.6! 22.51 43.9_~_29i__1_: __ §! 0.08! 2.94! I i ' I i 
24! 85! 109! 161 ! 12.21 19.61 28.21 241 1: 51 0.05! 3.60! i ' t 
28! __ _Jlli_ _ __!~j_-~9i _1L3.[4Q.3!33-:-1:28-I --1 r---5\ (!.25/ 2.11 i I I I _j___!f----j 
1--....=.c_,__: , ; , i I i 1 , I i ! i , 1 - i i 
iCF2 ~CF4:cF5jCF6 iCF7 !CF~ i 'CD1 'CO2 ICD3 iCD4 !cos lco6 1CD7 !COS •CDS iCD10 
P-Test i 1.06i 0.87: 0.83i 1.491 120!1.19!P-Test i 3.631 7.541 32.451 2.10/ 9.161 3.55 1.961 26.73 2.801 14.93 
11 9.33i 2.23! 1.39i 2.01 ! 2.93! 1.89i 1 ! 3.96i 5.271 50.00i 2.72! 14.97 4.33, 2.60! 23.0Sl 4.25i 33.26 
2i 27.53i 17.51 i 3.72i 4.481 3.641 7.71 ! 2: 9.71 ! 58.40! 35.501100.00i 5,.101 71.71 I 6.69 12.691 19.43i 20.25 
4;100.001100.00:100.ooi 100.ooi 100.001100.00: 4! 100.00! 100.001100.oor 95.711 69.491100.001100.001100.001100.oo, 51.92 
~ 56.281 36.791 37.40i 39.20i 27.951 42.38! 6/ 46.76i 100.00\ 100.00I 25.031100.00 23.64 49.521 47.791 43.861 100.00 
a: 13_91 i 1.osU9.11l 10.s3: 14.77! 21.66! s1 2~5.741 1s.1s1 6.421 61.83 7.431 1s.3s1 12.ss 4.04/ 32.01 
___.!lL 19.15~\---i.-1.~L~Lt!!£L L[.QI ___ 12! 3.67[__11_~!.H' 75.101 1.471 7.66 8.20 2.64! 17.02 6.32: 32.92 
16! 1.431 0.7'._~· 1.0~L 1.37! 1.431 0.7~L--1§.LJ~.76 34.291 2.27 10.09 4.46. 1.961 8.37 1.62! 28.96 
201 1.39l1.()7hj5i 1.211 1.43J 0.95i 20! 7.09! 7.!11 30.821 2.401 12.53 3.55 1.981 8.00 2.1531 20.14 
241 1.02! 0.78! 1.05! 0.951 1.0G_LJ~.1~1 2.91 ! 5.811 39.181 1.951 7.54 4.461 1.271 5.19 2.63 1 13.91 
2sl 2.04' o.53i 1.05! 1.1s1 o.s61 o.s11 2s1 16.2s1 4.371 21.42 1 3.3sl 10.211 2.841 1.6s1 5.871 2.63! 11.6s 
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Raw Data 
Low Frequency Fatigue Raw Data 
!CF2 !CF4 CFS !CFS ICF7 \CFS !Mean !Max iMin !SD i I i 
Pre-test I 74.61 70.0 77.01 73.01 76.01 52.6! 70.Sl 771 531 9! I 
lmmad PfT i 26.31 25.0 0.01 0.0i 17.01 40.81 181_\ 41 I 01 16\ I i ! 
_ 21 41.7! o.o 0.01 0.01 0.01 40.Sj 13.8) 421 01 21 l ! I i 
41 0.01 o.o o.o\ a.al 0.01 53.7! s.o: 541 01 221 I ! 1 
6! 0.01 39.7 O.O_Ll2.1 I 0.0! 48.0i 26.SL.._121 01 31 ! I I 
81 35.Si 0.0 0.01 75.01 34.401 61.41 34.4! 751 01 31 ! i I 
12! 0.0! 71.9 63.SJ 81.2\ 76.Si 69.2! 60.41 81 l 01 30! ! ! I 
161 82.0! 84.5 _l t I i 83.31 851 821 21 ! I 
201 80.61 : , I : ao.61 81! 81!#####! I i ' 
281 76.61 74.51 77.00I 77.1 ! 82.91 66.Si 75.8! 831 67! 51 I I 
ICD1 :co2 'C03 :c04 !CDS :CDS IC07 :cos :cog iC010 !Mean Max !Min SD 
Pre-test I 83.51 69.Si 79.41 77.6! 77.41 77.31 58.81 65.51 74.5~ 71.51 73.5 841 591 7 
lmmad PfT I 35.1 i 50.00I 57.11 36.0i 47.0I O.Oi 34.01 21.01 0.01 0.01 28.0 571 OI 22 
21 55.oo! 55.2! 71.81 50.0I 57.ooJ 46.0I 0.01 22.01 49.21 51.71 45.8 72\ o 20 
41 76.81 65.001 75.001 10.6\ 66.51 a2.a1 33.71 s0.3165.001 so.al 64.s 831 34 14 
61 77.00! 76.0! 79.11 43.Sj 72.31 82.00! 72.71 66.0170.00I 45.31 68.41 821 44 13 
Bl 68.001 68.001 68.001 65.0I 68.001 ao.91 7~L ss.al 74.01 67.ol sa.7 a11 ss s 
121 67.00I 67.00! 67.00l 67.00! 67.00I 67.00i 67.00! 74.3167.00I 65.0I 67.5 741 65 2 
281 74.Si 53.0i 77.41 77.61 76.81 84.0I 60.31 64.8175.00I 75.31 71.9 841 53 9 
!ND1 lND3 IND4 :ND5 iND6 IND7 iMaan 1Max !Min !SD I i 
Pre-test I 79.s: 83.5\ 80.0I 68.0\ 62.0i 64.7! 73.0\ 841 62\ 91 
lmmad PfT I 80.00! 74.8! 62.0I 69.01 53.0I 58.Si 66_.2! -8'-'0+i --5-"3+-1 --1-0+-I _ __, __ I I L.. ! 
21 81.4\ 73.9! 73.11 75.01 63.01 64.0! 71.71 81! 631 71 
41 ss.s1 1s.a1 11.21 ss.11 13.31 sa.11 11.s1 001 sa,_1 ---4'--1----
s1 11.21 79.5! 12.al s1.01 12.21 sa.sl 71.91 ao·1 671 4: 
I 
t 
I 
a1 11.21 s1.s1 73.s~.41 53.0I 11.a1 sa.s1 111 531 a1 i 1 
121 73.501 72.00! 73.21 81.0! 60.0I 74.Si 72.4! 81 ! 601 7\ I l I --
28\ 71.0L..1§:.?' 67.7! 81.91 77.81 73.Si 74.71 82i 68! S! I , ! 
1------+: __ l___: ~ i i l l I I i I : l 
1---.-! __ _j_ ICFS !CD !ND i i I I ICFS jCD IND l 
!CFS (n !CD (n =iND (n =!sa Isa 1sa ! iCFS (n :co (!!lli_D (n =!sa Isa Isa I 
P-Tast i 70.Si 73.5! 73.01 3.7! 2.3i 3.7iP-Tast I 100\ 100! 1001 5.2! 3.1 I 5.01 
1-PfT I 18.2! 28.0I 66.2! 6.Si 6.81 4.111-PfT I 25.81 38.0! 90.61 9.21 9.21 5.6 
l-'--'-:...;._--2-'---1 --'--13=.ar4s.a! 71.71 8.61 6.4! 2.8! 21 19.51 62.31 98.2! 12.1 l 8.71 3.81 
41 9.01 64.6! 71.9! 8.91 4.4; 1.7! 41 12.71 87.81 98.4! 12.6 5.91 2.31 
8! 34.41 68.7! 68.8! 12.51 2.0l 3.41 81 48.71 93.4, 94.21 17.7, 2.11 4.6! 
121 60.4\ 67.Si 72.4!1i.31 0.71 2.7! 12! 85.61 91.81 99.1 I 17.4 0.1; 3.61 
61 26.6\ 68.41 71.91 12.Si 4.21 1.71 Si 37.7\ 93.0! 98.41 17.8\ 5.71 2.31 
28i 75.8! 71.9! 74.7! 2.1 i 2.91 2.01 281 107.Sj 97.8! 102.3! 2.91 3.91 2.71 
I ! ! 1 i \ Isam ' i , I ! 
Pre-test i 100.01 100.0j 100.0\ 100.0LJ..QQ_,QJ 100.0! O: 1 ! i I I 
lmmad PfT ! 35.31 35.7! 0.0! O.Oi 22.41 77.6! 11.Si i i I 
21 ss.s1 0.01 o-:or- o.o! o.o! 77.6 14.3, ! i 1 1 i 
41 0.0! 0.01 0.01 0.0! O.Ol 102.1 rn ! I I I ! 
61 0.0! 56.7! 0.01 98.81 0.01 91.2 19.3! I i i I ! 
Si 48.0! 0.0! 0.01102.7, 45.31 116.7 20.2' ! i , : 
12! 0.0! 102.7! 82.6! 111.2! 100.81 131.6 18.8\ i I I i • 
28! 102.7\ 106.4; 100.0\ 106.4! 109.8) 126.4 3.8i l , i I I 
iCD1 !CO2 !C03 !CD4 !CDS !CDS CD7 [COS iCD9 ICD10 Isam ' i 
Pre-test I 100.01 100.Q! 100.01 100.01 100.0I 100.0 100.0i 100.01100.0! 100.0! O.Ol ; 
lmmad PfT j 42.01 71.81 71.9! 46.4! 60.7! 0.0 57.8! 32.11 0.0! 0.01 9.2: , 
21 65.9! 79.3! 90.41 64.4l 73.61 59.5 0.01 33.6! 66.0i 72.31 8.21 I 
_____ 4~.! 93.4i 94.~91.0\ 85.91 107.1 57.3! 92.1 ! 87.2\ 69.9! 4.41 1 
6\ 90.71 109.2! 99.61 56.11 93.41 106.1 123.6! 100.81 94.01 63.4\ 6.41 i 
Bi 90.7\ 97.7! 98.6! 83.81 96.0! 104.7 122.~! 99.3\ 93.7! 3.Sj ! 
121 90.71 96.3i 98.6! 86.31 96.0I 106.o 112.01 113.4! 99.ol 90.91 2.9! I 
281 89.2( 76.1 ! 97.Sl 100.0i 99.2\ 108.7 102.6i 98.91 99.0! 105.31 2.91 i 
iND1 IND3 !N~DSIND6:ND7 sam ! iCFS(rlCD (n=IND (n=6) I 
Pre-test I 100.0! 100.0I 100.01100.0! 100.0I 100.0 0.0!P-Tast I 100.0! 100.0! 100! 1 
lmmad PfT 1100.601 89.61 77.51101.51 85.51 90.4 3.711-PfT l 28.Si 38.31 91 I 
21 102.41 88.51 91.41110.31 101.61 98.9 3.21 - 21 22.3! 60.5! 991 
41 87.9! ss.sl asm_io1.s1 11a.21 105.3 4.6! 1LJ.LQ.: a1 .. -"-ot· ---'1-'-00~1 ____ 1__ 
61 89.61 95.2! 91.0I 91!:fil_ 116.51 106.0 4.21 61 41.1r--s--i7 991 ! 
a1 s1.11 a1.31 s1.s1102.1, as.s1 111.0 4.s1 al s2.1'""': -9=7_-3+-1-...,..ss~1---+----+i-1 
121 92.301 86.201 91.5! 119.1' 96.81115.3 5.s: 12! 88.21 98.91 1001 I 
2a1 89.31 s1.sl 84.s1120.4:12s.St113.6 7.2' is: 1oa.s: 97.7! 1041 
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Raw Data 
Pain 
1D 1 ! I I ,D Si 61 61 51 5 10 I I i lD I i , ! '0 I ! , ' 1 ID! ID ! ! ! ;O 
IE ! I i I iE i ' i i 51 51E ! Si 81 Si 81 81E I ! I i ,E ' : I I !El 1E ! ! ! IE 
IF I , I 41F I i i ! 6! 6/F ! 8_ 8 8 8! 8!F I I I 2' I IF I i I I !F: iF ! i iF 
c;02 i 11 2 ! 31 41 5 i 11 2 i 3 I 41 51 I 1 I 21 3 4 i 5: ! 1 ! 21 31 41 5 i i 1 i 21314 ! 5 i i 1 1 11 2 i 3 l 4 5; 
!A , l I i !A i I i I i IA I I l :A I I j ! I IA , : l i 1 !A; CF:A I 2! ! : iA 
,s I i I i i 18 i i 4i 51 41 '8 I ! I \ 618 i I I I I ,s ! i I ' i iBi 18 i 1 i I I I iB 
!C l t 1 re I I I Si s: 1C i 6/ 6iC ! r l ; :c ! ! 10 1 j 'Cl IC i f i !C 
----ro I t ! I ! iD ! J ! 4! 4! !Q. ~ l ) 6/ 6! 6iD ! ! i i t 1D ! ! ! ! ! iOi iD ~ I l i 1 !D 
--t?-f--+-h-31----lt~+~+-~HKH+?-~J-&{H-{-t?l---+----I--{ n-~!H-~ I H-lfi---i? I ,- -:--+ ~:f-
c03 i 1 i 2 j 31 4 ! 5 i i 11 2 i 3 i 41 51 i 1 2 i 3 i 41 5 I 1 1 i 2 I 3 I 4 51 ! 1! 2 ! 3 i4 I 5 i i i i 11 21 3; 4 ! 5 i 
IA ' ! ' I ' !A ' 21 31 3, 2; 2,A , , / I 'A: I ! 2' ,A ' ! ! I I IA, CFJA / I 41 41 4, /A 
18 I- I I i iB I I I I I 18 ! , I I 18 I I I I IS i I I I i 181 18 I I 11 11 11 iB 
IC , 1 I I 'C I 31 41 41 3i 31C I I I I ! !CI I i I IC ! I 01 I iCI :C I ; I : ! IC 
~Q I I I I ID I 51 51 SI 51 510 I I 81 SID I i l I !D ' ! i I_ ID! tD I 1 21 21 2' iD 
iE ; 1 i i iE , 51 Si 5, s1 s,E , ; , s s1 s1E, , 1 1 iE ; 1 1 1 iEi ,E i 21 21 21 4i 21E 
1F 1 31 2: 2 31 3!F 1 41 41 41 s 1 s:F i I s1 s 1 s1F ! , 1 1 :F , ; : 1 :F • ,F , 21 31 31 3! 3/F 
CD4 i 11 21 31 41 51 I 11 21 31 41 5! ! 11 2 3 41 Si I 11 21 31 41 51 ! 11 21314!51 i i i 1/ 21 31 41 Si 
A I I i I IA I 31 31 41 41 SIA i 2 ! !A I I 21 31 3 JA_j__i _LU !Al C~A I I I I I ,A 
B I I I I 218 I I I I ! 818 I i 18 I ! 3! 21 2 iB l i ii 1181 'B I I ! I 1 !B 
__&_, 1 i ~
1 
1 
3
:g : ! : ~! si sic I I i 2: 2: 3!C I i 1 2, 21 21c 1 1 :01 ,c, 1c , , 1 : : ,c 
ID I 31 3,1 31 51 4, 8,D D, I 2i if !D I I I ! i :D! ID / ! i I / iD 
__J_E 1 41 41 4 41 41E I I 41 51 i SIE I 2 21 2! 21E ! ; I 31 31 iE ! I i I , IEJ.__j_E i i i 1 ; 2'E 
iF , 41 41 4 41 41F I 41 41 3! 31 S!F I 4 31 31 i SiF I i 3! 31 I 2!F-, ! I I ! iFi iF I I I i ' 1:F 
CD6 I 11 21 3 41 SI I 11 2! 3! 41 51 I 1, 2 31 41 51 i 11 2! 3! 41 5 1 ' 11 21314151 I ' I 11 21 31 41 Si 
,A 1 ' i IA 1 : I I i ,A , i i IA i i I i ' iA : ! i 1 1 iA: CFSA 1 ! I 1 i 1 !A 
18 1 I I 31 31 18 I 1• 11 11 1! 18 I 11 1! 11 1' 18 I ! I I I 18 I I ! i 191 !8 ! I 11 11 1! !8 
,C I I I 21 I IC i l 21 21 i IC I 1 2 2! 1 'CI ! ' 21 2· !C 1 : 101 1 tC! 1C I I l 1 ' •C 
~D I i I 21 ! ID I Si 4i 41 51 SID I 5 41 41 4! SID I I i I :o ' I I ! ' 101 :D i ! 11 1' ; 10 
iE i 21 21 2i 21 2iE i 41 51 61 5! 51E I 41 5! 51 51 5iE I I I i I !E I i I i I 1E1 'E I ! i , : IE 
C06 i 11 2t_~I 4i 51 i 11 2! 31 4! 5i I 11 21 3! 4! Si ! 1, 21 31 41 51 i 1i 21314:s: I I I 11 2! 3! 41 51 
JA i
1 
__ i_ _______ L .1 __ 1A L 1_1 ___ J_ 1___1 ,A LI I i\A __ 
1
1 ___ _1
1
_
1
_;
1
, -11 _____ JA_)_t _____ /1_1,,A1 __ cF~_A --~ 21 J _ _: _ _:_ _J_~--
IB : i 11 ! 18 I 1f ! i I iB I I I fi:B, 1, 11 18 ' ! i 1 ! ,Bl 18 1 11 ! 1 ' 18 
JF 1 2! 2i 21 2! 2!F 1 2: Si 8i 8/ SIF l 2 8, 8 s: SiF i i I , I iF i ! i l IF i iF I i 11 2i IF 
iC i i ! 31 , iC i 11 , , i iC i i i i : IC i 1 1 i 1 i 11 iC 1 , iOI i 1Ci &._j__l ! ! :c 
,o i , 1 , 10 1 1, 1, 1: 1, 2,0 , 1 , 1, 1: 10 1 ! 11 1: 11 ,o , 1 1 : 1 ,o; :o : 1 1 , ' o 
!E i I I I , IE ! I ! , I IE I ! I 1 i 1 I iE I i 11 1 i 1 ! iE I i ! I i iE: iE ! I i i IE 
IF I i I I \F ! 31 i i I 3iF I 1 I i IF I I ! I IF ; I i i !Fl :F I 1 ' i ' ,F 
CD7 i 11 21 31 41 SI ! 11 2! 31 41 51 I 1 2 31 4! Si I 1 ! 21 3, 4 51 ! 11 2,314!51 , 1 I 1 ! 21 3! 4! 51 
!A i : I i I IA I I I i ! IA ! I I i IA I I ! I iA i I I I I :Ai CFiA l ! i I i iA 
,B ! ! 51 5i 51 IB I 51 61 6! 61 !B 1 I 1 ! ' iB' ' ! / 'B ! I : i 'Bi !B I i 1i 1l 1l !B 
IC I i I 61 i IC i 51 71 7! 7, SIC I I I 'C i I ! I IC i I (01 ! ,Ci !C I I 1 ! 1 11 iC 
ID ! i i 6, I 'D I 51 71 7! 7, SID ! I I i 4!0 I I ! 31 31 ,D i , ' ' ! !Di iD i 1! 1i 11 1'0 
iE I 5i 51 Si 51 S!E I 51 51 Si 51 71E I I I I :EI I ! 31 I !E i i i i i !Ei •E ! i 21 21 2! 2:E 
iF , 61 61 61 61 61F I 6i 61 4i 4i 8iF i , i 51F i i i 1 ,F I I , ' ,F! •F i ! ! 2! 2' 2'F 
CD8 I 1 i 21 3 _ '1 i 5 I ! 1 ! 21 3 ! '! l 5 ! l 1 21 3, 4 ! 5 1 1 1 ! 2 I 3 ! 4 / 5 i ' 1 i 213 14 ! 5 ! ! i i 11 21 3 ! 4: 5 I 
IA; I i I I IA I 21 21 2! 21 IA i , ' \ l !At I , i I !A I i I\ !A!CF8A i 21 3, 2i 1;A 
18 I ! i 2 2· •B ! 31 3\ 3; 3i !B ! I i ! I 18 i I ! 1 ! :s ! ! 1 ! ! !Bi 18 , i , !8 
:c , , , 21 21 1c 1 1 1 31 31 2:c : 1 11 ; ,c , , : 01 , ,c ; 1 , :c: 'C , , s, 61 s1 ,c 
IF I 2! , I ' 21F ! 41 4! 31 31 2:F , I 2! 2! 3iF ! I ! ! i ;F i I I ! ! iF: 'F i 3! 3i 2: 31 1 !F 
CD9 1 1f 21 3! 41 Sl l 11213,41 Si I 11 21 31 4! s, l 1\ 2! 31 41 s, ; 1! 2314:5! i 11 21 31 41 Si 
1A 1i ' 1!A I 2! 2i 3i 3i 2!A I i \A I : ! 'A I , I ! 1 !Ai CFllA , •A 
~--------11 __ 8EJ1,.:----+-· i-}/---i- 21c I 31 31 4; 41 41c i 31 31 4! 4, 5'C' l 2! 1, 11 :c i !---i°l_j_:~; __ Ji_8E'---i- I : -i-~~ 
--
1
~-- }i~ 1--l--4!-Jt--ll--~~1~+-~~-~-~f-~~-H~+-+--fr---f-Hi-ll-~-l- + --1 --- 1 
18 1 : 1 , 11B ! 3: 31 4i .:ii 418 i 2i 21 3 1 2; 21s: : :s I 1 ; ; i ·'B'. ·B 1 ·s 
1F i i i 31 31 31F \ i l f i 7:F ! i I I j 9!F i I I i ! SiF : ~ 1 j 1 :Fi ;F ! I [ i .F 
co10 ! 1i 21 3: 41 s1 rf;2i " 1 4! ST : 1! 2' 3: 41 Si ; 1; 2i 3/ 4: sl 1: 213;4:s: 1~ 21 3! 4l s; 
:A i ! j 1 i 1) !A l l I i : IA ! j I ; IA i l i j j :A i l : 1 !A! CF~A l l I A 
8 I i 11 11 18 i 1, 2\ 21 21 !8 i I 2! 21 2! '-Bi i i I IS i 1 \ ! : :s: B 1 : - ; i B 
lC I I I 21 21 IC I 21 21 21 2\ ~---L-l.l 31 3i 1 !C; I -i-.L_lf._L_.l_J.Qj__L.J~-i---l.<; _ _j__L_-!-- C 
'D l i iii2/1i[)i3i2! 21 2H-h° i I 3! 3i 3; 2-rof i i : I iD i ! ! i I iD1 ,o i I I 1 :o 
,E ! 2! 2! 1iE I 4, 1! 1' 1, 4'E ; 2! 4i 4! 4, 3!E ! i : 1 'E I I I ' i !Ei 1E i 1 , 1 ' E 
IF ! I I 41 41F i i I 31 31 41F i 11 1 ! I 5iF I I ! , ! 1 IF , I I I I !FI IF I i I ·F 
I I 11 21 31 4! Si I 11 213T 41 51 : 1• 2 3 41 5, ! 11 213i4151 1: 2!3l4l5iT ' I 1, 21 3, 41 5: 
I i ! ! l I I ! l ! i I i l ! i i I I / i i I I 1 ! I ! ! i ! ! \ I 
,CF1CF4CF§CF _CFlCFJ!rnE!~ll 
1
cD1CDiCQiCD<CD~CD CD co: CD[CD,maan jCF2!CF4iCF! <;:FRCF,CFSlmaanl i I i :CD11<;0Jcofco, CD5CD6ICD 1 
o-ta! ol 01 0 1 o ~ ol ojp-te, ojo1__g_h1 _01 Q_! o o o O! 01 o!o-cas o.oi 0_0 10_0 00.00! 0010_0 , i , !0-ta• oc9!0_010_0100 o_o! ool oo 
1 21 21 s1 2 11 19 s 11 2"1f s 1ITT41 2 1s 13 ffi141#1 111_s11_s11_1 1_511_413_s11s 1 1 1 1 11 2s13012_5,3_4 2_11 2_0 s_s 
2 24!18115116 19!25!2012114117125116121110 24 22 231221#1 21Ul2_612.31Tu016_112.5 11T"1 2: 4_1!35!40\5_44_211_5;6_0 
4 161151 81 16 01 51 101 41101161 81111 211 5 21 9 211181 #I 411_9! 4_011_031:0_01 2012_1 I ! I i 4! 80160!8012.713_71 1_01 4_5 
6 1 91 91 2i 5 Di Si Sj 61 1_WLl: 1~-!.-h.Jll 3! O[jJ_L 1i s: 611_0112,1_0 14100; 00i0_8\ i I i ; 61 2_0;2_012 __ 0124/2_0, 1_01 3_0 
Si o: 01 o: o: o: o~µ:µp.~t=~ oi o, orT o: 01 8~F"100:00: 00:001 : I : : 8'. OO~OfOO 00100'. 00 
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Raw Data 
Pain 
i 41 ; i i , 161 I I I 81 I i 
1, 2 3i 4 5i I 11 2i 3i 4! 51' ' 1·
1
1 2,1· 31 411 
51 11 21 3j 41 51 
1A: ' / ;A! !A i ; I I IA 
18 I I i 181 I 18 ! 18 
\ IC i !Ci IC i ,C 
10 I :01 I ! !D ! ' !D 
i ,E i iEi i iE I I IE 
I iF ! I IF! !F i I !F 
1 2i 31 4 51 I 11 21 3! 41 51 I 1\ 21 3 41 Si I 11 2 3 4 Si 
2 11 li 11 :A I 2· IAI I I IA I I 1 !A 
31 1i 1! 1 i 18 ! 4! ! 18 I 11 1 ! 18 I I I 18 
31 1, 1 i 11 1 iC i 2, 21 21 2! IC: / 1 11 !C I I O ' IC 
1 1i 11 11 310 I 2 2, 2i 1101 I 1 1 1 •D ! I iO 
1!~ -~1~~-~t~H-~·-2Pl--t~l 1----,---r~+ :-+--------:~-
1 21 3i 41 Si i 11 2 3i 41 Si I 1; 2 3 4 51 11 21 31 4 51 
2 2: 2 IA I I 11 1: li liAI I IA l I iA 
2 61 6i 6 318 I 1111·11 18 I ! 18 I ! I iB 
61 61 61 6IC 1:5 2 21 ' 1iCI 11 IC O IC 
61 61 6 610 1 ·21 2 21 31 4101 I 2 3 ID 10 
61 61 6 61E ' 41 41 Si 51 51Ei i i iE I i ~ 
1 5 ' SIF I 3 31 41 41 4'Fi 21 1 21F ' I IF 
21 31 41 SLL!_I 21 31 41 51 1 11 21 3 4 51 11 2 3 4 Si 
I iA I ' 21 21 2\ !Al I I IA I IA 
2! 2 218 I 21 21 21 181 11 1, 1 18 I iB 
2i 2 4iC i I 41 41 41 ICI i ti 11 11 IC I O IC 
2! 2 4!0 l I 61 61 61 10: 1 2 1 I 2 ID i ID 
41 2 212 4IEI 16161 61 !El I 11 I IEI I IE 
2. 3i I 41F I l i IF I I IF I IF 
11 2 31 4 51 I 1 21 31 4! 51 I 11 2 3 4 51 1 2 3 4 51 
I I IA i i IA1 IA i IA 
I 11 I 18 ! I I 18/ 18 i ! I !B 
I 2i 21 1 IC I I j l !Cl 1C I O 'C 
I 21 21 110 I 1 11 11 11 IOI !D I ID 
i 31 31 21E ! 1 11 11 11 IE! !E I IE 
31 3! 31 31 3,F / I l ' i ·FI I IF I I iF 
1 ! 21 3! 41 5! i 11 2! 3, 4 1 51 I 1 ! 21 3 4! 51 ! 1 21 3 4 51 
: I : iD ! i 4 4 t 61 IOI I 2 21 ID I ID 
i I 31 31 iE i 31 21 21 !El I iE I ! !E 
11 11 11 1 11F i 4 5 ! 21FI I I I IF I I IF 
1 21 31 41 51 I 1! 2 31 41 51 t 1i 21 31 4 51 21 3 41 51 
11 11 11 iA I ! I iAi !A I i 'A 
1 11 11 1!8 I I 18 1 ,8 I iB 
, 11 1t 1i 1!C I . 01 ,Cl I i IC I i , 1C 
I ID: ! IOI ;O i 10 
11 1! 1' 1'E i IEI IE 1 , ' IE 
i 1! ti 1i 1iF i I iFi iF 1 -i---,,..!.._U !F 
11 21 3! 41 51 i 1 21 31 41 5: ! 1/ 21 3 41 Si 1! 21 31 4!5i 
41 6 61 61 !Ai 1 !Ai IA i IA 
21 7 71 71 iB ! ! iB< 18 I ! 18 
1 7! 71 7, 31C ! IC! :C I i , i ,c 
51 ~: ~I ~: 51~ l , 1 : 2' 1 ' ~~l : I 0 \ ; -{-t-f-t+i !~ 
11 s, 41 si 21F l ! I : IF! ! I t IF 1 ! 1 ,F 
1: 2! 31 41 Si 1 I 2 3, 4! 51 t 1 i 2 31 4i Si I 1 t 2i 31 41 s\ 
i IA I ! I IA, I iA ! i i IA 
1--.......... ---..--+--•' !§..j__L i ,
1
e: , 
1
, 1 le , 1 i , 1e ~ r-r~--i 1 '.c1 1 1 1 ic I I i 1 4 c;_ 
--·l----!---±+---1~-:-+-+-+--: --i~iT~F-1--:--~~-I f-1-1 i--1~ 
: I iF ~ !Fi I i !F 11! i i f F -
1, 2! 3L.&_fil : 1j 2_ 31 41 Si ; li 2 31 41 51 i 11 21 31 4 Si 
I l ~~-+-I I I iA I I I I ,A I I I I I IA 
1 IBt I! ~i i ! I \ 18 \ i I I !8 
I I i ,F I I I I iF i I llF I ! I ! !F 1r-21 31 4\ s! f1t2T3: 4; Si 1 11 2 3 41 s1 11 2 31 4 .... sr-
l I I i I I i i ! I I I i ! I 
CD8C0SCD1Cimean iCFiCD , iCF~CDi ; I I I I i I 
0.010.0. 0.010.0I !SitiSites(n=:lntetlntensi~seise se lse I i I I i 
... 2.61 1.9 1.912.81Prel 01 O Pre0.010.01 10.01 0.0 0.0~QL' I , l_l__L_L_ 
2.913.81 23l3awt_a110 1,1a1_2.s1131Lill9~J2,31 ~-1 _r-I 1 ___ ..
1.914.5 2.7'431 2120:19 2125~~1 15j07i04~ ! T ! 
~ 1 2.a, 1011.81 4, 1~-J-l~ , 41ULl..L .. 2.0, 0.610.1· 1 , 1 1 , i-+-o.onwroo,o.o 61 5; 5_~, 6108!....!J!.L_ .. : 1810.2 021 I I I ! I I i 
I I I , 81 01 01 81001 O.Oi oo: 0010.01001 I I i : I l : 
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Raw Data 
Isometric Force Raw Data 
iCF2 !CF4 ICF6 :CF7 iCF8 iMean iMax 
1
Min iSD i I i ! 
P-Test I 214i 329! 175[ 1891 2371228.7! 3291 175 1 61 i I I I 
41 1371 145! 1071 1101 161 i 132.0! 161 i 107\ 23: i I i 
81 147! 184! 127.0! 130.0! 164! 150.3! 184, 121: 24! i ! i 
121 153! 1781 147! 140i 199! 163.4! 199! 140i 25! ! I ! 
16i 152! 199! 171 ! 14_~04! 174.0i 204! 14:~~! i ' 
201 167i 206! 171, 1221 2081 174.81 208! 122! 35! i : ' 
241 192! 234! 183! 139\ 208\ 191.3\ 234! -139\ 35i I I ! 
28i 1~262! 171 ! 1491 218! 198.4! 262! 1491 441 , i ! 
!C01 !CD2 iCD3 :C04 :cos--n:o~:CD~D8 iCD10 :Mean !Max \Min !SD 
P-Test I 2201 282i 368i 229! 210i 146! 2431 305! 302[ 256.11 3681 1461 
4i 168! 232.0! 358: 174, 170\ 121' 191 i 283! 205! 211.21 3581 121 i 
Si 187! 232! 3671 169! 189i 117! 2211 2601 280! 224.6! 3671 1171 
12! 1aa1 217! 3541200! 1961 1301 214! 257! 278! 226.0I 354: 130! 
161 2~!1._11§1_~_21 1871 21511 1431 233i 2931 ?97•1: 235.1 I 332! 1431 
201 228! 2261 3521 1931 223, 134! 2351 2871 277 -239.41 352! 134! 
- 24! 2201 236.0! 339! 208f 233t 142: 227' 306[_1~!.LJ43.61 3391 1421 
~~2041 246! 326! 2041 221t 148: 256! 328! 278i 246.1 i 3281 148! 
lND1 !NC53 iND4 iND5 -iND6 !ND7 :Mean !Max !Min :so 1 1 i 
P-Test i 187\ 312\ 361 \ 2071 3291 287! 280.6! 361 l 187! 691 ! , 
4i 219! 270i 368\ 193! 330! 268\ 274.7i 3681 19:f! 661 ! i 
r----~8~! --=-2oor-312! 4061 203! 389i 269i 296.Si 4061 2001 891 i ' 
1~201 i 3461 386! 177! 3821 297! 298.2! 3861 177! 91 i I 1 
r---,-:161 i0-51~31 390.of 2os1 400.0J 3061 306.Si 4001 2osr-· 86i I I 
~22i 3161 392\ 2181 419! 2961 310.4! 4191 218j 84! ! I 
~241 200.0i 294\ 391 j 210.01 425.0i 275.01 299.2 1 425! 2001_ 921 i i 
~28-1 -1891 291 [ 395! 202\ 435! 257! 294.6\ 435LJ..891 101 \ I i 
j i ! l ( i l I ! i : l 
i , \CFS 1CD !ND ! ' iCFS iCD iND 
65 
71 
72 
64 
61 
61 
58 
59 
1-=--c:--,...-.!_CF,S (n 1CD (n •ND (n ~SE iSE !SE i iSEM iSEM 1SEM 
P-Test i 228.7! 256.1 \ 280.61 27.11! 21.71 28.21 ' 01 0~ 
4i 132.0I 211.2! 274.7! 10.3 23.7! 26.8! CFS (n_if_Q_(i:i_~ND (n ::i 4.1 ! 3i 4.3 
___,_~j 150.3; 22'!.:§ .. ~296.51 10.7J 24.11 36.3iP-Test i 100! _'!.Q.Qj_ 100! 2.9j 2.61 3.8 
121 163.41 226.0, 298.2, 10.9; 21.2'; 37.0i 4\ 57.7! 82.4\ 97.9! 5.51 1.91 4.3 
161 174.0i 23s.11 306.sr---i1.a! 20.1i 3s.01 a: 65.71 87.7! 105.61 6.4! 2.a1 3 
20i 174.8! 239.4! 310.4i 15.7! 20.4! 34.2: 12\ 71.41 88.21 106.2i 6.7! 2.8! 4.2 
24i 191.3) 243.6! 299.21 15.6\ 19.31 37.7! 16! 76.0! 91.8! 109.21 6.11 2.21 5.3 
28! 198.4! 246.1; 294.6! 19.6\ 19.61 41.2! 20: 76.4! 93.4! 110.6! 3.71 2.9! 6.3 
i ! i ! ! 24: 83.6! 9,...50,--;·1 ..... 1_1"'""0'"""'6--=.6,....: __ ..__ ___ --; 1----'~~ i I ! : . i 28i 86.71 96.1 ! 104.91 i ! 
1-=-=----lff_~ __ Ef4 !CF_~ ___ £EL_J_<;F8 __ ;... :ND1 :ND_3 :N~ __ ,ND5 jND6 !ND7 ! 
P-Test I 100.01 100.0! 100.01 100.01 100.0!P-Test ! 100.0! 100.0t 100.Q! 100.0i 100.01 100.0! 
41 64.01 44.11 61.1 ! sa.2i 67.9! 4: 111.1: 86.s: 101.91 93.21 100.31 93.41 
8! 68.7! 55.9i 72.6i 68.Si 69.~l a: 107.0' 100.0! 112.5: 98.1: 118.21 93.7: 
121 71.Si 54.1: 84.01 74.1: 84.0! 12! 107.5' 110.9! 106.91 85.5: 116.1 ! 103.5, 
16! fi.O! 60.Si 97.7; 76.t- 86.1' 16, 109.6: 106.7! 108.0i 99.0! 121.6! 106.6! 
--201 78.0i 62.6! 97.71 64.6' 87.8'! 201 118.7' 101.3! 108.6\ 105.3: 127.4: 103.1: 
- 24i 89.7, 71.1, 104.6! -73.5! .. 87.8! 241 107.0: 93.3! 108.3 1 101.4! 129.21 95.Si 
- 2a1 90.2! 79.6i · 97.7T7a.aT- 92.01 2ai 101.1 ! 93.ITTo9Ai-97.6i 132.21 89.s: 
- -- ico1 --1co2--i<;o3 !cD4 ·:cos --~D6 :co1 :cos _ tfD10]" ; , : 
P-Test 1 100.0! 100.0: 100.0i 100.0! 100.0! 100.01 100.of 100.0' 100.0i , ___ : __ 
4: ~ s2.3: 97.3T 1s.ot a1.o]_ a2.9: 1a.s: 92.a1 67.9\ l 
81 85.01 82.3, 99.8173.8' 90.0l 80.1; 90.9: 85.2: 92.7i 
- 12 i as.s i 77 .o ! 96.2 r 87 .3, 93.3 i 89.o i ·-a.:...,a-.1.,.,.:-84·=--,.3'"'"!-=9=20---=·7"1_'~:~_-_-_-_-~---_-_-=._-:_-_-_-_-_-~---_-_-_' 
_161 91.4i 76.2r-·rcr2Taft1-1oi4! .. 97.91 95.9! 96.1! 98.3! , , 
20 1 103.6i 80.11 95.7! 84.3' 106.2! 91.8! 96.71 94.1! 91.7! ! I ! 
=-~4L 100.or 83.7! __ -92.1J ___ 90.8!_ 106.2T ___ 97.3! _93.4! 100.3! 93:or=. ! __ I _;__--
-- 28l 92.4-a1.21 aa!t __ a9.1LJ..Q8.~_ 101.41_1os.3!_ 101.st_~2.1, ___ ~ __ i i __ 
c1s--: ~ 16sr··-2w ·-·222:~-329\ 174f-- 11s+- 189: 237:-=~-~ :me;n13;sd 53: .. 
cd I 22oy 282L_ 368! 229..L_210J 1461 243: 305! 236! 302! 254._I -=62,c.;I __ ., 
nd i 187! 207 1 3~7i 207! 3291 287: ' i ; 271: 70! 
----: ···---L .. - · ___ : ______ i ______ 1---r __ , __ ; ---··---'. ---------'. ·······---'. __ 1 : 
~ -1-·-·--+··------·····-·;--··--·----+-·-·---------:-----------~---··-----------; ·------: ·-----·-····; ----+-----: ----1:---1 
--
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Raw Data 
Peak Torque (PT) Raw Data 
iCF2 iCF4 \CFS :cF? ICF8 !Mean iMax iMin ISO i ! ; i I \ 
P-Test I 371 501 221 191 351 32.61 501 19! 131 ! j ! 
41 271 181 12! 8.0j 23! 17.61 271 8! 8! ! ! ! 
8! 18! 19.0! 141 8.01 28! 17.41 28! 81 7! ! ! ! 
' i ;121 11.01 201 141 Bi 261 17.0i 261 81 71 ! 
i I 
i I 
! I ! 
201 23i 27\ 181 14i 31 ! 22.6/ 31 i 14i 7\ I 
24! 261 311 181 111 33! 23.81 331 111 --9,-!---!--...,.:--~-
161 16! 27i 16! 121 34! 21.0i 34/ 12! 91 i 
i I I 28! 30\ 341 18! 11! 34! 25.41 34! 111 101 i 
ICD1 !CO2 !CD3 lCD4 :cos ICD6 jCD7 iCD8 JCD10 !Mean \Max !Min !SD j 
P-Test I 271 421 641 31 ! 221 231 34! SOi 451 37.6! 641 22! 141 
41 20! 34.0! 61! 181 191 16! 27! 421 31! 29.8! 611 16! 151 
81 231 34\ 601 20! 161 14! 28\ 381 391 30.21 60! 14! 14i 
121 231 30! 581 231 191 201 281 37! 431 31.2/ 58\ 191 13\ 
161 24l 301 561 22i 18! 181 30.0i 39.0.l_-,4=5\c---:-3-:-1._3~i_.-,5-:-6t-! --~ 
~~I 241 311 ss, 24.01 18.0I 1s.01 331 41 I 47! 32.41 ss1 
J 34.01 521 261 18 19\ 35i 421 461 32.91 521 
18i 131 
18i 131 
181 121 
20i 11\ 281 241 381 521 271 20i 22! 33! 45! 41 ! 33.61 52! 
! ! 
! ! 
' 
i 41 24! 461 61 I 23/ s?! 421 42.2! 61 i 23! 1s: 
IND1 !ND3 IND4 IND5 !ND6 JND7 !Mean !Max lMin ISO i 
23i 531 57. 24! ssl 38! 43.3i ssl 231 1s1 
81 22i 451 59.0I 231 61 I 391 41.Si 61 l 221 17! i I 
1 I 
' I 
i ! 
I ! : 
121 23i 45.0i 571 24i 57\ 47! 42.21 57! 231 15i 
161 22! 45.0i 57.0~I 64.o,
1 
371 41.51 641. __ 22_,1 __ 1_7\~ __ l__ __c __ _ 
201 20! 46! 571 241 71; 42i 43.3! 711 201 19! i 
,___2_4.r-T1.oi 461 61 ! 25.0I 66.0j 40.0I 43.21 661 21 i 18i 
281 221 461 571 261 61 i 38i 41.7! 61 i 221 1Si i ! 
i ! 
! i 
! i ! i ! I i ! _,l __ +-f ___ ! ___ i __ 
l : : : : r 1 i I t : 1 
i l i ICFS iCD IND I i i iCFS iCD 1ND , 
iCFS !CD !ND !SE iSE ISE i !CFS (n jCD (niND (n =iSE !SE iSE t 
P-Test i 32.61 37.61 43.3! 5.51 4.61 7.2!P-Test I 1001 100! 1001 16.81 12.21 16.6! 
41 17.61 29.8/ 42.21 3.41 4.8, 6.51 4i 53.91 79.2! 97.4! 10.4! 12.71 15.0! 
8! 17.41 30.21 41.51 3.7/ 4.81 6.8: Si 53.3\ 80.3! 95.81 11.3! 12.71 15.?i 
~2i ___ 1?.01 ___ 31.2L 42.2L 3.11 __ 4.21 _s.2L ____ 121 __ s2.11_s2.9! ___ 97.4i ____ 9.sL__ 11.1_L__14.3!_ _______ _ 
16! 21.01 31.3! 41.51 4.0!- 4.31 6.91 16! 64.41 83.2! 95.8! 12.21 11.4/ 15.91 
201 22.61 32.41 43.3! 3.0i 4.41 7.9: 20i 69.31 86.1 / 100.01 9.21 11.7! 18.2! 
24! 23.8! 32.9i 43.2! 4.1: 4.0! 7.4: 24i 73.0! 87.5! 99.7! 12.5! 10.Si 17.0i 
28! 25.4i 33.Sj 41.?i 4.Si 3:1.L_ 6.5\ 28i 77.9i 89.3: 96.3! 14.1 i 9.8! 15.0! 
l ~ l : l l ! i : \ ! i ~ 
iCF2 iCF4 !CFS !CF? !CFS isem : iND1 iND3 iND4 !ND5 !ND6 iND7 :sem 
P-Test i 100.0i 100.01 100.0i 100.0I 100.0i O.O!P-Test : 100.0l 100.0i 100.0i 100.0i 100.0! 100.0i 0 
______ 4! ___ 73.0! -·- 36.o~--- 54.51_ 42~1, __ ss.?t ____ s.91 ________ 4( __ 104.3_! as.st __ 107.o~ ___ 95.8i ___ 87.7[ _ 110.s: ____ 4.1 
8! 48.6! 38.0, 63.Sl 42.1 i 80.0i 7.71 Si 95.?J 84.9i 103.5! 95.81 93.8! 102.6! 2.8 
12: 45.9! 40.ol S3.6/42~:-74.3i- s.7!- 12: 100.0! 84.91 100.0: 100.01 87.?l 123.7! s.s 
16/ 43.21 54.0j 72.7! 63.2! 97.1: 9.2i 16i 95.7! 84.9! 100.0! 100.0! 98.51 97.4' 2.3 
_-1QL s2.21 54.01 s1.sL 73.7: ss.s 1 s.3! 201 87.o[ ss.s1 100.0: 100.o: __ 109.21 110.s: 4.2 
24i 70.3! 62.0I 81.8i 57.9! 94.3i 6.71 24! 91.31 86.Si 107.0! 104.21 101.5! 105.3 1 3.4 
281 81.1 i 68.ol 81.81 57.9! 97.1 j 6.7\ 28! 95.?i 86.8\ 100.01 108.3\ 93.8! 100.0: 2.9 
iCD1 !CO2 iCD3 iCD4 !CDS :CDS iCD7 !CD8 iCD10 Jsem ! i i : 
P-Test4-! - 10704.01 t---10801.0of-10905. 03: 10508.01 l- 10806.04 :-- 10609. 06 !1 ··. 10709.04[ _10804. 00 ! 10608. 0911 --3 07 ! -··- --1--T-_-__ -.... -._-::~-... --;. 
i .: •I •;.....__:_0•: • .f .i •, ,i i ; 
8/ ss.21 s1.01 93.81 64.Si 72.7/ so.9j 82.4! 76.oi ss.7/ 3.6! 1 : i 
121 85.21 71.4! 90.61 74.2\ 86.41 87.0! 82.41 74.0I 95.61 2.7i I i I 
'--161 88.9L 71.4L __ 87.51 71.0L __ 81.8L 78.:u_. _ 88.2! 78.01 100:2_L ___ 3.1 i ____ i ·-----L. ______ L__ 
201 88.9J 73.81 8fsl 77.41 81.8! 78.31 97.11 82~.41 3.31 I ! ·---.-: __ 1 
241 88.9! 81.0I 81.31 83.9! 81.81 82.61 102.9! 84.01 102.21 2.9i I i i 
28: 88.91 90.51 81.31 87.1 i 90.91 95.7! 97.11 90.0I 91.1 \ 1.51 I , 1 
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Raw Data 
Average Peak Torque (AT) Data 
ICF2 !CF4 lCF6 !CF7 !CF8 !Mean !Max iMin !SD i i ! i 
-P-Test ! 36.01 48.0I 20.0! 16.0! 34.3 30.91 481 16 131 1 i i ! I 
41 25.7! 15.71 11.3! 8.00i 21.31 16.4! 26! 8\ 7! I ! \ 
81 18.0! 18.00I 13.3! 8.00/ 27.3! 16.9! 27! 8 71 I ! / 
I i , 
! 
' 
12 17.00I 19.Si 14.0i 8.0i 25.0' 16.7i 251 81 s: ! 
1s 1s.3l 24.ol 15.3i 9.3. 33.o/ 19.4i 331 91 9i I 
I 
I 20 20.3j 25.71 17.0i 10.7j 30.71 20.91 31 ! 11 i 8i i ; 
241 22.01 29.0I 16.71 9.7! 30.3 21.st 30! 101 9! ! i ! i 
I i 
!SD I 
191 14! 
281 28.0! 32.0I 16.0I 10.3\ 32.71 23.81 331 101 101 : I 
lc01 !CO2 ICD3 iCD4 !CDS ICDG 'CD? lcoa ico10 :Mean Max !Min 
P-Test ' 25.0i 41.0I 61.71 30.0j 20.31 19.0! 33.31 47.0I 43.7! 35.7 1 62! 
4 17.0! 33.31 60.0! 17.0 16.7 14.0i 26.7! 41.5 29.0! 28.4 GO! 141 151 
8 23.0! 33.31 57.7/ 19.7 16.0! 14.0! 26.71 36.3! 38.7/ 29.5 58, 141 14; 
12 21.71 28.31 56.7/ 21.7 17.71 16.31 26.31 35.7! 42.31 29.6 571 161 131 
16i 13i 
161 131 
17! 121 
1s1 23.01 29.31 s4.o! 21.01 1s.31 11.01 2s.01 38.o' 44.3i 30.2: 54i 
20 23.01 31.0i 54.0i 23.0! 16.01 17.01 32.01 40.0 45.0i 31.2 54i 
241 23.0! 33.0I 50.31 24.7 17.21 17.0!32.71 41.7 45.31 31.7! 50! 
281 23.01 36.31 50.7! 26.31 19.51 21.0l 32.31 43.0 41.0i 32.61 511 20! 111 
!ND1 !ND3 !ND4 !NOS lND6 !ND7 !Mean iMax Min ISO i i I 
: i 
: 
' 
P-Test 21.0/ 51.7! 54.31 23.31 61.3) 35.7! 41_.2_';! __ 61-+1 __ 2_1 ,_! __ 1_7,_. __ !..-----'----
4 23.0i 45.3! ss.01 22.11 ss.o: 41.3\ 40.1: 56 231 1s 
8! 20.31 43.71 56.0I 22.7/ 55.71 36.31 39.11 561 20: 161 i I I I 
12 22.31 45.0! 56.3i 23.71 55.31 42.31 40.8i 561 22: 15 ! ! 
i ; : 16 20.31 45.0i 56.0! 23.7 60.01 35.31 40.1 l 601 20i 161 
' ! 201 19.71 45.51 55.71 23.3j 65.31 39.0i 41.41 65 20! 18\ 
I i : 241 21.01 46.0I ss.01 24.ol 62.0 39.ol 41.31 s21 211 111 
281 22.01 45.31 55.0\ 25.31 60.0, 37.7! 40.91 601 22: 151 I i 
; 
' 
i I / ! ! I I J ; 
/ : i iCFS CD ND I : ICFS !CD IND ! 
ICFS !CD \ND 1SE ISE iSE i 1CFS (n !CO (n!ND (n =iSE SE 1SE i 
P-Test I 30.9! 35.71 41.21 5.71 4.6i 6.9IP-Test I 100! 100! 1001 18.4 12.8! 16.7! 
41 16.4i 28.41 40.71 3.21 5.0i 6.1i 41 53.01 79.Si 98.7\ 10.3 14.01 14.8i 
Bi 16.9i 29.5! 39.1 \ 3.1 i 4.51 6.31 81 54.61 82.Gi 94.9 10.0 12.Gi 15.21 
12! 16.71 29.Gi 40.81 2.8! 4.3! 6.0i 12! 54.0! 82.9: 99.0I 9.0 12.01 14.Si 
16/ 19.41 30.21 40.1 i 4.1: 4.31 6.7: 16! 62.7! 84.Si 97.3 13.2 12.01 16.2! 
20i 20.9; 31.2: 41.4: 3.4i 4.3! 1.2: 20! 67.61 87.31 100.41 11.0 12.0! 17.4: 
241 21.51 31.7! 41.3! 3.81 4.o: G.7! 24i 69.sl 88.7' 100.2 12.2 11.2: 1s.2: 
28! 23.8! 32.6! 40.9! 4.Sj 3.6! 6.3: 28i 77.0! 91.3! 99.2! 14.5 10.01 15.2i 
[ j ! ! [ I ! ! j 
iCF2 :CF4 iCF6 !CF7 \CF8 !sem 'ND1 iND3 'ND4 iNDS ND6 :N07 !serr 
P-Test \ 100.0i 100.0i 100.01100.0! 100.0I O.O!P-Test: 100.01100.0! 100.0\ 100.0 100.0i 100.0i 0.0 
41 71.4i 32.7! 56.5! 50.0i 62.1! 6.5 4! 109.5! 87.Gi 103.1 ! 97.4 91.4! 115.71 4.4 
a1 so.o! 37.51 66.5! 50.01 79.6! 7.31 8! 96.7i 84.5• 103.11 97.4 90.9! 101.1! 2.a 
12! 47.2: 40.61 70.0! 50.0I 72.9r---s.si 12: 106.2! 87.o• 103.7! 101.1 90.2: 118.5/ 4.7 
161 42.51 so.o: 76.~/ 58.1 ! 96.81 9.8! 16i 96.7! 87.0, 103.1 101.7 97.91 98.91 2.3 
20i 56.4!53.51 85.0! 66.9! 89.51 7.3i 20: 93.8! 88.0i 102.6 100.0 106.5; 109.2[ 3.2 
~~.l_§0.4! 83.5i Go.s! 88.3_L_§_.2'__ 24! 100.01 89.0: 103.1 ! 103.0 101.1 i 109.21 2.7 
28i 77.8! 66.71 80.0I 64.41 95.31 5.5 1 28! 104.81 87.6\ 101.3\ 108.6 97.9\ 105.Gi 3.1 
\CD1 !CO2 ICD3 iCD4 :cos iC06 :CD7 iCD8 iCD10 isem i . I 
f-P--T-e-st..---i -1-00.0i 100.ol 100.01
1 
~00.0I 100.of-10().Qj1oo--:of"100.o! 100.0i. OI ' i 
41 sa.ol 81.21 97.2! 56.71 a2.3L__ZY._L_?._o.2: 88.31 66.4! 4.1 1 I 
81 92.0, 81.21 93.51 65.7j 78.8! 73.7; 80.2! 77.2! 88.Gi 3 , : 
12! 86.Bj 69.o! 91.~~~81.2! 85.8; 79.0! 76.0I 96.8; 3.11 i i 
161 92.0_, 71.51 87.51 70.0 1 80.31 89.5, 87.11 80.9l'i01.4, 3.3! • I 
_ 201. 92.0 .. !._ 75.GL 87.5i 76.7L_l?.81 89.51 96.!..L_85.1j 103.0I 3.1j , __ __j_ 
241 92.0! 80.51 81.5! 82.31 84.7! 89.51 98.2! 88.71 103.7 1 2.61 i 
281 92.0T-~a2:-21 87.71 9"6.TI""110.51 97.0! 91.5\ 93.a: 2.61 ' 1-
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INFORMED CONSENT FORM 
The aim of this research is to establish the time course of recovery in muscle damage following a 
maximal eccentric contraction in persons diagnosed as having Chronic Fatigue Syndrome (CFS) or 
Overtraining Syndrome (OTS), and whether this time course of recovery differs to persons 
asymptomatic to CFS or OTS. The results of this research has the potential to improve rehabilitation 
from OTS or CFS. 
The study will be conducted over a five week period at the Exercise Physiology Laboratory at the 
Joondalup campus ofEdith Cowan University. As a subject you will required to perform thirty five (7 x 
5) maximal eccentric contractions in the biceps of your non-dominant arm on one occasion to elicit 
damage. Testing will entail six maximal concentric contractions, one maximal isometric contraction and 
eight contractions activated by tetanic stimulation on the same arm after performing the eccentric 
contractions. Initially there may be localised tenderness in the biceps muscle following the eccentric 
contractions and as part of the research, the level of muscle pain will be determined by myometer. A 30 
µ1 blood sample will be taken for analysis on every test day of the study, and will be taken from your 
finger following pin prick. Testing will take place at pre-test and+ 1, +2, +4, +6, +8, + 12, from then on 
every four days till the conclusion ofthe study. All testing information is confidential and will only be 
used for the purpose of this study. Information will be kept under lock and key, and your data only 
identifiable through a number coding system held by the principal researchers. Data used in analysis 
will not include any names. During the period of research we request that you make no major changes 
to your exercise and nutritional habits. Participation in this study is purely voluntary, and you may 
withdraw at any time, for any reason. 
Any questions about this study can be directed to: 
David Wright 
Principal Investigator. 
Dr Colin James 
-
-Exercise Physiologist., Human Movement Dept., Edith Cowan University. 
I have read the informed consent above, and any questions have been 
answered to my satisfaction. I agree to participate in this study realising that I may withdraw at any 
time. 
I agree that the research data obtained from this study may be published, provided I am not identifiable. 
I understand and agree that the Edith Cowan University Human Movement Department will not be held 
responsible for any injury or permanent damage sustained. 
Participant Date 
Investigator 
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Examples of isometric MVC & 20 50 Ratio Traces 
f!mllU. CFS2p,..lel!ll-li<MVCand:iQ:5Qlq nee, «IOV, 
50nw, sqtllrl WWI, 0.325 *1'41, 
1»m~m-----ffl-=---Q 
NwmtadU1MPIN'*811.t1)Hz. 
E!Jlllll..2. CF Sl 20:50 Hz ralo l days posi-damago, 400., SOms, 
square wwe. o •so an"'O 
,~n~~~rn~~~n~~~~n= 
N.,mbarol...,.lNtai,•11at10Hz. 
f.iml.Cl..2. CF S2 20:so HZ raao 8 days post-danaga, 400¥, 50rna_ 
squa,e wwe, 0.4 75 a"1). 
Eilllllll- CFS2 20'.50 Hz ra!O 12 days poot,ctam,go, 400V. 5Dms, 
square wa¥e, O.!iOO arro. 
Ellllill..2. CF Sl 20:50 r:&iD imntdlatalt' posl-darnaie, 400V, 5Dms. 
:m 
squan ww1. O ..t50 arro. 
2'D 
= g 
! "" 
,a, 
:m 
= 
"" g ! ,.., 
,a, 
,noMm=~--=m====--
N.,mbw GI·~- 911M11 • 10tz. 
fjgsni CFS2 20:50 HZ raiO 4 dayspOSl-dlrNQe, 400V, SOrns, 
!1111Uanl W'ft •• 0 4 75 arr'C) 
Nvmta, ol•-..• .__ lllll 10Hz 
f.llnU..J, CF2 20:50 HZ r•toe days post,daml'QI. ~. 5Dms. square 
W'ftl', 0.500 amp. 
3D 
"" 
: ,.., 
1 ,a, 
!D 
.a, 
.Elc.ua.l CFS2 :io:so Hz ,:mo 16 &ayspcst-c:nn:ao•. 4DC'Y, so~ 
square wa"t'I, a. 400 amp. 
i~I 
- I 
·:1 •'L l"l. t. N .. rl n. ..JY Orr~.,--,-~..-..,...--,~-..,> 
1 no &4 a,1m1211..s,m1m21123Z:S274::a531DD'~ 
Nu"'tarC'ltaff'll)M !a.•11.M CHz. 
:m 
XD 
g"" 
j "'" 
,m 
0 
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Examples of isometric MVC & 20 50 Ratio Traces 
f!mlU CFS2 isDnWtr1c MVC and 20:50 HZ nlllo 20 dll'S posl-
damaQ0. 400., 50ms,squn-,, 0.450 arci. 
,~~~m~~ffl~ffi~D•~~••w 
Numtarot1ar1QIN .._lll10Hz 
E!ml!Ul- CFS4 lsanelric MVC, and 2050 HZ raDo • pnt-1991, '°°'· 
50ms. squarewwe, O.:JlO all'C). 
1 24 47 70 CDt'Cl13.11at111S2CB2312512773D3Z33413D 
Nu,nt.af ,anp.,,. ••• .- 10Hz 
Elllllll..11- CFS-4 20:50 HZ raUo2 daysposl-d...,ge, 400.., 50n., 
SQuarewwe, o.,50a1l). 
1g 31 ~ 73 '" 1CD 121 ,.., 1m 1&1 1m 211 235 251 211 2m 
NuMbafQf larlQM .... a 10Hz 
fillll!ljj,. CFS• 2050 HZ ratio 8 ..... poa-•-o•. ,oo,, 51ms, 
squatlwa\11•, 0.500 arl1,I. 
1Mq~~~~~~~~=mxo=--
Numt.fa....-.-.. .. .a1101c 
ElllYIIJ.ll, CF S2 -rte M\IC and 21150 Ht rallo • po ..... 28 d ... s 
"1W clamaQo b<lUI. 400¥, 50ms. squor•-•. 0.325 =c,. 
XD 
00 
1~S~~--D----~---=-Numta,Cl'..,_,IN '*-nM ,ONz. 
fllnllLl2. CFS• 20:50 HZ rslto irnnedt'"ely post darrao, bout, ,oo,, 
50ms. squn-•. 0. JOO arci. 
:m 
= 
g"" 
j "" 
,m 
00 
""' 
XD 
g"" 
j "" 
,m 
"" 
0 
·00 
,~G~m~~-~=m==~=-u 
Nu,nt. ct .-.p ..... .., at 10 Ml: 
Ei.all!l..li CFS•lsanetncMVC and21l50 HZralio 4 dayspool-
damage, 400,, 50ms, squan, wwe, 0. 550 all'C). 
Elllulu.a. CFS• lsc>-rtc MVC and 20:50 HZ ratio 8 d.,.s pos,. 
damao•. •oev. 50ms, squa,ewwe. 0.850 arrc,. 
"""''* ol .-,.P ... -- .at 10 ttz. 
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Examples of isometric MVC & 20 50 Ratio Traces 
<O 
3CD 
g ffl) 
j"" 
"" 1cc 
Elalul..lZ. CFS4 l...,..trlc MVC and 20:51 Hz 11tiO 12 da,s posl-
d.,,..go, 400.. 5011'111. ,quan wwo, 0.475 lff'!I. 
"' 0---------------1~nG~~ffl~--~-G-~~~ 
Numllard,.,.,..'*-al10Hz 
Elall!IJj. CFS4 ISOmolric MVC ond 20:50 Hz rallo ot posl-tosl 28days 
post damage, 400¥', SOms. SOJare 'W!IVe, 0.300 aff'P. 
3CD 
"" g 2CD 
i '"' 
,cc 
1 :» TT 1,.:, 1!9 1Qt ?»'Zf:6 XDM 391 "'G<P 4m!B!tSl1 s;g e,em, 
Nu,nt.. a.._ .. , '*•at1011z: 
flllllm.ll.. CD4 20:50 Hz ~o irmedlalely post-damage, 400v, 50ms, 
squarewwt., 0.275 amp_ 
3CD 
"" g 
j '"' 
'"' 
1 2 .. 41 10 CiD11D1:1>1t1:1852C82312:etfflXD3Z!'3e3S 
Mum• d...,,.M ...,.a.t 'l)Hz. 
Elmlcl.ll. C04 iscmetric MVC and 20:50 Hz rallo 4 days pCJSl.damaoa. 
40Dv, 50ms, souse-•. 0.275amp. 
= 
= g 
j "" 
,m 
"' 
,~nG~~m=-=~-e-~~~ 
N\lffltarQft.ilplM '*•"• 'll Hz. 
flmlll.ll. CfS4 loOmelri: MVC and 20:51 Hz rllllo 1& da,spost, 
damage, 400v, 50mo. SG1ill9-I, 0.J75 lff'!I. 
,~mm~-=a-an--e•-= 
Numta, d......, W19'1.al10H:r: 
= 
"" g 
i '"' 
ICC 
= 
2CD 
g '"' i ,cc 
3CD 
2CD 
g '"' ! ,cc 
0 
·CD 
tlllY!J..2Q. C04 lsomllrtc MVC and 20:50 Hz ratio at p, .. 1es1, 400., 
50ms, square ..... , 0.275 amp. 
,omm~H---=~-~~-e= 
Numtard,..,.._..__,..'OHIL 
Eiml!LU, C04 20:50 Hz ratto 2 days PoOt damago, 40Dv, 50rrw, 
SQUa"l'NiWI. 0.275 al11J. 
NvmtlllrGl.-..ia.la•a•'llHz. 
Eillllll..2.I.. co• 20:50 Hz ratto 6 da,s poSl-damage, 400.. 50ms, 
squ••....,•. 0.275 arro. 
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Examples of isometric MVC & 20 50 Ratio Traces 
f!llllll..ll. C04 lsam1Cnc MVC '"1d 20:50 Hz ratio 8 days pall dnogo, 
400V, 50'"' 9QII··-.. 0.275 arc,. 
3CIJ 
= g 
! "" 
1CD 
t:= 
J tm 
1(1) 
1~m~m~~~~maa~~~o• 
N...-tardUfl't> .... ft.al'llHz. 
EJiullLlZ, C08 lsomdric IIIVC and 20:50 Hz ratio at pr,.te,t, 400V, 
50ml. squa,.ww,. 0.325 affl). 
1~s~~-~~~---~-•~~ 
N11,nbttC11h~IN 11*41'1 al 10N& 
.Ellul!!.lS. CD8 20:50 Hz ratio l dlrfsposl-damago, 400V, 50ms, 
squarewr,,e. 0.325 a,ip, 
1~~m=~~~~-m==~=c• 
N,fffltard..-nplN .... 1111/1,'l)Hz. 
Eislllll..ll.. C08 20:50 Hz ratio 6 dlrfs posl-damago, 400.. 50'"' 
,quare \1118V8, 0.32S ar11). 
1 23 41!5 tJ1 a; 111 t331CD1771ClQ221242m29'3»33t31D 
N .. Mt.tCli'•.,,.,._ _,....,_.10Hz. 
g 
flmuJ.2a. C04 ltomo111e MVC '"1d 20:50 Hz ratio Ill pOOf.tesl 28 doys 
.n. demooo, 40IJY, 5tmo, ,ciun wa,o, 0.275 arrc,. 
:m 
"" 
= 
! "" 
1CD 
1 «J 7Q 1•1er1G11231!1274303m:»t43>CDeCB5""51111!135 
Nuffibalofeat0M-.11.al10Hz. 
Ela!ul.ll. coa 20:50 Hz ratio mrnodta""' poSl-damogo, 400V, Somo. 
SQu•e wwe, O. 325 .,.... 
:m 
1(1) 
t 30 s, BB t'fl 14117'!52°'2:D lm20l 33J343318 0 ~«IS 
N11MNfcl-,..pM&*-1i11,10Ma:. 
~ COB isan1trtc MVC and 20:50 Hz raao 4 days post-damage, 
400., 50ms, ,qu•ewa,e, ll325 arrc,. 
3'D 
:m 
""' 
t:""' 
1 "" 
1CD 
0 
·"' 
Ellllllill C08 lsomolrt IIIVC '"1d 20:50 Hz ratiO 8 dlrfS post damage, 
400V, Sams, squa,o _., o.ns amp. 
3'D 
3IJJ 
,a, 
1 30 s a; 1,a 1.,ci11'2CM2312fSZ20l 33:J343318 a ~e 
N11,ntmof--0 .. ••111at,OHz. 
: 
:m 
:m 
2'D 
rm 
'"' 
,cc 
"' 
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Examples of isometric MVC & 20 50 Ratio Traces 
El!lll!l.il, M:l7 ISometrtc MVC and 20:50 HZ ralo 12 days after l)f9, 
tesl. 400v, 50ms, :,quare w.111, 0.275 •l1'0. 
Numbafof•ampM -*••10HI: 
Eillllll.il, M:J7 iscmetrtc MVC and 20:50 HZ ralo at pos~tesl 28 days 
attar p,.ttsl, 400¥, 50ms, :,quarowwe, 0.275 an'C). 
:m 
:m 
"' 
0 
·"' 
Numbafotaamp• l*MM10Hz. 
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F Values and Full Statistical Findings 
Repeated Measures 2 way ANOV A 
Test Parameter D.F F 12 
---------------------------------------------------------------------------------
Creatine Kinase 
Between Subjects (19,2) 10.62 < 0.001 
Within Subjects (190,10) 33.70 < 0.001 
Interaction (190,20) 14.22 < 0.001 
Low Frequency Fatigue 
Between Subjects (19,2) 30.68 < 0.001 
Within Subjects (133,7) 18.10 < 0.001 
Interaction (133,14) 6.86 < 0.001 
Isometric Force 
Between Subjects (17,2) 18.99 < 0.001 
Within Subjects (119,7) 18.76 < 0.001 
Interaction (119,14) 5.84 < 0.001 
Peak Torque (PT) 
Between Subjects (17,2) 19.20 < 0.001 
Within Subjects (119,7) 20.91 < 0.001 
Interaction (119,14) 5.83 < 0.001 
Average Peak Torque (AT) 
Between Subjects (17,2) 21.47 < 0.001 
Within Subjects (119,7) 20.10 < 0.001 
Interaction (119,14) 5.70 < 0.001 
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F Values and Full Statistical Findings 
Students Independent t-test 
Test Parametet Mean D.F 
Delayed Onset Muscle Soreness (time course) 
Not significant 
Delayed Onset Muscle Soreness (intensity) 
6 days post- CFS 0.80 
damage CD 1.80 14 < 0.05 
Eccentric Damage Bout 
3rd set CFS 82.70 
CD 91.50 14 < 0.05 
4th set CFS 72.10 
CD 88.50 14 < 0.001 
5th set CFS 69.90 
CD 86.60 14 < 0.001 
6th set CFS 62.10 
CD 82.50 14 < 0.001 
7th set CFS 59.90 
CD 82.90 14 < 0.001 
